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ABSTRACT 
 
Environmental factors are strong determinants of diabetes-predictive biomarkers. 
We found these environmentally-determined biomarkers included, advanced 
glycation end-product serum carboxymethyl lysine (CML), a glycotoxin and 
diabetes-associated autoantibodies, are largely determined by familial shared and 
non-familial non-shared effects respectively. Serum CML emerges as an 
additional diabetes-risk determinant additional to autoimmunity. Low-risk non-
diabetic identical twins failed to identify an alteration in insulin secretion or 
sensitivity predisposing to type 1 diabetes (T1D). Antigen-specific antibodies in 
autoimmune T1D are also found in adults presenting with non-insulin requiring 
diabetes known as latent autoimmune diabetes of adult onset (LADA). Antigen 
specific antibodies in childhood and adult onset diabetes are similar with the same 
dominant isotype. European LADA patients compared with ‘type 2 diabetes’ 
patients are usually non-insulin requiring, younger, leaner and female. LADA is 
more prevalent than T1D, yet neither encompasses all adult-onset autoimmune 
diabetes. Prevalence of Metabolic Syndrome is significantly higher, in ‘type 2 
diabetes’ than in adults with LADA or T1D. Excluding glucose as a variable, 
Metabolic Syndrome is not more prevalent in autoimmune diabetes than in 
controls. Metabolic Syndrome is not a characteristic of autoimmune diabetes.  
Our evidence indicated that autoimmune diabetes is more prevalent in adulthood 
(9.7% of 6156 patients) than childhood and that presentation with non-insulin 
requiring diabetes is the norm, not the exception.  
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Autoantibodies to CD38 antigen reported as a feature of non-insulin requiring 
diabetes, are not so in childhood onset diabetes and do not add to the panel of 
diabetes associated auto-antigens.  
This thesis suggests that autoimmune T1D of adult onset is prevalent, initially 
usually non-insulin requiring. Moreover T1D is, in part, non-genetically 
determined, likely involving more than one non-genetic effect and includes a 
broad clinical spectrum of severity, not overlapping with ‘type 2 diabetes’. The 
precise cause or initiating factor of the disease still remains a mystery. 
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CHAPTER 1 
1.10. INTRODUCTION 
Diabetes was recognized by the ancient Egyptian, who mention a disease with 
excessive urinary output. The verbal distinction between diabetes insipidus and 
diabetes mellitus, where diabetes means passing a fountain of urine, was first 
made in the 18
th
 century (William Cullen and Johann Peter Frank). When the the 
physician Aretaeus of Coppadocia (81-138 AD) said that "Diabetes is a 
mysterious illness" his thoughts reflected our current understanding. He described 
it as 'a melting down of the flesh and limbs into urine', this, reflected the weight 
loss and excess passing of urine that occurs in acute, undiagnosed diabetes. 
Diabetes is a devastating disease, associated with substantial morbidity and 
mortality. The term diabetes, without qualification, usually refers to diabetes 
mellitus, which is associated with excessive sweet urine, (known as 'glycosuria') 
but there are several rarer conditions also named diabetes. The most common of 
these is diabetes insipidus in which the urine is not sweet (insipidus meaning 
"without taste" in Latin); it can be caused by either kidney (nephrogenic diabetes) 
or pituitary gland (central diabetes) damage. 
The word "insulin" was coined in 1909 by the Belgian, Jean de Meyer (1878-
1934) for the hypothetical pancreatic hormone; later, Frederick Grant Banting 
(1891-1941) and Charles Herbert Best (1899-1978) adopted this term after having 
themselves initially proposed the word "isletin". The discovery and introduction 
of insulin therapy in 1921, one of the 20
th
 century's greatest medical discoveries, 
heralded the cure of diabetes. Tragically, initial optimism proved unfounded as 
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insulin treatment did not lower blood glucose levels consistently to within the 
normal range. As a consequence glucose levels remain elevated with tissues 
exposed to chronic hyperglycemia and an altered glucose fat and protein 
metabolism. This in turn lead to devastating complications leading to retinopathy 
(causing blindness), nephropathy (causing kidney failure) and neuropathy 
(leading to amputation of limbs), a hallmark of the disease. 
T1D is an autoimmune disease in which the target tissue is the endocrine 
pancreas. Human and murine diseases share a number of similarities. In both the 
disease is spontaneous, occurs at a young age, have a similar genetic features and 
progresses in two steps: infiltration of the pancreatic islet cells with lymphocytes 
(insulitis), followed by the pancreatic islet beta cell (-cell) destruction, 
hyperglycaemia ensues together with an altered glucose, fat and protein 
metabolism. In the non-obese diabetic (NOD) mouse, islet infiltration of T cells, 
B cells, macrophages and dendritic cells starts at 3-4 weeks of age (Lo et al., 
1993), (Miller et al., 1988). The susceptibility to T1D is determined by a 
combination of both multiple genetic as well as environmental factors (Tisch & 
McDevitt 1996), (Leslie & Elliot 1994). What initiates the disorder whether a 
viral infection, an environmental agent or an autoimmune stimulus to a self-
antigen is not known, but that the subsequent gradual destruction of the  cells is 
immune mediated is no longer in any doubt. 
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1.11. CLASSIFICATION OF DIABETES 
For many years clinicians have used the terms for T1D and type 2 diabetes 
synonymously, with IDDM and NIDDM respectively. The American Diabetes 
Association, (ADA) 1997 classification abandoned the latter and retained the term 
T1D, ‘type 2 diabetes’ impaired glucose tolerance (IGT) and gestational diabetes 
(Seisler et al., 1998). In this manuscript I will use the ADA classification 
throughout. More recently the Royal College of General Practioners and NHS 
Diabetes (Farmer 2011) have suggested changes to the criteria due to the use of 
the ADA criteria leading to misclassification, misdiagnosis and miscoding in the 
UK. The latter could however result in incorrect classification or for that matter 
missed classification of patients with diabetes, as the proposal outlines a 
simplified categorization based on hyper-glycaemia to separate diabetes from no 
diabetes with genetic and secondary diabetes placed in separate categories. 
Diabetes mellitus is a condition characterized by the presence of hyper-glycaemia 
resulting from autoimmune destruction of the insulin producing  cells.  
TID presents mainly in childhood and in early life and accounts for about 20% of 
cases in Europe and North America, affecting about 35 million people world-wide 
and may even be double that number. It can be caused at any age and is the 
second commonest chronic childhood disease after asthma, with a substantially 
greater morbidity and mortality. It has been established that diabetes mellitus is a 
genetically and clinically heterogeneous disorder. Given the difficulty in treating 
the disease, the last 30 years has seen a concerted effort to try and understand the 
cause of diabetes with a view to better predict and thereby prevent it.  
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1.12. DIAGNOSTIC CRITERIA 
In 1997, an expert Committee of the American Diabetes Association proposed a 
modification to the diagnostic criteria for diabetes, by lowering fasting plasma 
glucose at which diabetes can be diagnosed to 7.0 mmol/l (because a fasting value 
of 7.8 mmol/l defines a greater degree of hyper-glycaemia than a 2 hour value of 
11.1 mmol/l) (Expert Committee 1997). This simple fasting value is preferred for 
diagnosis to the more complex 75g OGTT. Though there have been subsequent 
modification to this classification, it remains the classification used in this thesis.  
Subjects with IGT also have an increased risk of macrovascular complications as 
well as other cardiovascular disease risk factors including hypertension, 
dyslipidaemia and obesity. Because of these factors diagnosis of IGT in 
apparently healthy individuals has important prognostic implications.  Subsequent 
diagnostic criteria have incorporated glycosylated haemoglobin A1c levels but 
will not be considered here.  
1.13. EPIDEMIOLOGY OF TID 
T1D is a multifactorial disease, primarily caused by an autoimmune destruction of 
the pancreatic beta cells leading to an absolute insulin deficiency and a need for 
insulin therapy for survival. People with TID require exogenous insulin for 
survival to prevent development of ketoacidosis. The disease is caused by non-
genetic, probably environmental, factors operating in a genetically susceptible 
individual to initiate a destructive immune process. Autoantibodies to the islet cell 
antigens (ICA), the neuronal enzyme Glutamic Acid Decarboxylase (GAD65), 
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tyrosine phosphatase like molecule (IA2ic) and the more recently described zinc 
transporter) a multi-spanning trans-membrane protein that resides in the insulin 
secretory granules Slc30A8 (ZnT8, can be detected many months or even years 
before the diagnosis of clinical diabetes and are markers rather than the cause of 
the disease (Figure 1.1). 
 
Figure 1.1: A schematic model of development autoimmune T1D.  
A genetically predisposed individual exposed to an immunological trigger at a 
critical time that initiates an autoimmune process, resulting autoimmunity (Islet 
infiltration and autoantibody formation to Islet cell antigens including GADA, 
IAA, IA2A and ZnT8) and a gradual decline in beta cell mass, detection of 
autoantibodies ante-dates the progressive loss of beta cell function leading to 
impaired glucose tolerance and diabetes. (Modified from Eisenbarth GS. T1D 
mellitus: a chronic autoimmune disease. N Engl J Med 1986; 314: 360-368)  
IAA = Insulin autoantibodies, GADAb = Glutamic acid decarboxylase, IA2Ab = 
IA2A and ICA 512 Ab and ICA= Islet cell antibodies, ZnT8= Zinc Transporter.  
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The incidence of TID is rapidly increasing in specific regions and is showing a 
trend towards earlier onset in different populations with a high variability in the 
ethnic populations  (LaPorte et al., 1985). The overall age adjusted incidence of 
TID varies and is less frequent in Asia than in Europe. The incidence of TID in 
Japan and China is about 1:100,000/yr and in South India about 10.5:100,000/yr  
(Karvonen et al., 1993), (Ramachandran et al.,1996). In contrast, the incidence of 
TID in Sweden, Finland and Sardinia ranges from 28 to 40:100,000 per year 
(Green et al., 1992), (Anonymous 2000, EURODIAB ACE Study Group), 
(Onkamo et al., 2000). There is a large variation in the incidence of TID in the 
different populations analysed and furthermore the incidence of the disease seems 
to be increasing in all populations. Furthermore Finland and Sardinia, the two 
regions with the highest frequency, are 3000 km apart and Estonia Finland's 
neighbouring country has an incidence rate half that of Finland. It is predicted that 
the incidence of TID will be about 40-50% higher in 2010 than in 1998 (Struan et 
al.,2009). This data suggests that there was an equatorial divide for the disease 
incidence for TID (Karvonen et al., 1993), (Ramachandran et al.,1996), however 
this is not thought to be as strong as was previously attributed (Muntoni 1999) as 
high incidence rates similar to the European populations have been noted in 
Kuwait and Puerto Rico (Atkinson & Eisenbarth 2001). There is a wide difference 
in the incidence rates within ethnic groups and this is probably due to a 
combination of both genetic and an environmental background affecting the 
outcome of the disease incidence in the different geographical locations. The 
EURODIAB study (Anonymous 2000), indicates an increase in the incidence rate 
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of TID of 3-4% in the European countries. The incidence of TID varies both with 
age and sex, with males predominant in postpubertal young adults (Blohme et al., 
1992), (Karvonen et al., 2000). Examination of the rates of TID as a function of 
age at onset shows rates of increase of 6.3%, 3.1% and 2.4% in populations of 
children aged 0-4 years, 5-9 years and 10-14 years respectively. The increase in 
incidence has been most obvious in the group under 5 years of age (Tuomilehjto 
et al., 1999), even though the diagnosis of diabetes is still fairly rare among 
infants. These findings support the impressions of the health care professionals 
indicating that they are seeing an increase of cases of TID, especially in the 
younger children.  
Studies have shown that allergic as well as autoimmune diseases are not evenly 
distributed among continents and countries and suggested a north-south gradient 
with the incidence of disease decreasing from the north to the south. It is thought 
that this could be due to environmental as well as genetic factors. In Sardinia the 
incidence of T1D is high as compared to residents of neighbouring countries as 
well as Sardinians who migrated to continental Italy (Muntoni et al., 1997). The 
contribution of the genetic factors seems small in comparison to the environment, 
though twin studies suggest that the genetic contribution is potent in childhood 
but decreases thereafter (Salvetti et al., 2000), (Leslie & Castelli 2004). The 
environmental factors could account for the rapid rise in allergic as well as 
autoimmune diseases in developed countries.  
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1.14. AUTOIMMUNE DIABETES IN ADULTS 
Autoimmune TID has been classically described as a childhood onset insulin 
requiring condition but it is now becoming increasingly recognised that this may 
not be the case as autoimmune diabetes presenting in adults which may or may 
not require insulin is becoming a major concern to the healthcare system. In fact 
requirement of insulin and the time to insulin therapy has led to clinicians to 
postulate the distinction of those who are put on insulin immediately at diagnosis 
(as TID) from those who remain free of insulin for at least 6 months after 
diagnosis of diabetes classified as LADA.    
LADA is defined clinically by three criteria: 1) Age at diagnosis > 30 years of 
age; 2) Presence of autoimmune features; 3) Free of insulin therapy for at least 6 
months after diagnosis. This condition is sometimes referred to as ‘Type 1.5 
diabetes’, ‘Slowly Progressive Diabetes (SPIDDM)’, ‘Double Diabetes’, 
‘Antibody positive type 2 diabetes’ and progressive insulin dependent diabetes 
(Naik & Palmer 2009), (Palmer et al.,2005). Misdiagnosis of adults as patients 
with type 2 diabetes is often a feature at presentation of the condition in the 
general population where such cases may be a little overweight, insulin resistant 
with signs of metabolic syndrome which clinicians generally associate with type 2 
diabetes. LADA is commonly found in the Caucasian populations with 4-12% of 
patients presenting with type 2 diabetes with autoantibodies at diagnosis (Zinman 
et al., 2004). 
In contrast to type 2 diabetes, defects in insulin secretion through  cell loss and 
islet cell dysfunction are a prominent features of TID. Numerous studies have 
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documented the progressive loss of  cell function during the pre-clinical and post 
diagnosis periods of the disease process. However, the physiological relationship 
between insulin secretion and insulin resistance still holds and determines the 
state of glucose tolerance in individuals. It has long been recognised that islet 
cells when stressed by rising blood sugar levels are up-regulated both 
metabolically and immunologically (Bjork et al., 1992). Beta cell stress 
(glucotoxicity) can result from the cells own low functional mass, or due to 
insulin resistance, both of which reduce the feedback control and blood glucose 
rises.  
Blood glucose concentrations, do not rise linearly with  cell loss or with insulin 
resistance, but only slowly to the point whereby the capacity of the feedback 
control loop is exceeded and diabetes ensues. All patients who develop diabetes 
of whichever type, progress down the same path of deteriorating blood glucose 
control which can take months, years or decades. Insulin resistance at whatever 
age it may emerge, increases  cell stress and intensifies an autoimmune response 
in those individuals who are genetically predisposed to develop diabetes. The 
phenomenon of insulin resistance with progressive rise in body weight, has been 
increasingly noted at a younger age at presentation of type 2 diabetes over recent 
time. This phenomenon might be doing the same for TID by promoting the 
immunological accelerants of  cell death in a progressively younger age group. 
 
The possibility of preventing ‘type 2 diabetes’ in subjects at high risk became the 
focus for a number of studies in patients with impaired glucose tolerance (IGT) 
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(Pan et al.,1997), (Tuomilehto et al., 2001). IGT is defined as hyperglycaemia 
(with glucose values intermediate between normal and diabetes) following a 
glucose load (Alberti and Zimmet 1999) (Table 1.1), and affects nearly 200 
million people worldwide. IGT represents a key stage in the natural history of 
‘type 2 diabetes’ as these people are at a higher future risk than the general 
population for developing diabetes (Zimmet et al., 2003). Approximately 40% of 
subjects with IGT progress to diabetes over 5-10 years, but some revert to normal 
while others can have IGT without developing diabetes. A proportion of patients 
presenting with non-insulin requiring diabetes presenting with IGT can have 
autoimmune changes, fewer features of metabolic syndrome, lower body mass 
index (BMI) and a lower waist hip ratio as well as lower HDL cholesterol, such 
that and at diagnosis rapidly go on to insulin requirement (Leslie et al., 2006) such 
patients are termed as LADA (Pozzilli  & DiMario., 2001). 
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 Glucose concentration in mmol/l (mg/dl) 
 Plasma Whole blood 
 Venous Capillary Venous Capillary 
Diabetes 
mellitus 
Fasting 
value 
>7.8 (104) >7.8(140) >6.7 (120) >6.7 (120) 
Or 2 hour 
after 75g 
glucose 
load 
>11.1 (200) >12.2 (220) >10.0 (180) > 11.1 
IGT 
Fasting 
value 
<7.8(104) <7.8 (140) <6.7(120) <6.7 (120) 
Or 2 hour 
after 
glucose 
load 
7.8-11.0 
(140-199) 
8.9-12.1 
(160-219) 
6.7-9.9 
(120-179) 
7.8-11.0 
(140-199) 
 
Table 1.1 WHO diagnostic criteria for diabetes and Impaired glucose tolerance 
(WHO 1999)   
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1.15. WHAT ARE THE REASONS FOR THIS DIABETES EPIDEMIC? 
ENVIRONMENT OR GENES? 
The evidence is that T1D is increasing in prevalence because of environmental 
effects. The reason for this is based on population studies which have 
demonstrated a dramatic increase in the disease within a relatively short period of 
time and certainly too short a period to be genetically driven. In support of this 
proposal, migration studies have shown that children moving from a low risk 
country to high disease-risk country acquire the disease risk of the new 
environment. The incidence of T1D in Sardinia is high as compared to residents 
of neighbouring countries as well as Sardinians who migrated to continental Italy 
(Muntoni et al., 1997). The contribution of the genetic factors seems small in 
comparison to the environment. Another trans migratory study of children 
migrating from the Pakistan and India to the UK reported a rise in the incidence 
of T1D from 3.1/100000 before migration to 11.8/100000 thereafter, similar to the 
non Asian children of 12/100000 (Bodansky et al., 1992). Data of migration 
studies have shown that T1D in children who migrated from Pakistan to the 
United Kingdom is the same as the non-immigrants in the United Kingdom (11.7 
per 100,000) almost 10 times the incidence in Pakistan (1 per 100,000) (Bach 
2002). Environmental factors could account for the rapid rise in allergic as well as 
autoimmune diseases in the developed countries. Both genetic as well as 
environmental factors (dietary factors and viruses) together are thought to have an 
impact on the incidence of T1D as well as the national health services. 
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Finally, the threshold for developing T1D appears to have changed so that 
children with T1D have less HLA genetic susceptibility today than many years 
ago, e.g. the Barbara Davis Diabetes Centre have shown over the last 40 years a 
decrease in the HLA D3/4 in individuals (Steck et al 2011).  Thus, the epidemic 
appears to reflect an interplay between genetic risk and environmental risk in 
which the environmental risk or effect has increased in Europe and North 
America while the genetic risk sufficient to lead to the disease has decreased; 
these principle have been outlined in the ‘Threshold Hypothesis’ (Wasserfall C et 
al, 2011).    
 
Environmental and behavioural factors include sedentary lifestyle, nutrition (Low 
Birth weight) and obesity have been put together to explain the increase in 
incidence of diabetes. Two schools of thought have been put forward to explain 
the changing risk of non-communicable diseases (NCD) such as T1D: ‘the thrifty 
genotype’ and the ‘thrifty phenotype’.  
1.16. ‘The Thrifty Genotype Hypothesis’ (Neel 1962) provides an explanation 
for the high prevalence of type 2 diabetes in the Pima Indians, Australian 
Aborigines and Pacific Islanders, as being due to an evolutionary thrifty genotype 
promoting fat deposition and storage of calories in times of plenty, which would 
have been advantageous to the hunter gatherer populations. However in the 
modern world the abundance of food prepares the individuals at risk for a famine 
that never results leading to obesity. Another pathway to obesity is likely to be the 
maternal-foetal environment during pregnancy. The effects of hyper-nutrition 
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during pregnancy as in the offspring of Pima Indians women with type 2 diabetes 
which accounts for 40% of type 2 diabetes in that population (Dabalea et al., 
1998).  
 
1.17. ‘The Thrifty Phenotype Hypothesis’ on the other hand, is based on the 
epidemiological observations, linking, low birth weight with the risk of adult 
disease (obesity, diabetes and hypertension). Hales and Barker,  hypothesized 
(Hales & Barker 1992) that intrauterine malnutrition leads to reduced birth weight 
and permanent changes in physiological structure and function, which predispose 
to disease in adult life. Both factors, that is intrauterine environment and low birth 
weight, are probably relevant given the appropriate environmental and genetic 
background.  Less clear is whether either of these hypotheses are relevant to the 
origins of T1D.  
 
1.18. HYPOTHESIS FOR AUTOIMMUNE DISEASE 
A number of other hypothetical models have been put forward to try and explain 
the pathogenesis of T1D.  
1.181. The ‘Accelerator Hypothesis’, argues that TID and type 2 diabetes are 
one and the same, distinguishable only by their rate of beta cell loss and the 
accelerators responsible (Wilkin 2001). The ‘Accelerator Hypothesis’ identifies 
three processes which variably accelerate the loss of beta cells through apoptosis: 
constitution, insulin resistance and autoimmunity. The first accelerator, a 
constitutionally (intrinsically) high rate of beta-cell apoptosis, is necessary for 
41 
 
diabetes to develop but in itself is rarely sufficient to cause it. Insulin resistance, 
the second accelerator, results from weight gain and physical inactivity which 
further increases beta cell apoptosis and accounts for the rising incidence of TID 
as well as type 2 diabetes in the industrially developed countries. Finally the third 
accelerator operates in a genetically defined subset of patients with both an 
intrinsic lesion of beta cells and insulin resistance developing beta cell 
autoimmunity. 
1.182. The ‘Overload Hypothesis’ implicates beta cell overload resulting from 
insulin resistance, high growth rate, physical stress and increased insulin 
requirement, leading to accelerated beta cell damage (Dahlquist G. 2006). Insulin 
dependency is the end stage towards which all types of diabetes move to and the 
notions of TID and non-insulin requiring diabetes as separate diseases becomes 
irrelevant. Of the three accelerators, one is intrinsic and two are acquired. Insulin 
resistance, the second accelerator, is associated with visceral fat mass as well as 
ageing and is widely believed to explain the epidemic rise of type 2 diabetes in 
the industrially developed world. Evidence that obesity or weight gain are 
associated with T1D risk is substantial, but evidence that there is another 
accelerator associated with beta cell apoptosis is less evident (Dahlquist G. 2006). 
 Other hypothesis try to reconcile aspects of T1D disease process and includes the 
1.183. ‘Copenhagen model’, where beta cell destruction is the result of an 
interaction of the environment, the immune system and the beta cells themselves 
releasing cytokine and free radicals in genetically susceptible individuals (Nerup J 
et al. 1994).  
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1.184. The ‘Hygiene Hypothesis’ states that a lack of early childhood exposure 
to infectious agents, symbiotic microorganisms (e.g., gut flora or pro-biotics), and 
parasites increases susceptibility to allergic diseases by suppressing natural 
development of the immune system (Strachan 2000). This hypothesis was 
originally formulated for asthma (Strachan 2000). Other diseases, such as the rise 
of autoimmune diseases and acute lymphoblastic leukemia in the young in 
developed nations, have also been linked to the hygiene hypothesis.  
1.185. The ‘Fertile Field Hypothesis’ implies that microbial infections provides 
a temporary state conducive to reactivity to self, leading to autoimmunity which 
has been implicated in TID and multiple sclerosis (Matthias et al., 2003). 
However, no single micro-organism has been identified in the cause of human 
auto-immune disease. Multiple hits from the same or different microorganisms 
could provide an opportunity for the autoimmune disease to manifest in a 
genetically susceptible individual. Alternatively, multiple hits from a range of 
non-genetic effects including infections could be relevant.  
 However while these hypothesis may help in defining the development of T1D in 
some individuals, none of them quite captures the reason for the general increase 
in the incidence rate of the disease, a polygenic disease with multiple 
environmental insults. The importance and contributions of nature (i.e. genetics) 
over nurture (i.e. environment) in TID has recently been put together by 
(Wasserfall C et al 2011) in the ‘threshold hypothesis’ as a graphical model with 
genetic and environmental load and the interaction in TID.  
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1.186. The ‘Threshold Hypothesis’, is illustrated by arranging the odds ratio for 
the genetic as well as the environmental components that interplay in this disease. 
Of the genetic and environmental components, the rare mutation of the Forkhead 
Box P3 (FOXP3) and the Autoimmune Regulator (AIRE) genes contribute the 
highest risk for autoimmune diabetes involving beta cell destruction and 
modulation of the immune system. Of the known environmental factors 
pancreatectomy and beta cell chemical toxin pose the highest risk component with 
an odds ration > 7.0. (Figure 1.2). 
From the threshold hypothesis we note that the HLA region with an odds ratio 
close to 7.0, which has the highest genetic association after FOXP3 and AIRE 
followed by the next closest regions the non MHC loci being INS VNTR, 
PTPN22, CD25 and CTLA4 before dipping below an odds ratio of 1 
exemplifying the HLA-DQB (protective alleles) (Wasserfall C et al 2011). The 
HLA accounts for the major genetic risk component in children and young adults.  
With respect to the environmental factors, the risk posed by toxins or 
pancreatectomy, outweigh other environmental factors, however dietary factors, 
infections, perinatal as well as postnatal environment as well as the gut microbiota 
could well interplay with the genetic susceptibility alleles to provide a 
combinatorial effect. The threshold hypothesis posits a model as presented in 
Figure 1.2 to highlight the combined impact of both the genetic and environment 
factors together to reach a threshold above which disease ensues. The model 
further confirms that the environmental factors alone or genetic susceptibility 
alone does not equate to disease but rather the interaction of these factors provide 
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a combinatorial increased risk factor. With globalisation as well as migration 
genes find themselves in environments to which they are ill adapted to, leading to 
increased disease incidence. The threshold model combines the genetic as well as 
environmental impacts and studies currently underway such as the TEDDY study 
will allow these questions to be answered.  
1.187 The ‘Molecular Mimicry hypothesis’ is defined as structural similarity 
between foreign peptides (e.g. virus peptides) and endogenous peptides (e.g. 
normal component of pancreatic  cells), which is responsible for immunological 
cross reactivity. An abnormal immune response to that particular virus protein 
may contribute to the pathogenesis of diabetes through immunity to that particular 
viral peptide, at the same time, to pancreatic  cell proteins. Molecular mimicry 
might be one of the mechanisms perpetuating autoimmunity to islet self 
autoantigens. The cause of autoimmune diseases however is unknown, but it 
appears that there is an inherited predisposition to develop autoimmune disease in 
many cases. However in a few types of autoimmune disease (such as rheumatic 
fever), a bacterial or virus protein triggers an immune response to peptides, such 
that antibodies or T-cells attack the normal cells because they recognise a part of 
the peptide structure that resembles a part the infecting microorganism. One such 
example proposed in TID is the PEVKEK region found on the autoantigen 
GAD65 and also found on the coxsackie virus. 
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Figure 1.2: A hypothetical model to depict the impact of genetic as well as 
environmental factors in T1D (Wasserfall C et al 2011). 
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1.19. PATHOPHYSIOLOGY OF AUTOIMMUNE DIABETES 
Diseases of the immune system such as T1D, rheumatoid arthritis, coeliac disease 
and multiple sclerosis, affect about 5% of Caucasoid populations (Vyse & Todd 
1996). These diseases are characterised by features of autoimmunity: the presence 
of autoantibodies and self-reactive T cells, sensitivity to agents such as 
cyclosporine that suppresses the immune system and a universal genetic 
association with the major histocompatibility complex (MHC) on chromosome 
6p21. Relatives of patients are at significantly increased risk of developing the 
disease or, indeed, of other autoimmune diseases; families with TID tend to have 
increased frequencies of rheumatoid arthritis, coeliac disease, thyroiditis and 
multiple sclerosis. This familial clustering of disease is consistent with a genetic 
component of the disease aetiology. It is clear, however that even a sufficient 
complement of susceptibility polymorphisms at disease associated genes, both 
inside and outside the MHC, does not always lead to the development of disease 
at the clinical level, as genetically identical twins are often much less than 100% 
concordant.  
In the spontaneous mouse model of autoimmune T1D, the nonobese diabetic 
(NOD) strain, the frequency of disease is less than 100%, with about 50-80% of 
females developing diabetes by 220 days and 10-50% of males (Wicker 1995). By 
contrast disease frequency decreases if NOD mice are deliberately or accidently 
infected with bacterial, viral, or parasitic organisms (Todd 1991). These 
observations challenge the view that TID is initiated by an environmental trigger. 
Instead, the data from NOD mice are consistent with an intrinsic immune 
47 
 
aetiology, perhaps also a target organ defect, in which the disease penetrance is 
modified by multiple environmental factors acting in both a positive and negative 
way during different stages of disease development.  
Concordance for T1D in identical twins is consistently less than 100% and 
approximates to 50% in children and even less as the age of onset becomes older 
(Leslie & Castelli 2004), (Gardner et al 1997). Incomplete concordance of twins 
may be a consequence of the typically aggressive microbial environment in which 
we live. However, other factors could be responsible and include random events 
and missing heritability one cause of which could be due to gene-gene as well as 
gene environment interaction together with epigenetic modification (Clarke AJ 
2010). It was suggested that one reason TID is increasing in frequency (Strachan 
2000) is because standards in sanitation and health care have improved 
dramatically over the past 30 years. This hygiene hypothesis was originally 
formulated for asthma and allergic diseases which postulated that infections 
protected from atopy (Strachan 2000). Consequently, the environment appears to 
have become more permissive for the development of autoimmunity to the 
pancreatic insulin producing  cell since our immune system is not as ‘educated’ 
as it used to be when antibiotics and sanitation were less evident. A recent study is 
consistent with this model: multiple infections during the first few years of life 
were associated with a reduction in risk of T1D
 
 (Gibbon et al., 1997). 
It may well be that TID can be either accelerated or precipitated by infection. 
Rubella viral infection is such an example, but even in rare rubella virus 
syndrome patients also have the established MHC susceptibility markers (Hee 
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Suk Jun and Ji Won Yoon., 2002). Coupled with the fact that 30% of European 
cases carry the MHC risk haplotypes, HLA-DR4 and/ or DR3 (Noble et al., 1996) 
it can be concluded that gene polymorphisms are necessary for the development 
of disease and could, in many cases, be almost sufficient in an appropriate 
environment, e.g. FOXP3 or AIRE gene mutations as discussed by Atkinson and 
colleagues (Wasserfall C et al 2011).   
 
1.20. ENVIRONMENTAL FACTORS  
Both genetic and non-genetic factors contribute to the development of T1D. The 
low concordance rate of TID in identical twins less than 40% (Barnett et 
al.,1981), though age at diagnosis dependent, suggests that environmental factors 
play a significant role in the disease penetrance. A number of environmental 
factors are thought to play important roles in the pathogenesis of childhood onset 
TID including infections (entero-virus infections), dietary factors (early exposure 
to cows milk), vitamin D intake, perinatal (uterine environment) as well as psycho 
social factors (stress early in life, illness, death in family or divorce) have all been 
implicated. Vitamin D has been reported to have a beneficial protective effect in 
the regulation of the immune responses and also associated with a lower risk of 
TID, however to this end there have been conflicting reports. A recent report in 
the Diabetes Autoimmunity Study in the Young (DAISY) has shown that neither 
vitamin D nor 25(OH)Vitamin D in childhood were associated with risk to islet 
immunity or progression to T1D. However despite this, no single factor has been 
clearly identified as the trigger of autoimmune beta-cell destruction. 
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Twin studies have helped to define the importance of genetic and environmental 
factors in the aetiology of disease (Martin et al., 1997), (Smith 1993), (Utz et al., 
1993), Brix et al.,1998), (Nanki et al., 1996), Ebers et al., 1986), (Allen et al., 
1967), Hassan et al., 1966), Lehtovirta et al., 2000). By measuring concordance 
rates (both twins affected) in identical (MZ) and non-identical (dizygotic) (DZ) 
twins, estimates of genetic influence can be obtained.  
In primarily genetic disorders, concordance rates should be higher in MZ than 
dizygotic twins, because MZ twins share the same genes 100% as well as the 
environment unlike fraternal twins who share 50% of the genes but the same 
environment. Differences between MZ twins must be due to factors not coded in 
the germ line, i.e. non-germ-line genetic (e.g. somatic) or environmental factors.  
Diabetic twin studies have provided important information about the causes of 
diabetes including the cause of TID.  Twin studies have shown that T1D is due to 
non-genetically determined factors, probably environmental agents, operating in 
genetically susceptible individuals.  The environmental event operates over a brief 
period in early childhood to induce an immune process which destroys the islet ß 
cell.  ß cell destruction in some is chronic and progressive, leading to TID, but in 
others it can remit without diabetes developing.  In the months or years before the 
onset of TID, clinical, immune and metabolic changes can be detected and these 
changes are predictive of diabetes. The nature, intensity, extent and persistence of 
these immune changes distinguishes twins who develop TID from those who do 
not.  In an analysis of a combined study of diabetic twins from the United States 
and United Kingdom of 187 twin pairs many followed for up to 40 years, 
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indicates that non-germ-line genetic or environmental factors play an important 
part in both the development of T1D and in the rate of progression to disease 
(Redondo et al., 2001). In both countries the rates of progression and concordance 
were similar and it seems likely as a consequence that the genetic and non-genetic 
factors causing T1D are also similar in the two countries. An age-related 
heterogeneity, was observed with higher progression to diabetes for twins of 
patients diagnosed at a younger age (Redondo et al., 2001). Most non-diabetic 
twins did not develop diabetes at an early age, up to 25% of the twins who 
progressed did so after more than 14 years of discordance. 
A number of environmental factors have been implicated in the cause of diabetes 
including viruses (Hee Suk Jun and Ji Won Yoon., 2002) and diet in the form of 
early exposure to cow’s milk in infants, each implicated to the increased 
incidence of diabetes. It is suggested that some components of cow’s milk in its 
pasteurised or homogenised form in particular β-casien may well contribute to the 
increased triggering of an autoimmune reaction in genetically predisposed 
individuals. The most abundant protein in Cow’s milk is the A1 form of β-casien 
and its commonest genetic variants are A1, A2 and B β-casein. Cow’s milk β-
casien consists of 209 amino acids, the A1 and A2 variants differ only at position 
67 which has histidine in A1 and proline in A2 milk. Another variant B β-casien 
has histidine at position 67 and is less frequent than A1 or A2 in cow’s milk of 
European origin.  Studies in the NOD mouse model have shown that diabetes 
development can be delayed by the introduction of dietary modification’s 
including hydrolyzed cow’s milk (Elliot et al., 1988), whilst other studies have 
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shown a differential effect with cow’s milk or wheat (Beales et al., 2002) where 
the highest incidence rate of diabetes was in the control group fed on wheat, corn, 
soy, alfalfa, Oats, fish meal and cellulose and no milk. In that study  (Beales et al., 
2002) concluded: “A previous result that A1 β-casein was more diabetogenic than 
A2 β-casein in NOD mice was not confirmed”. 
Another hypothesis that A1 and not A2 β-casein may increase diabetes 
development in genetically susceptible individuals by the release of opoid peptide 
β Casomorphin 7 (BCM-7) which affects the immune system such that 
autoantibodies against β-cells are more likely to be formed , however this remains 
to be confirmed in humans (Monetini 2002). These effects are most prominent 
after weaning suggesting that early life events in exposure to new food’s early in 
life may have a modifying influence in the progression to diabetes (Daniela et al., 
2009). Early exposure to an environmental insult may well initiate an immune 
response however it is not clear whether cow’s milk alone is the causative factor 
in diabetes development. The TRIGR study, a study that aims to identify 
environmental factors which cause T1D, should clarify whether weaning to a 
highly hydrolysed formula may protect children at risk by delaying or preventing 
the development of diabetes. Preliminary studies by Knip and colleagues (Knip 
2010) showed a decreased risk of positivity to diabetes associated autoantibody. 
There still remains however, the possibility, that an early environmental or 
nutritional factors, act as co triggers in the development of T1D.  
Early exposure to other proteins may well be responsible including heat modified 
proteins such as Advanced Glycation End (AGE) Products.  
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1.21. ADVANCED GLYCATION END PRODUCTS (AGE) 
Glycosylation is the enzymatic process that attaches glycans to proteins, lipids or 
other organic molecules. This enzymatic glycosylation is fundamental to the 
biological function of cellular proteins as well as RNA and DNA and have 
strucutural as well as functional roles in membrane and secreted proteins in the 
normal physiology. The general O-glycosylation has also been shown to be 
present in the Bacteroides Fragilis and is necessary for the bacteria to colonize 
mammalian intestine (Fletcher et al., 2009). The majority of proteins synthesized 
in the endoplasmic reticulum (ER) undergo glycosylation which is an enzyme 
directed site specific process as opposed to the nonenzymatic chemical reaction of 
glycation of proteins, lipids as well as nucleic acid via the formation of highly 
reactive intermediates.  
This nonenzymatic glycation reaction is also known as the Maillard reaction and 
the realisation of the importance of this reaction began in the mid 1970’s with the 
study of HbA1c a naturally occurring human hemoglobulin which was elevated in 
diabetic patients. This nonenzymatic glycation called Advanced Glycation (AGE) 
is the result of the reaction of glucose with proteins, lipids and nucleic acids to 
form AGE. AGE accumulates in the body naturally as a result of chronological 
ageing. Furthermore this process is substantially accelerated under the 
hyperglycaemic oxidative stress conditions present in a prolonged diabetic 
cellular milieu.As we age the cumulative exposure of the bodies protein, lipids as 
well as nucleic acids to reducing sugars in the blood and lymph allows their 
nonenzymatic glycation to form AGE. These AGE induce the cross linking of 
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long lived proteins such as collagen and elastin in the extracellular matrix, 
promoting stiffness and affecting the normal physiological function. AGE 
formation occurs over months or even years which is why long lived proteins of 
the extracellular matrix, collagen and elastin are most vulnerable to AGE 
accumulation. Furthermore AGE bind to AGE specific receptors RAGE, found on 
all cell types (smooth muscle & endothelial cells) including immune cells 
(macrophages, monocytes, T-Cells as well as dendritic cells), inducing 
intracellular signalling leading to increased oxidative stress, production of 
reactive oxygen species and activation and production of a cycle of pro-
inflammatory cytokines leading to micro-vascular as well as macro-vascular 
damage (Wautier & Schmidt 2004 ).The level of AGEs increases both during 
physiological ageing as well as in pathophysiological settings such as diabetes 
mellitus, RA. Alzheimers disease (AD) and MS (Sternberg et al., 2010). 
 
1.22. GENETIC FACTORS 
It is well established that T1D has a strong genetic component. The frequency of 
the disease is higher in siblings of diabetic patients (in the UK it is 6% by age 30) 
compared to the general population (0.4% by age 30) (Field 2002). This is 
unlikely to be due to shared environmental factors as clinic- and population-based 
studies have demonstrated higher concordance rates for T1D in identical 
compared with non-identical twins (Salvetti et al.,2000), (Hyttinen et al.,2003).  
Genetic influences on T1D are most potent in childhood-onset T1D (Salvetti et 
al.,2000), (Kumar et al., 1993), (Vyse & Todd 1996). However, even in 
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childhood-onset T1D the majority of identical MZ twins remain discordant for the 
disease and the concordance rate falls even further with increasing age at 
diagnosis of T1D (Gardner et al., 1997), (Leslie and Delli-Castelli 2004). Current 
explanations for the high rate of T1D discordance between MZ twins include 
environmental triggers of T1D that operate on one twin and not the other, or 
differences at the molecular level e.g. mosaicism due to skewed X-chromosome 
inactivation in females and different repertoires of T-cell receptors and antibodies 
resulting from somatic rearrangements, or epigenetic effects.  
However, although various environmental exposures have been proposed to 
trigger T1D, including early infant diet, viral infection and toxins, conclusive 
evidence for an environmental agent is still lacking and there is no proof that the 
molecular differences mentioned above are the basis of T1D discordance in MZ 
twins. In light of the facts that only a few genomic susceptibility regions have 
been found, no environmental agents conclusively identified, and the high rate of 
disease discordance in MZ twins, it is proposed that penetrance of T1D may, in 
part, be influenced by epigenetic factors. 
1.23. WHAT ARE AUTOIMMUNE DISORDERS 
Autoimmune disorders are diseases caused by the body producing an aberrant  
immune response against its own tissues.  The immune system sometimes, will 
cease to recognize one or more of the body's normal constituents as "self" and will 
respond to it as foreign and create autoantibodies to it, – antibodies that attack the 
55 
 
cells, tissues, and/or organs. This causes local inflammation and tissue or organ 
damage which can subsequently lead to autoimmune disorders.   
The cause of autoimmune diseases however is unknown, but it appears that there 
is an inherited predisposition to develop autoimmune disease in many cases. In a 
few types of autoimmune disease (such as rheumatic fever), a bacteria or virus 
triggers an immune response, and the antibodies or T-cells attack the normal cells 
because they recognise  a part of the structure that resembles a part of the 
structure of the infecting microorganism (molecular mimicry). 
Autoimmune disorders fall into two general types: those that damage many 
organs (systemic autoimmune diseases) and those where only a single organ or 
tissue is directly damaged by the autoimmune process (localized). However, the 
distinctions become blurred as the effect of localized autoimmune disorders 
frequently extends beyond the targeted tissues, indirectly affecting other body 
organs and systems.  
A major feature of the immune system is its ability to inflict damage on cells. 
Therefore, it must confine this activity to cells that are of potential threat, such as 
cells in the body that have become infected or neoplastic, whilst remaining 
unresponsive or tolerant to the normal cells of the body. As the regulation of the 
immune system is very important in the context of human disease, a disordered 
response may result in a breakdown in tolerance leading to auto-immune disease 
or immune deficiency. 
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In general autoimmune diseases can be divided into two categories: organ-specific 
and systemic autoimmune disease. In organ-specific autoimmune disease, the 
immune response is directed to a target antigen unique to a single organ or gland, 
so that the manifestations are largely limited to that organ. In systemic 
autoimmune disease, the response is directed toward a broad range of target 
antigens and involves a number of organs and tissues. 
 
1.24. ORGAN-SPECIFIC AUTO-IMMUNE DISEASES 
Damage to the target organs in organ-specific auto-immunity can occur as the 
result of direct cellular damage by humoral or cell-mediated mechanisms or by 
stimulating or blocking autoantibodies. In this instance, the immune system 
usually targets discrete antigens present on the tissue. Gradually, the cellular 
structure of an affected organ is replaced by connective tissue, hence, the function 
of the organ declines. T1D mellitus and Hashimoto’s thyroiditis are good 
examples of this type of autoimmune diseases (Table 1.2). 
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Disease Organ/Tissue 
T1D Mellitus Pancreas, islets 
Hashimoto's thyroiditis, Graves' disease  Thyroid Gland 
Celiac disease, Crohn's disease, Ulcerative 
colitis  
GI tract 
Multiple sclerosis  Myelin sheath 
Addison's disease  Adrenal 
Primary biliary cirrhosis, Sclerosing 
cholangitis, Autoimmune hepatitis  
Liver 
 Stiff Man Syndrome (SMS)  Affects axial 
muscles 
 
Table 1.2: Localized Autoimmune Diseases: Table shows the organs and 
tissues affected by specific autoimmune disease  
 
1.25. SYSTEMIC AUTO-IMMUNE DISEASES 
Autoimmune diseases with systemic manifestations reflect a generalised defect 
in immune regulation that result in hyperactive T-cells and B-cells. Tissue 
damage is widespread, both from cell-mediated immune responses and from 
direct cellular damage caused by autoantibodies or by accumulation of immune 
complexes. Examples include systemic lupus erythematosus (SLE) and 
Rheumatoid arthritis (Table 1.3).   
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Disease Organ/Tissue 
Rheumatoid arthritis (RA) and 
Juvenile RA (JRA) 
(joints; less commonly 
lung, skin 
Lupus [Systemic Lupus 
Erythematosus] 
(skin, joints, kidneys, 
heart, brain, red blood 
cells, other) 
Scleroderma  (skin, intestine, less 
commonly lung) 
Goodpasture's syndrome  (lungs, kidneys) 
Wegener's granulomatosis (blood vessels, sinuses, 
lungs, kidneys) 
Polymyalgia Rheumatica  (large muscle groups) 
Guillain-Barre syndrome  (nervous system) 
 
Table 1.3: Systemic Autoimmune Diseases: Table shows the organs and 
tissues affected by specific autoimmune disease where there is a generalized 
defect involving T as well as B cells. 
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1.26. ELEMENTS OF THE IMMUNE RESPONSE 
Functional or structural damage to self-cellular components caused by the 
immune system is not fully understood. The immune system can suddenly target 
its own cells tissues and organs for destruction, generally known as 
autoimmunity. Most of the distinct types of autoimmune diseases are rare, but 
collectively autoimmune diseases affect millions of individuals throughout the 
world. Tolerance to self may be broken because normally occurring autoimmunity 
is not controlled, either centrally due to deficient elimination or lack of functional 
inactivation or inhibition of auto-reactive lymphocytes in the thymus or in the 
periphery (Kroemer and Martinez 1992). However, there is no evidence to 
suggest that the initiating events in the immune response are different whether the 
antigen is to self or non-self.  
 
1.27. INNATE AND ADAPTIVE IMMUNITY 
There are two functionally different types of responses to invading microbes. 
Innate (natural-genetic) responses we are born with and occur to the same extent 
however many times the infectious agent is encountered, whereas acquired 
(adaptive-environmental) responses improve on repeated exposure to a given 
infection. The innate responses use phagocytic cells (neutrophils, monocytes and 
macrophages), cells that release inflammatory mediators (basophils, mast cells 
and eosinophil’s) and natural killer cells. The molecular components include 
complement system, acute phase proteins and cytokines.  
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On the other hand acquired immune responses involve the proliferation of antigen 
specific B and T lymphocytes, which occurs upon specific recognition and 
binding of antigens. Specialized cells, called antigen-presenting cells present the 
antigen to lymphocytes leading to specific responses. Specific recognition and 
binding of antigens is dependent on several cells, the following are the most 
important. 
1.28. LYMPHOCYTES  
Lymphocytes are wholly for the specific immune recognition of pathogens, so 
that they initiate the adaptive immune responses. All lymphocytes are derived 
from bone-marrow stem cells, but T lymphocytes then develop in the thymus, 
while B lymphocytes develop in the bone marrow. Adaptive immune responses 
are generated in the lymph nodes, spleen and mucosa-associated lymphoid tissue. 
These are referred to as secondary lymphoid tissues. In the spleen and lymph 
nodes, the activation of lymphocytes occurs in distinctive B and T cell 
compartments of lymphoid tissue. The mucosa associated lymphoid tissues 
include the tonsils, adenoids and Peyers patches, which defend the mucosal 
surfaces. Diffuse collections of lymphoid cells are also present throughout the 
lung and the lamina propria of the intestinal wall  (Peter and Roitt 2000). 
1.29. B CELLS 
Each B cell is genetically programmed to encode a surface receptor specific for a 
particular antigen. Immunoglobulins (Ig) and T cell receptors (TCR) are two types 
of proteins produced by B cells. Having recognised its specific antigen, the B 
cells multiply and differentiate into plasma cells, which produce large amounts of 
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the receptor molecules in a soluble form which can be secreted, termed as 
antibody. B cells are essentially little antibody factories, able to switch on high-
rate synthesis and secretion of antibody molecules when stimulated by recognition 
of the "appropriate" antigen.  
Recognition and response in B cells are perfectly co-ordinated, because their 
surface antigen-receptor is the same antibody as they will secrete when stimulated 
by a specific antigen. Thus only specific antibody molecules are made which can 
bind to the stimulating antigen and help in its disposal, and thereby production of 
unwanted antibodies is avoided. It is the formation of plasma antibody that forms 
the foundation of the so called humoral immune response. 
 
1.30. ANTIBODIES 
Structural differences between immunoglobulins are used for their classification. 
The type of heavy chain an immunoglobulin possesses determines the 
immunoglobulin "isotype". More specifically, an isotype is determined by the 
primary sequence of amino acids in the constant region of the heavy chain, which 
in turn determines the three-dimensional structure of the molecule. Since 
immunoglobulins are proteins, they can also act as an antigen, thereby eliciting an 
immune response that generates anti-immunoglobulin antibodies. However, the 
structural (three-dimensional) features that define isotypes are not immunogenic 
in an animal of the same species, since they are not seen as "foreign". For 
example, the five human isotypes, IgA, IgD, IgG, IgE and IgM are found in all 
humans and as a result, injection of human IgG into another human would not 
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generate antibodies directed against the structural features (determinants) that 
define the IgG isotype. However, injection of human IgG into a rabbit would 
generate antibodies directed against those same structural features.  
 
 
 
Figure 1.3: Schematic structure of IgG (which exists as a single major subclass) 
The heavy chain (H) and light (L) chains are composed of variable (V) and 
constant (C) domains and are linked by inter and intra chain disulphide bonds. 
IgM is a pentamer and IgA a dimer. 
 
 
IgG has the general formula of gamma2 kappa2  or gamma2  lambda2 which 
denotes that one molecule of IgG is composed of two gamma heavy chains and 
two light chains of either type kappa or type lambda (Figure 1.3). The structure of 
the IgG molecule has been determined in part by proteolytic digestions and 
reductive dissociation of the molecule.  
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The four IgG subclasses (IgG1, IgG2, IgG3 and IgG4) occur in humans in 
different proportions ranging from 66%, 23%, 7% and 4% respectively and have 
different properties as shown in table 1.4 (Meulenbroek 2008). The glycoprotein 
immunoglobulin G (IgG) is a major effector molecule of the humoral immune 
response in man, accounting for about 75% of the total immunoglobulins in 
plasma of healthy individuals. The immunoglobulins of the other four classes, 
IgM, IgA, IgD and IgE each of which has characteristic properties and functions, 
constituting the other 25% of the immunoglobulins (Spiegelberg 1974). 
Antibodies of the IgG class express their predominant activity during a secondary 
antibody response. Thus the appearance of specific IgG antibodies generally 
corresponds with the maturation of the antibody response, which is switched on 
upon repeated exposure to an antigen. In comparison to antibodies of the IgM 
class, IgG antibodies have a relatively high affinity and persist in the circulation 
for a long time. During an antibody response the isotype and subclass of 
antibodies can be shifted without changing the specificity. The dominance of IgM 
in the beginning of an antibody response is switched after re-exposure to the 
antigen and switched into other classes of antibodies, for example IgG in serum.  
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 IgG1 IgG2 IgG3 IgG4 
Adult serum levels (g/L) 4.9-11.4 1.5-6.4 0.11-0.85 0.03-2.0 
1-6 months 1.8-7.0 0.4-2.1 0.2-0.80 <0.1-0.3 
6-12 months 2.0-7.7 0.3-2.3 0.2-1.0 <0.1-0.4 
Half life (days) 21 21 7 21 
Antibody response to proteins ++ +/- ++ +/- 
Antibody response to 
polysaccharides 
+ ++ _ _ 
Antibody response to 
allergens 
+ _ _ ++ 
Binding to Protein A 
sepharose 
++ ++ _ ++ 
     
Table 1.4  Modified from Meulenbroek 2000 
 
1.31. IMMUNOGLOBULIN PRODUCTION  
The production of immunoglobulins by B-cells or plasma cells occurs in different 
stages,polypeptide chains of immunoglobulins are encoded by three non-linked 
clusters of autosomal genes, one cluster coding for the heavy chains of all classes 
and subclasses, a second one for kappa light chains and a third one for lambda 
light chains. These three gene clusters are called, the H, κ and λ gene families 
respectively. In Humans the H gene family is on chromosome 14, the κ  gene on 
chromosome 2 and the λ gene family on chromosome 22.  
Each B-cell can make only one heavy chain and one light chain, although the 
isotype of the heavy chain may change. Initially, a mature B-cell will produce 
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primarily IgD (and some membrane IgM) that will migrate to the cell surface to 
act as the antigen receptor. Upon stimulation by antigen, the B-cell will 
differentiate into a plasma cell expressing large amounts of secreted IgM. Some 
cells will undergo a "class switch" during which rearrangement of the DNA 
occurs, encoding the IgG, IgE or IgA. Upon secondary induction (i.e. the 
secondary response), these B-cells will differentiate into plasma cells expressing 
the new isotype. Most commonly, this results in a switch from IgM (primary 
response) to IgG (secondary response). The factors that lead to production of IgE 
or IgA instead of IgG are not well understood. 
  
1.32. ROLE OF AUTOANTIBODIES IN DIABETES 
Autoantibodies to islet cell antigens can be detected many months or even years 
before the diagnosis of clinical diabetes (Verge et al.,1996), and can appear early 
in infancy or at any age,  Insulin autoantibodies (IAA) appearing early in children 
but not exclusively (Yu et al. 1996),(Kimpimaki 2001)  with a broader antibody 
pattern in adults. The detection of a low titre single autoantibody positivity may 
represent a perfectly normal background activity, whereas presence of high titre 
multiple autoantibodies reflect aggressive beta-cell damage and a rapid 
progression to overt clinical disease (Kulmala et al.,2001), (LaGasse et al., 2002). 
Autoantibodies to islet antigens, are not thought to be directly involved in the 
destructive process as reported previously reported by (Martin et al., 2001) 
showing that a B cell deficient patient developed diabetes indicating that B cells 
are themselves not required for disease development (Martin et al., 2001). 
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Autoantibodies are predictive in high risk patients as well as in the general 
population, where positivity to multiple islet autoantigens confers the highest risk 
(Bingley et al. 1994; Bingley et al. 1997; Verge et al. 1998; Kulmala et al. 2001; 
LaGasse et al. 2002). The Islet Cell Antibody (ICA) assay has largely been 
replaced with autoantibodies to Glutamic acid decarboxylase (GADA) 
(Baekkeskov et al. 1990), tyrosine phosphatase like protein antigen (IA2A) (Lan 
et al. 1996) and more recently ZnT8A (Wenzlau et al. 2007). 
1.33. ISLET CELL ANTIGEN (ICA) 
Islet cell antibodies (ICA), recognizing islet cytoplasmic antigens, were first 
described in newly diagnosed T1D patients (Bottazzo et al. 1974) and comprise a 
number of autoantigens including GADA and IA2A. The presence of organ-
specific pancreatic antibodies provided the first evidence for T1D as an 
autoimmune disease Bottazzo et al. 1974; MacCuish et al. 1974). Insulin 
autoantibodies (IAA) however are not recognized in the ICA test, because insulin 
and c-peptide leach out from the unfixed frozen tissue sections during sample 
preparation. The ICA assay however is difficult to standardize and highly 
dependent on the operators expertise including, the availability of sufficient 
antigen in the sections employed. Increasingly, studies use antigen specific 
autoantibody assays and that is what we have done.  
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1.34. GLUTAMIC ACID DECARBOXYLASE (GAD65) 
The enzyme Glutamic acid decarboxylase, catalyzes, the conversion of L-
glutamine into γ-amino butyric acid (GABA), the major inhibitory 
neurotransmitter in the brain. Key experiments carried out by Baekkeskov et al, 
(Baekkeskov et al.,1990) reported from detergent lysates of biosynthetically 
labelled human islet cells that the 64 kDa protein was GAD65 which is also 
expressed at lower concentrations in the pancreatic islets of Langerhans (Christie 
et al. 1992). 
There are two isoforms of GAD, GAD65 and GAD67, with molecular masses of 
65kDa and 67kDa (Bu et al. 1992). Human pancreatic islet cells only express the 
lower molecular weight GAD65 isoform (Hagopian et al. 1993), an intracellular 
membrane anchored protein consisting of 585 amino acids and the GAD65 gene 
located on chromosome 10p11 (Bu et al. 1992). Autoantibodies in T1D 
predominantly recognize the 65 kDa isoform of GAD where as patients with Stiff 
Person syndrome (SPS) can react with both isoforms, the latter recognizing both 
linear as well as conformational epitopes and the former recognizing 
conformational epitopes. Enzymatic methods employed earlier recognized 
conformational epitopes and patients with SPS recognized both GAD65 and 
GAD67 from brain extracts. Most GADA methods measure the ability of sera to 
immunoprecipitate GAD. They have been applied as enzymatic assays, 
radiobinding assays (RBA), liquid immunoprecipition assays and enzymes-linked 
immunosorbent assays (ELISA). Historically RBA have provided stronger 
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specificity as well as sensitivity in the Diabetes Antibody Standardization 
Programme (DASP) than ELISA, latest ELISA participation in DASP have 
performed equally as well as RBA assays.  
At diagnosis, approximately 50-80% of newly diagnosed type 1 diabetic patients 
can have GADA antibodies (Bonifacio et al.) and often persists in sera for many 
years after the diagnosis (Savola et al. 1998). GADA can also be detected in 
patients with SPS (Levy et al. 1999), where we found approximately 80% of the 
patients have GADA, with a broad GADA isotype profile (Lohmann et al) 
1.35. TYROSINE PHOSPHATASE LIKE MOLECULES 
One of the proteins comprising the islet cell antigens is a transmembrane tyrosine 
phosphatase like molecule insulinoma-associate antigen- 2 (IA2) comprising of 
979 amino acids with a molecular mass of 105847 (Lan et al.,1994). The molecule 
consists of an intracellular, transmembrane amino acids 605-979 and an 
extracellular domain with a signal peptide, found in neuroendocrine cells as well 
as the pancreas. Trypsin treatment of tyrosine phosphatase like molecule IA2 
yield a 37 and a 40kD fragment which are immunoreactive with sera from 
diabetic individuals (Christie et al., 1994), (Lu et al., 1996), (Payton et al.,1995). 
Autoantibodies to the islet cell antigens comprise of GAD65 as well as IA2 and 
can be detected many months before diagnosis of T1D and we and other have 
found are highly predictive of the disease (Atkinson and Maclaren., 1994), 
(Bonifacio et al.,1990), (Christie et al., 1992).  
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1.36. INSULIN AND INSULIN AUTOANTIBODIES (IAA) 
Insulin is a major autoantigen central to glucose control in regulating energy as 
well as glucose metabolism. Insulin is secreted from the β cells in the pancreas 
which comprise 70% of the pancreatic islets. Insulin is a polypeptide comprising 
of 51 amino acids, with a molecular mass of 5808 Da, comprised of the A and B 
chains of 21 and 30 amino acids held together by disulphide bridges. Insulin is 
synthesized in the insulin secretory granules as pre-proinsulin and cleaved to 
release C-peptide and insulin. Insulin autoantibodies (IAA) were first described in 
untreated diabetic patients (Palmer et al., 1983). Insulin autoantibodies are 
frequently detected in children and are correlated inversely with age at diagnosis 
and are less prevalent in subjects diagnosed in adulthood (Zeigler et al., 1999). In 
another study of twins discordant for diabetes IAA were less frequent in the non-
diabetic twins suggesting that IAA do not appear before development of TID and 
furthermore are not a consequence of the disease; using, an ELISA assay (Wilkin 
et al., 1985) The original IAA assays using polyethylene glycol (PEG) in 
conjunction with 
125
I labeled insulin and ELISA assays have been vastly 
improved by the incorporation of the use of immunoprecipitation using Protein A 
Sepharose with 
125
I labeled insulin in  the microassay system (Williams et al., 
1997). Despite this difficulties still remain in the standardization of the micro-
assay. Furthermore IAA are, most frequently detected in childhood but less 
frequent in adulthood in whom diabetes is reported to be increasing at an alarming 
rate worldwide. As an autoantigen IAA are a valuable marker in children at risk 
of autoimmune diabetes but less so in adults. In this report we elected not to test 
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for IAA due to difficulty in assay reproducibility as well as the lower frequency of 
these antibodies in adult cases with autoimmune T1D. 
 
1.37. ZINC TRANSPORTER ANTIGEN (Slc30A8) 
ZnT8 is a multispanning transmembrane protein involved in the accumulation of 
zinc in the intracellular vesicles. It is expressed at high levels in the pancreatic 
islets (Chimienti et al.,2006). Zinc itself plays an important role in the pancreatic 
beta cells where its content is the highest incorporating two zinc molecules with 
six insulin molecules to form hexamers. Approximately 60% of newly diagnosed 
type 1 diabetic patients are found to be positive to ZnT8 while less than 2% of 
healthy controls tested positive for ZnT8 (Wenzlau et al., 2007). 
Autoantibodies to beta cell antigens GADA, IA2A, IAA and ZnT8 are now 
extensively used in the prediction as well as a diagnostic tool. The risk of 
developing T1D is substantially increased in the first degree relative of T1D 
patients in comparison to the general population (risk general population 0.5%). 
The risk of developing TID can be stratified from <1% up to >70% by using 
various combination of risk markers (Zeigler & Nepom. 2010) including younger 
age, decreased first phase insulin response, presence of multiple autoantibodies, 
“the greater the combination the greater the risk” as originally described (Christie 
et al., 1992). 
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 1.38 T CELLS  
Resting T cell look very much like resting B cells, but when they respond the 
difference becomes apparent. T cells have no specificity towards particular 
antigens. There are several different types of T cells, which have a variety of 
actions. One group interacts with B cells and help them to divide, differentiate 
and make antibody. Another group interacts with mononuclear phagocytes and 
help them destroy intracellular pathogens. These two groups of cells are called T-
helper (TH1, TH2) cells which carries CD4 marker and mainly helps or induces 
immune responses (Mosmann et al. 1996). A third group of T cells is responsible 
for the destruction of host cells which have become infected by viruses or other 
intracellular pathogens, this kind of action is called cytotoxicity and these T cells 
carry the CD8 marker and are predominantly cytotoxic cells. CD4
+
 T cells 
recognise molecules in association with MHC class II molecules, whereas CD8
+
 T 
cells recognise antigens in association with MHC class I. CD8 positive cells 
differentiate into cytotoxic T cells that kill the infected target cells, while the CD4 
positive subset of T cells help to initiate the immune response. The latter can be 
further subdivided into T helper class 1 and class 2 cells (Th1 and Th2). The Th1 
cells stimulate macrophages to stimulate the production of IgG1 antibody isotypes 
that are effective in opsonising pathogens by phagocytic cells. The Th2 cells on 
the other hand initiate an immune response by stimulating naïve B cells to 
produce antibodies and can also subsequently initiate the production of other 
antibody isotypes, including IgA and IgE including subtypes of IgG (Peter and 
Roitt., 2000). 
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Although T cells have similar genetic mechanism as B cells for the generation of 
T cell receptor (TCR) diversity, they differ in that they react only with antigen 
bound to class I or class II molecules of the MHC on antigen-presenting cells. The 
T cell receptor has similarities to the antibody molecule, but with important 
differences. The T cell receptor can be thought of as a hand reaching out to feel 
the surface of neighbouring cells, with some fingers devoted to contacting MHC 
molecules and others probing for peptide bound to them.  
 
1.39 MAJOR HISTOCOMPATIBILITY COMPLEX  
The major histocompatibility complex (MHC), a cluster of more than a dozen 
genes, whose products are expressed on a variety of cells, which act as "guidance 
systems" and enable T cells to recognise antigens on cell surface (Klein & Sato, 
1998). The MHC molecules are part of the immunoglobulin "supergene" family 
and appear to have evolved from the same primordial gene as immunoglobulin 
and T cell receptor molecules. Human MHC, is also known as the human 
leukocyte antigen (HLA) system which is located on chromosome 6 and on 
chromosome 17 in mouse extending over the same region of the DNA molecule. 
The function of the MHC molecules is to bind to pathogen derived peptide 
fragments subsequently presented to T-cells leading to the destruction of the 
pathogen. The nomenclature reflects the way in which these molecules were 
characterised, i.e. as antigens that allowed alloantibodies to bind and destroy 
leukocytes. Thus, although they are known as antigens, they are only recognised 
as such when exposed to non-self immune system. Furthermore because these 
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antigens are expressed on human leucocytes, the alloantigens became known as 
human leucocyte antigens (HLA's). 
 
1.391. MHC MOLECULES 
Three classes of molecules have been identified as encoded within the human 
MHC namely Class 1,11 and 111 respectively. Class 1 proteins are the 
transplantation antigens and are present on every cell of the mammal and are 
responsible for rejection of foreign tissue. Class 1 proteins are defined 
serologically by their antigenic properties and in humans the classical 
transplantation antigens are HLA-A, B and C. Class 11 proteins are found on the 
surface of both B and T lymphocytes as well as macrophages. These proteins are 
involved in the cellular interaction necessary to execute an immune response. 
The MHC is polygenic and there are several MHC class I and class II genes, 
encoding proteins with different ranges of peptides-binding specificity. The MHC 
genes are, in fact, the most polymorphic genes known. These properties of the 
MHC, polygeny and polymorphism, make it difficult for pathogens to evade 
immune responses (Piertney & Oliver, 2005). 
At least three properties of MHC molecules are affected by MHC polymorphism: 
the range of peptides bound; the conformation of the bound peptide; and the 
interaction of the MHC molecule directly with the TCR. Thus the highly 
polymorphic nature of the MHC has functional consequences, and the 
evolutionary selection for this polymorphism suggests that it is critical to the role 
of the MHC molecules in the immune response. 
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The association of the MHC with T1D has been known for more than 20 years 
(Nerup J., 1974) (Thorsby & Undlein.,1996), (She., 1996). Experiments with the 
NOD mouse, in the BB rat model of TID and in humans have led to the current, 
widely accepted conclusion that it is the MHC HLA class 11 immune response 
genes themselves, are the major determinants of MHC-associated susceptibility 
to, and protection from, T1D. Lack of the charged amino acid at position 57 of the 
class II β chain is the principle genetic susceptibility component, conversely the 
presence of a charged amino acid is associated with protection from T1D (Wicker 
et al., 1995), (Morel et al,. 1988). It is also generally accepted that the association 
of MHC molecules with autoimmune disease is due to the fact that the 
polymorphic amino acids in their peptide binding sites govern the affinity of 
peptide binding and therefore the capacity of an individual to mount an immune 
response to an antigen, whether it be a foreign or self-antigen (Tisch & McDevitt, 
1996). Although there are serious gaps in our understanding, we can conclude that 
a necessary, but not sufficient, step in the development of beta cell destruction is 
the recognition by T lymphocytes of one or more  cell proteins bound to the 
MHC class 11 molecules. The HLA region has the highest genetic association as 
discussed earlier under the threshold hypothesis, after FOXP3 and AIRE. The 
HLA accounts for the major genetic risk component in children and young adults. 
A number of non MHC loci also contribute to the disease risk for TID but have a 
lesser impact and include PTPN22, (variations in this gene leads to increased 
autoimmune attack), the polymorphic cytotoxic CTLA4 gene on chromosome 
2q33 (Nistico et al., 1996) (a member of the immunoglobulin superfamily 
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expressed on T helper cells and mutations in this gene have been associated with 
autoimmune disease including T1D, Graves' disease, Hashimoto's thyroiditis, 
celiac disease, systemic lupus erythematosus). The HLA class 11 genes on 
chromosome 6p21 accounts for 30%-50% of TID genetic risk (Noble et al., 
1996). Other non HLA TID loci with a relatively smaller effect include the insulin 
gene (INS) on chromosome 11p15 (Bell et al., 1984), the protein tyrosine 
phosphatase PTPN22 gene on chromosome Ip13 (Bottini et al.,2004), the 
interleukin 2 receptor, alpha (IL2RA) and interferon induces helicase C domain 1 
(IFIH1) genes as well as other genes discovered with genome-wide association 
studies (GWAS).  
One study has shown that the high risk genotype DQ2/DQ8 was infrequent in 
LADA compared to juvenile onset T1D (Tuomi et al., 1999), thus the genetic load 
in LADA is less than that seen in juvenile onset TID but similar to that seen in 
adult onset diabetes (Tuomi et al., 1999). The genetic impact and load in 
childhood and adults can show differences for example the INS gene associated 
with TID is not associated with T2D, whereas other genes (IDE/HHEX, 
SLC30A8, CDKAL1, CDKN2A/B, IGF2BP2, FTO, and TCF7L2 associated with 
type 2 diabetes are not associated with T1D. Furthermore TCF7L2 associated 
with type 2 diabetes is also associated with LADA. So it can be implied that the 
latter are a distinct group of patients with a decreased genetic load as well as 
autoimmune features similar to T1D with presence of autoantibodies. 
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1.40. PATHOGENESIS AND NATURAL HISTORY OF AUTOIMMUNE DIABETES 
T1D is believed to be a T-cell mediated autoimmune disease in which insulin 
producing  cells of the pancreatic islets of the Langerhans are destroyed. The 
most widely used animal model of autoimmune diabetes, the non-obese diabetic 
mouse (NOD) (Delowitch & Singh 1997), is one of the rare spontaneous models 
of the disease that allows us to study the kinetics of the events during prediabetes, 
particularly in the pancreas. In spite of extensive investigation, the etiology of the 
autoimmune attack in NOD mice and human patients with TID is still unknown. 
Many distinction between the two have led to dissatisfaction with the NOD mouse 
and it will not be discussed further here (Atkinson & Leiter 1999). 
 
1.41. AUTOIMMUNE DIABETES AND GENDER 
The susceptibility to autoimmune disease is a characteristic feature and it has been 
estimated that up to 6.7.million women in the United States are affected with 
autoimmune disease compared to 1.8 million men. Autoimmune diseases 
including hyperthyroidism, rheumatoid arthritis, thyroiditis, T1D, pernicious 
anaemia and multiple sclerosis account for 93% of the total (Jacobson et al., 
1997). The overall sex ratio for T1D is reported to be equal in children diagnosed 
under the age of 15 with an absence of a male sex bias (Dorman et al., 1994), 
(Beeson 1994)(Table1.4).  However, the evidence in patients with T1D diagnosed 
at a later age is less clear because there are few large studies of these patients 
(Gale & Gillespie., 2001). Of the few studies of middle-aged patients with LADA 
the gender ratio is generally not biased , that is the percentage of women in China 
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LADA ( 38% )(unpublished data personal communication RD Leslie), CARDS ( 
38% ) (unpublished data), NIRAD (38%)(Buzzetti et al., 2007)   and 4-12% 
(Zinman et al., 2004).  The relevance of these gender biases is that autoimmune 
diseases are seen to have a female bias and tend to present in middle-age. A 
glance at the Table 1.5 confirms that female bias and age effect, with the 
exception of T1D which is predominantly childhood-onset with minimal male 
excess.  An important theme of this thesis is then to what extent T1D is an 
exception to the general gender and age.  
 
Condition Peak onset (years) % Females 
T1D 2-15 45% 
Multiple Sclerosis 20-35 60% 
Rheumatoid Arthritis 20-40 65% 
Hashimotos 
Thyroiditis 
30-50 85% 
Thyrotoxicosis 30-50 85% 
Pernicious anaemia 40-80 60% 
 
Table 1.5 Gender and Autoimmune disease  
TID shows a similar prevalence up to the age of 15 with a male preponderance 
thereafter, unlike other autoimmune diseases where a female preponderance has 
been reported Data from Beeson. (Beeson 1994) 
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A number of factors have been implicated in the cause of TID, however, 
conclusive evidence for an environmental agent in the cause of TID is still 
lacking. Since only a few genomic susceptibility regions have been found, no 
environmental agents conclusively identified, and the high rate of disease 
discordance in MZ twins persists, the penetrance of T1D may, in part, be 
influenced by epigenetic factors modifying DNA such that genes are either 
switched on or off such that a particular phenotype is either expressed or 
repressed respectively. 
 
1.42. EPIGENETICS 
Epigenetic modifications, namely DNA methylation and histone modifications, 
influence gene expression by altering the chromatin state and are indispensable 
for maintaining cellular homeostasis (Bird 2002). The features of DNA 
methylation in mammals are that it occurs on cytosine bases that are immediately 
followed by a guanine (commonly referred to as CpG sites). Examples of 
epigenetic phenomena in mammals include X-inactivation (the transcriptional 
silencing of
 
most of the genes on one X-chromosome in female mammals) and 
parental imprinting (differential expression of an allele depending on whether it 
was maternally or paternally inherited). Not surprisingly, alterations of the 
epigenetic profile of the genome are associated with various human diseases, such 
as cancer.  
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1.41. EPIGENETICS AND VARIABLE EXPRESSIVITY  
Relevant to the hypothesis that epigenetic factors play a role in T1DM aetiology 
are studies in mice that have shown that the establishment of epigenetic states at 
some endogenous loci during early development can be stochastic, resulting in 
incomplete penetrance or variable expressivity of a phenotype among genetically 
identical mice reared in controlled environments (Morgan et al., 1999), (Rakyan 
et al., 2003). An example, in mice carrying the agouti viable yellow (A
vy
) allele, 
methylation upstream of this allele prevents ectopic expression of the gene, 
resulting in a normal colour coat and normal metabolic phenotype. However when 
the allele is un-methylated, the resulting phenotype is yellow in colour coat and 
development of type 2 diabetes. Crucially, this variability of phenotype resulting 
from an epigenetic change occurs in the absence of genetic variability or any 
identifiable environmental factors.  
Epigenetic variability or epimutations correlating with disease phenotypes, has 
been observed in humans, e.g. in a recent study of MZ twins discordant for 
Beckwith-Weidemann Syndrome, only the affected twin had lost epigenetic 
imprinting within a critical area on chromosome 11 (Weksberg et al., 2002). 
Considering the high degree of discordance for T1D between MZ twins, it is 
worth considering the possibility that epimutations influence the susceptibility to 
T1D. In support of an epigenetic component in the aetiology of T1D, parent-of-
origin effects (consistent with parental imprinting) have been associated with 
T1D. It has been noted that there is an increased risk of T1D in offspring when 
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the parent with T1D is a father compared to a mother, (Warram et al., 1984), 
(Bleich et al., 1993), (Bennet et al., 1997) reported that a particular insulin gene 
allele (that was previously reported to predispose to T1D) does not predispose to 
disease when paternally inherited, and this effect is influenced by the identity of 
the father's untransmitted allele.  
Interestingly, procainamide and hydralazine, used to treat cardiac arrhythmias and 
hypertension respectively, are both DNA methylation inhibitors that can induce a 
lupus-like disease in humans and T-cell autoreactivity leading to a lupus-like 
autoimmune disease in animal models (Richardson et al., 2004).  
There is strong evidence that DNA methylation profiles change with age (Issa 
2003). It is therefore possible that accrual of epigenetic variants during ageing in 
MZ twins, along with environmental insults may precipitate T1D in one twin but 
not the other, and such differences could account for the relatively greater impact 
of non-genetically determined factors causing adult-onset T1D as compared with 
childhood-onset T1D (Salvetti et al.,2000), (Kumar et al., 1993), (Vyse & Todd 
1996). Indeed, it has very recently been demonstrated that epigenetic differences 
can arise during the lifetime of MZ twins (Fraga et al., 2005).  
A recent study has shown that T1D–Methylation Variable Position’s (MVPs) 
represent disease associated epigenetic variation that antedates clinical disease. 
This study noted several MVP–TID associated genes including the HLA class 11 
gene, HLA DQB1 which poses the highest risk for TID, RFXAP, an HLA class II 
regulating element, NFKB1A, a regulator of apoptosis and inflammatory immune 
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responses, TNF, a key inflammatory cytokine associated with T1D in animal 
models, and GAD2 which encodes GAD65, a major T1D autoantigen involved in 
disease etiology (Vardhman et al., 2011). 
These findings including genetic, epigenetic as well as environmental factors 
alone cannot fully account for the differences in the concordance rates between 
twins discordant for TID however the interaction of these various factors may 
have an impact on the disease penetrance. 
1.44. Clinical Spectrum of Autoimmune diabetes 
The World Health Organization recognizes three main forms of diabetes mellitus: 
type 1, type 2, and gestational diabetes (WHO 1999) , which have, similar signs, 
symptoms, and consequences, but different causes and population distributions. 
The prevalence of affected adults with diabetes according to the WHO has 
increased from 1994-1995 in 100-135 million to approximately 246 million in 
2007, with more than 95% of the cases considered to be type 2 diabetes.  
Observations of prevalence (T1D and type 2 diabetes) from Germany has shown, 
a ten fold increase from 0.6% in 1960 to 6.9% in 2005 (Kolb & Poulsen 2010). 
This rapid increase cannot be attributed to genetic causes but rather to lifestyle as 
well as environmental factors including excessive calorie intake, sedentary 
lifestyle all promoting to the increased inflammatory state as well as obesity. 
Glucose intolerance of ageing is another additive factor in the increased 
prevalence   
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Ultimately, all forms are due to the beta cells of the pancreas being unable to 
produce sufficient insulin to prevent hyperglycemia. T1D is characterized by 
genetically determined predisposition, presence of autoimmune markers, 
aggressive beta-cell destruction, severe insulin deficiency and an immediate need 
for insulin replacement therapy. The destruction of beta cells leads to insulin 
deficiency and secondarily to abnormalities in carbohydrate, fat and protein 
metabolism. Polyuria, polydipsia and weight loss are classical symptoms of 
insulin deficiency, which if left untreated leads to life-threatening keto-acidosis 
wasting away and mortality. Patients are dependent on exogenous insulin for the 
rest of their lives, and even with good care they carry an increased risk of long-
term complications such as retinopathy, nephropathy, neuropathy and 
cardiovascular diseases.  
1.45. IMMUNOLOGICAL SPECTRUM OF AUTOIMMUNE DIABETES 
T1D can occur at any age and is most often seen in children, adolescents and 
young adults, characterized by T-cell mediated pancreatic islet cell destruction 
and loss of beta cell function. On the other hand classic type 2 diabetes is 
characterized with insufficient insulin secretion and peripheral insulin resistance 
without showing autoimmune features (Alberti & Zimmet 1998), (Naik & Palmer 
1997). Despite these characteristic criteria the distinction between type 1 and type 
2 diabetes is not always clear. The clinical evidence identifies a significant 
overlap between type 1 and type 2 diabetes. In the latter group a further 
distinction is made in adults presenting with T1D with immediate insulin 
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requirement soon after diagnosis and Latent Autoimmune Diabetes of Adult onset 
remaining free of insulin for at least six months post diagnosis. 
The discovery of Islet Cell antibodies (ICA) in 1974 in the sera of T1D provided 
the initial evidence that T1D was autoimmune in nature (Bottazzo et al., 1974).  
Clinical onset of T1D is usually preceded with the appearance of insulin 
autoantibodies in particular in the very young. Islet cell antibodies are routinely 
detected by indirect immunofluorescence technique using group O cryofixed 
human pancreas although a sensitive assay, it is prone to variability due to the 
antigenic diversity of the pancreatic substrate as well as the operator experience. 
The specific antigens that comprise ICA include GAD65, IA2, ZnT8 as well as 
other antigens, up to 80% of newly diagnosed type 1 diabetics show presence of 
ICA (Irvine et al., 1977) a highly sensitive assay with one caveat difficulty in 
standardization of the ICA assay.  
Subsequently the second key diabetes auto-antigen Glutamic Acid Decarboxlylase 
GAD65 was identified, followed by IA2 and Zinc Transporter antigen (ZnT8), 
each adding to the positive predictive value of these auto-antibodies. The ICA 
assay has now largely been replaced with assays for the auto-antigens GAD65, 
IA2 and more recently ZnT8 (Baekkeskov et al., 1990), (Christie et al., 1992), 
(Payton et al., 1995), Wenzlau et al., 2007).  
The presence of T cell reactivity as well as autoantibodies provides  evidence for 
underlying autoimmune process in T1D as well as LADA. It has been 
demonstrated previously that about 11% of subjects with type 2 diabetes were 
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also positive for ICA’s (Irvine et al., 1977). Since ICA are comprised of a number 
of antigens it has become evident that testing of autoantibodies to GADA and IA2 
clearly identifies the majority of ICA positive individuals and therefore by 
definition the presence of autoantibodies distinguishes patients with classic 
autoimmune T1D from non-autoimmune diabetes as well as LADA (Fourlanos et 
al., 2005).  
This thesis will focus on immunological features in T1D of adult onset, its 
prevalence and spectrum of severity which does not overlap with type 2 diabetes 
as well as provide evidence that TID is non-genetically determined in identical 
twins. 
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1.46. SPECIFIC AIMS 
1. Whether autoantibodies and Carboxy Methyl lysine (CML) are genetically 
determined and independently predictive of T1D.  
2. Whether autoantibodies, insulin secretion and insulin resistance are 
predictive and are genetically determined. 
3. Whether autoantibody isotype pattern in TID and LADA are similar 
4. Whether autoantibodies in adults presenting with type 2 diabetes are 
prevalent and similar to T1D and whether Metabolic Syndrome is associated with 
LADA and type 2 diabetes, but not T1D. 
5. Whether autoantibodies to CD38 are of any value as biomarkers in T1D, 
as well as ‘type 2 diabetes’. 
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CHAPTER 2 
2.0. WHETHER AUTOANTIBODIES AND CARBOXY METHYL LYSINE (CML) ARE 
GENETICALLY DETERMINED AND INDEPENDENTLY PREDICTIVE OF T1D. 
 2.1. Aim: Since both autoantibodies and increased CML levels are associated 
with T1D, we tested whether both are genetically or environmentally determined 
and whether they ante date the disease.  
 
2.2. Introduction: Overt clinical diabetes manifests in a genetically susceptible 
individual only after 90% of the pancreatic beta cells have been destroyed leading 
to impaired glucose tolerance followed by frank diabetes. Autoantibodies to 
GADA, IA2A, ZnT8 and IAA all comprise the Islet cell antigens and can be 
detected many months before the diagnosis of TID, a consequence of which 
results in hyperglycaemia. Prolonged hyperglycaemia leads on to complications 
of diabetes associated with the formation of Advanced Glycation End products 
(AGE’s).  
Glycosylation is an enzyme controlled reaction that connects a specific sugar to a 
specific protein or lipid at a specific location which is required for normal 
physiological function of biomolecules. Glycation on the other hand can occur as 
a result of intake from the diet or endogenously via non enzymatic glycation and 
oxidation of lipids and proteins. Advanced Glycation End products are a group of 
heterogenous compounds formed from the non-enzymatic glycation of proteins 
lipid as well as nucleic acids and in the process form highly reactive intermediates 
(Brownlee 1996),(Thomalley 1996). The two most commonly measured AGEs 
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are, Nε-(carboxymethyl) lysine (CML) (a glycoxidation and lipoxydation product) 
and carboxyethyllysine (CEL) (derived from methyl glyoxal formed by protein 
glycoxidation or enzymatic glycolysis with lysine residues), which are 
glycoxidation products, formed from glucose by sequential glycation and 
autoxidation reactions. Glycation itself is a random process resulting from the 
addition of sugar molecules to proteins and lipids without any enzymatic control 
thereby accumulating end products, affecting normal physiological function and 
activity. Carboxymethyl Lysine is formed by a process called the Maillard 
reaction which entails the addition of reduced sugars to amino acids or lipids to 
form glycated products called Amadori products.  
AGEs interact with receptors called RAGE a member of the immunoglobulin 
superfamily found on endothelial cells, smooth muscle cells, immune cells 
macrophages, monocytes as well as dendritic cells. Once formed in sufficient 
quantity the binding of AGEs to RAGE receptors leads to a cascade of reactions 
with the formation of highly reactive oxygen species as well as further formation 
of advanced oxidative protein products, oxidative lipid as well as AGE’s leading 
to a vicious cycle of activation, leading to further activation of the RAGE 
receptors.  Binding of AGE’s to RAGE receptors initiates signal pathways that 
amplify inflammation as well as oxidative stress as a result of the formation of 
reactive oxygen species thereby leading to cellular and tissue damage and death 
(Kislinger et al., 1999).  
It is well known that the levels of AGEs CML and CEL increase as a result of 
normal physiological ageing as well as pathophysiological changes such as 
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diabetes, Rheumatoid Arthritis, Alzheimers and Multiple Sclerosis (Sternberg et 
al.,2010). Altered monocyte/macrophage as well as proinflammatory responses 
have been documented in T1D including increased formation of AGEs which 
mediate inflammation through AGE receptors (RAGE) (Beyan et al., 
2006),(Mericq et al 2010). The levels of CML in the serum is determined by the 
endogenously produced CML which has been shown by our group in a classic 
twin study to be strongly inherited (Leslie et al., 2003), however tissue and serum 
levels of CML are also affected by the exogenous ingestion and absorption of 
dietary sources which have undergone AGEs formation via excessive 
temperatures in cooking process in the dietary intake of resources. Glycotoxins 
are formed via cooking foods quickly at high temperatures, such as browning of 
foods and caramelising of sugars. In the food industry such techniques are 
regularly employed such as the coating of French fries with sugar to enhance the 
appearance of browning when cooked at high temperatures. The exposure to such 
AGEs is increasing at an alarming rate in the developed nations and is of concern 
to the health of the future generations. 
2.31. Patient cohorts: We initially tested a population based cohort of samples 
from Ulm, Germany to test if autoantibodies and CML could predict those at risk. 
We then went on to test twins discordant for diabetes both MZ as well as DZ twin 
pairs and healthy twins, to determine the impact of genetic and non-genetic 
factors on them. School children of European origin (n=7,287) ascertained 
between 1989-2008 in Germany were also included and of these, 115 (51.3% 
female) were ICA positive at ascertainment, The latter group together with a 
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random selection of 2217 subjects were further tested at baseline for GADA, IA2 
and ZnT8 antibodies as well as CML. The school children had multiple samples 
taken and we included the initial and last sample pre-diagnosis of diabetes from 
these 115 cases in the analysis. Population study samples characteristics are 
shown in Table 2.1. All subjects participating in the study gave informed consent 
and the study was approved by Ethical Committee, Ulm. 
 
 
 
 
 
 
Variables T1D (n=33) No T1D (n=82) p-value 
 Mean (SD) Mean (SD)  
Age at inclusion 
(SD), in years 
13.48 (4.07) 14.24 (4.01) n.s. 
Follow-up 
[interquartile 
range], in 
months 
77 [58, 115] 94 [67, 130] n.s. 
Male, n (%) 18 (54.5%) 38 (46.3%) n.s. 
 
Table 2.1 Characteristics of Population Study samples from 115 ICA 
positive children tested for CML Means (SD) are given. 
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2.32. Twin study:  
We also tested a cohort of MZ and DZ twins for serum CML and diabetes-
associated autoantibodies (GADA, IA-2A and ZnT8A) to determine if they 
were genetically determined. The Twins cohort sited at St Bartholomew’s and 
The London Hospital at the Blizzard Institute comprises of a unique collection 
of 367 identical twins pairs which comprise the British Diabetic Twin Study. Of 
369 individuals in which the index twin has diabetes, 69 pairs are discordant for 
T1D and 237 pairs are concordant for diabetes.  Of the concordant twins 103 
pairs were concordant for type 2 diabetes and 134 pairs were concordant for 
T1D. Of the remainder 23 pairs have an index twin with Type 2 diabetes and in 
41 pairs the type of diabetes is uncertain.  We also have 81 pairs of non-
identical twins all of whom to date are discordant for Type 1 DM and 8 pairs of 
non-identical twins discordant for Type 2 diabetes.  
2.33. Twin subjects: 
Twins from United Kingdom (Caucasian) were ascertained, between 1967 to 
2010, with, either T1D or type 2 diabetes were studied, and their type of 
diabetes was determined by standard guidelines (Expert Committee on Diabetes 
1997), cases in which this definition was uncertain were excluded. 
Monozygosity was established in each twin pair as previously described, 
(Olmos et al., 1988). Classification of T1D was based on 1) control of diabetes 
with insulin from time of diagnosis, 2) diabetic ketoacidosis or marked 
ketonuria at time of clinical onset. Twins were followed prospectively until they 
either developed diabetes or remained free of the disease. The twins included in 
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the study met the following criteria: 1) European origin, 2) twin pairs initially 
disease discordant, 3) both twins available for study, 4) neither twin receiving 
drugs other than human insulin, 5) all had normal plasma creatinine, 6) diabetes 
initially excluded in the co-twin by oral glucose tolerance test and random 
whole blood glucose < 7.0 mmol/l. As controls for serum CML, we tested 168 
non-diabetic twins (39 MZ, 45 DZ pairs, mean age 51.3 (SD=14.1), range 21-
73).  
From our collection of twin pairs we identified 32 DZ and 32 MZ pairs 
discordant for T1D of similar age at diagnosis and disease duration at sampling 
(Table 2.2). All subjects gave informed consent and East London Health 
Authority Research Ethics Committee approved the study (Ref 07/Q0604/10).  
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Twin Cohort 
(MZ=monozygotic DZ= 
dizygotic) 
Diabetic Twin Non Diabetic 
Twin 
MZ Number of Twins 32 32 
Male, n (%) 20 (62.5%) 20 (62.5%) 
Age at test (SD) yrs 28.09 (16.41) 28.09 (16.41) 
Duration of follow up yrs 26.9 (11) 26.9 (11) 
Age at diagnosis (SD) yrs 17.1 (12.3) n.a 
Diabetes duration (SD) yrs 11.0 (9.2) n.a 
DZ Twins    
Number of Twins 32 32 
Male, n (%) 13 (40.6%) 12 (37.5%) 
Age at test (SD) yrs 28.00 (18.16) 28.00 (18.16) 
Duration of follow up yrs 19.9 (8.3) 19.8 (8.3) 
Age at diagnosis (SD) yrs 17.53 (14.45) n.a. 
Diabetes duration (SD) yrs 10.47 (8.65) n.a. 
 
Table 2.2: Characteristics of Twins tested for CML 
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2.4. Assays 
2.4. Carboxymethyl-Lysine [CML] assay 
AGE-CML was determined in batched assays from population based samples as 
well as twins samples in a single laboratory (Ulm, Germany) using a competition-
based ELISA assay using Carboxymethyl-Lysine specific monoclonal antibody 
(mouse monoclonal 4G9 (Alteon Inc., New York, NY, USA) as previously  
described (Wagner et al., 2001).
 
CML levels are expressed in ng/ml serum. Assay 
sensitivity was 5 ng CML/ml with intra-assay and inter-assay variability less than 
4% and 5% respectively.  
2.41. Diabetes-associated autoantibody assays: The radioimmunoprecipitation 
assays for the enzyme Glutamic acid Decarboxylase (GAD65) and IA-2ic 
(aminoacids 603-979), the putative intracellular fragment and GAD65, all employ 
in vitro transcription and translation systems (Promega Madison, Wisconsin) 
Human IA-2ic cDNA in the vector pGEM-4Z a gift from Dr Michael Cristie was 
in vitro transcribed and translated. Human islet GAD65 cDNA in the vector pB 
1882 (gift of Dr Thomas Dyrberg, Novo Nordisk, Denmark) was used according 
to the manufacturers instructions (Promega Madison, WI). For all antibody assays 
between 0.8-1.0 µg DNA was transcribed and translated  with SP6 ( IA-2ic) and 
T7 (for GAD65) RNA polymerase enzymes in a TNT coupled rabbit reticulocyte 
lysate system (Promega,Madison,WI) in the presence of 35S methionine (0.8 
mci/ml)(Amersham UK). Incorporated radioactivity was determined by 
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precipitation with 10% trichloroacetic acid and scintillation counting. For the 
immunoprecipitation in each assay 50 µl aliquots of 35S methionine (50,000-
75,000 cpm) labelled antigen were incubated overnight with 2µl serum (final 
dilution 1:25) in tris buffered saline tween. The immunocomplexes were isolated 
by adding 1 mg protein A-Sepharose, and counted on a multiwell Wallac counter.  
The radioimmunoprecipitation assays for the Zinc Transporter antigen ZnT8 
assays employ in vitro transcription and translation systems (Promega Madison, 
WI). ZnT8 cDNA in the vector pCDNA3.1 a gift from Dr John Hutton was in 
vitro transcribed and translated as described (Wenzlau et al., 2007). 
 
2.42. Transformation of Competent Bacterial cells for GAD65, IA2ic and 
ZnT8 
 
2.43. Materials:  
2.431. Competent cells JM109 Cat No L2001 (Promega) made competent by the 
method of Hanahan were purchased ready to use for the transformation and 
insertion of the vector DNA of interest.. Aliquots of the competent cells were 
stored at -70°C until required. 
2.432 Luria Broth Base for the cultivation and growth of bacteria (LB): 
Dissolve 15.5 g/L in distilled deionised water and autoclave for 15 minutes at 
121°C. Allow to cool before use with the addition of the appropriate gene 
resistant antibiotic namely Streptomycin, Ampicillin, Tetracycline, Kanamycin 
and or Chloramphenicol as required. 
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2.433. Luria Base Agar: LB Media is a generic rich media suitable for growing 
many aero tolerant species of bacteria, including E. coli, Bacillus subtilius, 
Staphylococcus auerus or Staphylococcus epidermidis and different yeasts 
including Saccharomyces and Candida species. Many kinds of molds will also 
grow (Aspergillus or Penicillium, for instance). However, the presence of these 
organisms on your plate generally represents contamination, and the plate should 
be discarded. LB agar will not necessarily support the growth of more fastidious 
organisms such as Streptococci, and pH media and conditions are less than ideal 
for culturing species of Lactobacilli from yogurt.  
 
2.434. Preparation of Luria Broth Agar (LBA) 
a. Suspend 35.6 g of Agar (Sigma Aldrich) in 1 L of distilled water in a sterile 
autoclave bottle. Components of LBA are shown in the table 2.3. 
b. Autoclave for 15 minutes at 121 °C. 
c. Allow the sterile agar to cool in a water bath at set at 55°C or until the flask is 
hand cool to hold. Add 5ml Ampicillin to the cooled agar from the stock of 
10mg/ml, to give a final concentration of 50µg/ml.  
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Tryptone (pancreatic digest of casein)  10 g/L 
Yeast extract  5 g/L    
NaCl   5 g/L    
Agar  15 g/L    
  
 
Table 2.3 Components of LB Agar 
 
2.435. Plasmid DNA for the transformation. A plasmid is a small circular piece 
of DNA (about 2,000 to 10,000 base pairs) that contains important genetic 
information for the growth of bacteria. In nature, this information is often a gene 
that encodes a protein that will make the bacteria resistant to an antibiotic. The 
GAD65 cDNA was in the vector PB 1882 and IA2ic in the vector PGEM4Z. Both 
GAD65 vector PB1882 and PGEM-4Z for IA2ic have the Ampicillin resistant 
gene in the plasmid construct.  
2.436. Plastics: Sterile 15 ml conical bottom Falcon tubes (Marathon Lab 
Supplies), Eppendorf tubes (Elkay) and sterile Petri dishes (Marathon Lab 
Supplies). Conical bottom 1.5ml screw cap tubes (Sarstedt UK) Sterile pipette tips 
(Sarstedt UK), 100ml and 50ml  Sorval centrifuge tubes (Sorval UK) 
 
2.437. Transformation Protocol 
a. Remove one vial of competent cells JM109 (Promega).Catalogue No:L2001, 
and thaw on ice and pipette 100µl into a sterile Eppendorf tube.  
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b. Add 10µl of the cDNA either for GAD65 or IA2ic as required. Set one tube as 
a control with no DNA and one tube with control DNA (pGEM-3Z) at a 
concentration of 0.1ng/µl. Mix gently and leave on ice for 10 minutes mixing 
gently every 2 minutes. 
c. Place the tubes in a water bath for 45-50 seconds at 42°C to heat shock the 
competent cells to allow the insertion of the test DNA to be inserted into the 
competent cells. 
d. Return the tubes on ice for a further two minutes. 
e. Add 900µl of ice cold LB Ampicillin medium to each tube and incubate on a 
shaking incubator (Grants shaker incubator) at 37°C for 1 hour. 
f. From the transformed reaction mixture 100µl of a 1:10, 1:100 and neat 
undiluted aliquot is inoculated onto LA Ampicillin plates and spread with a 
spreader after sterilisation in an open flame. The plates are incubated in a 
37°C incubator overnight. 
g. Colonies growing on the plates indicate the insertion of the gene as only those 
plates containing the insert grow in the Ampicillin agar plates, control plates 
should have no colonies growing. Single colonies were picked out and grown 
in a shaking incubator at 37°C for 4 hours in 10ml of LB Ampicillin medium. 
The culture was centrifuged and the pellet of cells reconstituted in 1ml of LB 
Ampicillin media before inoculating the content into an Erlenmeyer Flask 
containing 500ml LB Ampicillin medium and incubated at 37°C overnight. 
h. After the overnight culture the contents were placed into 100ml flasks and 
centrifuged in a Sorvall RC5B centrifuge at 5000 x g for 10 minutes at 22°C. 
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Discard the supernatant and reconstitute the pellet in the cell re-suspension 
solution for the extraction of DNA. 
 
2.438. DNA Extraction Reagents  
Plasmid DNA was extracted using the Plasmid Maxiprep System (Promega 
Catalogue No:A7270) according to the manufacturers instruction.  
Materials supplied with the system contains sufficient reagents and columns for 
10 isolations from 100–500ml of bacterial culture and includes: 
• 150ml Cell Resuspension Solution 
• 150ml Cell Lysis Solution 
• 300ml Neutralization Solution 
• 100ml Wizard® Maxipreps DNA Purification Resin 
• 125ml Column Wash Solution 
• 10 Maxi/Megacolumns with Reservoirs 
10 5ml Syringes 
• 10 0.2μm Syringe Filters 
 
2.439. Laboratory Equipment 
Sorval RC5B centrifuge capable of 1,300–14,000 × g 
New Brunswick shaker incubator 
 isopropanol (at 22–25°C) 
TE buffer 
Filter paper (Whatman® #1,GFA or GFC) 
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2.440. Preparation of column Wash Solution  
Before beginning, the Column Wash Solution (provided) was diluted by adding 
170ml of 95% ethanol to a final volume of 295ml. 
 
2.441. DNA Extraction  Protocol 
1. Pellet 100–500ml of cells by centrifugation at 5,000 × g for 10 minutes in a 
room temperature rotor in a 100ml centrifuge flask. Pour off the supernatant and 
re-suspend the pellet in 15ml of Cell Re-suspension Solution. (To aid re-
suspension, manually disrupt the pellet with a 12-inch applicator stick or by 
pipetting until no clumps are visible. Complete re-suspension is critical for 
optimal yields.) 
2. Add 15ml of Cell Lysis Solution and mix gently but thoroughly by stirring or 
inverting. Do not vortex. Cell lysis is complete when the solution becomes clear 
and viscous (up to 20 minutes). Add 15ml of Neutralization Solution and 
immediately mix by gently inverting the centrifuge bottle several times. 
Centrifuge at 14,000 × g for 15 minutes at 22–25°C in a room temperature rotor. 
3. Transfer the cleared supernatant by filtering it through Miracloth™ 
(Calbiochem Corp. Cat.# 475855), filter paper (Whatman® #1, GFA or GFC) into 
a sterile 50ml falcon tube. 
Measure the supernatant volume, then transfer to a centrifuge bottle. 
4. Add 0.5 volume of room temperature isopropanol and mix by inversion. 
5. Centrifuge at 14,000 × g for 15 minutes at 22–25°C in a room temperature 
rotor. 
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6. Discard the supernatant and resuspend the DNA pellet in 2ml of TE buffer. 
Thoroughly wash the walls of the bottle with TE buffer to recover all of the 
DNA. At this point, the pellet may not be visible. 
 
2.442. Plasmid Purification 
1. Add 10ml of Wizard® Maxipreps DNA Purification Resin to the DNA 
solution from Step 6 above, Swirl to mix. 
Thoroughly mix the Wizard® Maxipreps DNA Purification Resin before 
removing an aliquot. 
2. For each Maxiprep, use one Maxicolumn. Insert the Maxicolumn tip into the 
vacuum manifold port. 
3. Transfer the resin/DNA mix into the Maxicolumn. Apply a vacuum pull the 
resin/DNA mix into the Maxicolumn. 
4. Add 25ml of Column Wash Solution to the Maxicolumn and apply a vacuum to 
draw the solution through the Maxicolumn. 
5. To rinse the resin, add 5ml of 80% ethanol to the Maxicolumn and apply a 
vacuum to draw the ethanol through the Maxicolumn. Allow the vacuum to draw 
for an additional 1 minute. 
6. Place the Maxicolumn in a 50ml screw cap tube (provided by the user). 
Using a centrifuge with a swinging bucket rotor (e.g., Beckman JS-4.3 rotor), 
centrifuge the Maxicolumn at 2,500rpm (1,300 × g) for 5 minutes. 
It is essential that a swinging bucket rotor be used for this step. 
Remove the Maxicolumn and discard both the tube and the liquid. Place 
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the Maxicolumn back on the vacuum manifold. 
7. Dry the resin by applying a vacuum for 5 minutes. Remove the Maxicolumn 
from the vacuum manifold. Place the Maxicolumn in the 
provided Reservoir (50ml screw cap tube). 
8. Add 1.5ml of preheated (65–70°C) nuclease-free water to the Maxicolumn 
and wait 1 minute. Elute the DNA by centrifuging the Maxicolumn/ 
Reservoir at 2,500rpm (1,300 × g) for 5 minutes in a centrifuge with a 
swinging bucket rotor or at 1,300 × g for 5 minutes in a centrifuge with a 
fixed-angle rotor. 
9. A white pellet of resin fines may be present in the final eluate. Whether 
visible or not, it is important to separate the fines from the DNA. Remove 
the plunger from one of the 5ml Syringes and set it aside. 
10. Attach the syringe barrel to the Luer-Lok® extension of a 0.2μm Syringe 
Filter and pipet the eluate into the Syringe Barrel. 
11. Center the Filter over a 15ml plastic tube. Carefully insert the plunger into the 
Syringe Barrel and gently push the liquid into the tube. 
12. Transfer the eluate to a 1.5ml centrifuge tube. Centrifuge the tube at 
14,000 × g for 1 minute. This additional step will remove all resin fines that may 
be present in the final eluate. 
13. Immediately transfer the supernatant to a new micro centrifuge tube. 
Follow these storage recommendations: DNA is stable in water without 
addition of buffer if stored at –20°C or below. DNA is stable at 4°C in TE 
buffer. To store the DNA in TE buffer, add 150μl of 10X TE buffer to the 
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1.5ml of eluted DNA. 
DNA for the autoantigens GAD65 and IA2ic as well as ZnT8 were prepared as 
above and stored at -20°C in 10µl aliquots for use in the in-vitro transcription and 
translations. 
2.443. Determination of the concentration of recovered DNA. 
The concentration of the DNA recovered was determined on a Beckman DU 600 
analyser and the Optical Densities (OD) determined at 260nM and 280nM. A 
typical recovery for GAD65 and IA2ic are shown below. 
 
2.444. GAD65 DNA Concentration 
Optical Density 260nM =0.2118 
Optical Density 280nM =0.1342 
An OD of 1 = 50µg/ml 
Therefore 0.2118 x 50 x 1000µL =1059µg/L 
This is equal to 1.059µg/µL. 
 
2.445. IA2ic DNA Concentration 
Optical Density 260nM =0.1934 
Optical Density 280nM =0.1263 
An OD of 1 = 50µg/ml 
Therefore 0.1934 x 50 x 1000µL =0.967µg/L 
This is equal to 1.0µg/µL. 
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2.446. In Vitro Coupled Transcription and Translation of Recombinant 
Proteins 
The TNT® Coupled Reticulocyte Lysate Systems is an in vitro single-tube, 
coupled transcription/translation system. The TNT® Lysate Systems greatly 
simplify the process and reduce the time required to obtain in vitro translation 
results from transcribed RNA synthesized in vitro from SP6, T3 or T7 RNA 
polymerase promoters. In most cases, the TNT® Lysate reactions produce 
significantly more protein (two- to six fold) in a 1.5-hour reaction than standard in 
vitro rabbit reticulocyte lysate translations using RNA templates. 
 
2.447. Components supplied with the TNT® SP6/T7 Coupled Reticulocyte 
Lysate System.  
• 200μl TNT® Rabbit Reticulocyte Lysate 
• 20μl TNT® Reaction Buffer 
• 20μl TNT® T7 or SP6 RNA Polymerase 
• 5μg Luciferase T7 or SP6 Control DNA, 0.5mg/ml(c) 
• 25μl Amino Acid Mixture, Minus Methionine, 1mM 
 
2.448. Component not supplied: 
Plasmid DNA for GAD65,IA2ic or CD38 
Screw-cap conical bottom 1.5ml tubes 
Water bath at 30°C 
Micro-centrifuge (Haeraeus) 
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35S Methionine (Perkin Elmer) (500µCi stock solution) 
RNAsin inhibitor (Promega) 
All the components were stored at -70°C and multiple freeze thaw of the 
reticulocyte was avoided throughout.  
 
 
 
 
TNT® Rabbit Reticulocyte Lysate  25µl 
TNT® Reaction Buffer     2μl 
TNT® RNA Polymerase (SP6, T3 or T7) 1µl 
Amino Acid Mixture, Minus Methionine, 1mM   1μl 
*[35S]methionine (>1,000Ci/mmol at 10mCi/ml)  4µl 
*Take care when handling Radioactive material  
RNasin® Ribonuclease Inhibitor (40u/μl)    1μl 
DNA template(s) (1.0μg/μl)   1μl 
Nuclease-Free Water to a final volume of 50μl  15μl 
 
Table 2.4 Protocol for the Transcription/Translation of Protein 
For the in-vitro transcription/translation of the protein pipette into a 1.5ml screw 
cap sarstedt tube components as listed in table 2.4. Vortex for 10 seconds and spin 
in a micro-centrifuge for 10 seconds to allow the reaction mixture to be collected 
at the bottom of the tube and incubate in a water bath at 30°C for 90 minutes. 
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2.449. Purification of Translated Protein 
The translated proteins were purified by using the NAP 5 column (GE Healthcare 
Cat No 17-0853-02). The purification of the proteins is by the process of gel 
filtration. Molecules larger than the largest pores in the matrix are excluded from 
the matrix and elute first, in our case translated proteins GAD65 and IA2ic. 
Intermediate size molecules penetrate the matrix to varying extents, depending on 
their size. Penetration of the matrix retards progress through the column; very 
small molecules elute last such as free amino acids. Remove one column per each 
translated and place on a suitable column rack holder and allow the contents of 
the column to pass through the column to remove the preservative out from the 
column. Equilibrate the column by washing the column with 1 x Tris buffer 
Saline Tween (5.0ml x 2). The protein’s transcribed and translated were purified 
by passing the reaction mixture after dilution in 200µL of 1 x Tris buffer Saline 
Tween, through the NAP5 column as depicted in Figure 2.1  
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Step 1 Allow Excess buffer to flow through 
 
Step 2 Wash Column 2 x 5ml TBST 
Step 3 Dilute and load translate in 
200µl TBST 
 TBST 
 Step 4 Elute Protein in 1ml TBST 
Figure 2.1: Elution of Translated 
35
S Methionine labelled 
antigen (GAD65, IA2ic.  
All the proteins of interest are eluted in the haemoglobin fraction 
red in colour, (depicted here in blue in the cartoon) the smaller 
amino acids including the unincorporated 
35
S Methionine elutes 
through the column later and is washed out with excess water to 
reduce the amount of waste disposed as solid waste. 
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2.450. Determination of Radioactive Protein Incorporation 
The incorporation of protein translated was determined from the 50µl reaction 
mixture.  
1. Remove 2µl of the reaction and add 98µl of 1M NaOH/2%H2O2. 
Vortex briefly and incubate at 37°C for 10 minutes. 
2. Add 900µl of ice cold 25% TCA to precipitate the proteins. 
3. Prewash a Whatman GFA glass fiber filter with ice cold 5% TCA. Add 250µl 
of the TCA reaction mixture. Rinse the filter 3 times with 1.5ml of ice cold 
5% TCA.  
4. Rinse once with 2ml of acetone, allow the filter to dry at room temperature in 
the fume cupboard. 
5. Put the filter in a scintillation tube add 1ml scintillation liquid and count on 
the Wallac Micro beta counter. 
6. To determine the total counts spot 5µl of the reaction mixture directly onto a 
dry GFA glass fibre filter, allow to dry for 10 minutes and count after adding 
1ml scintillation liquid. This is the CPM of the unwashed filter = Total counts. 
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The percent incorporation was determined as follows: 
(CPM of washed filter (Step 5)/(CPM of unwashed filter (step 6)) x 50) x100  
 
Typical Incorporation of 
35
S Methionine into GAD65,IA2ic and ZnT8 
(CPM of washed filter (Step 5)/CPM of unwashed filter (step 6)) x100  
GAD65 Unwashed CPM Total counts =19428 CPM X50 
GAD65 washed CPM counts =72578 CPM  
  
Percentage incorporation = 7.5% 
 
(CPM of washed filter (Step 5)/CPM of unwashed filter (step 6)) x100  
IA2ic Unwashed CPM Total counts =20147 CPM X50 
IA2ic washed CPM counts =90865 CPM  
  
Percentage incorporation = 9.0% 
  
(CPM of washed filter (Step 5)/CPM of unwashed filter (step 6)) x100  
ZnT8 4.1 construct Unwashed CPM Total counts =19245 CPM X50 
IA2ic washed CPM counts =88865 CPM  
  
Percentage incorporation = 9.2% 
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On average 5-10% incorporation was achieved from each translation and 
approximately 20000-25000 CPM per 50µl was used in the radio-
immunoprecipitation experiments for all the antigens tested throughout. 
 
2.451. Assay for Glutamic Acid Decarboxylase (GAD65) 
The radio-immunoprecipitation assay for the enzyme Glutamic acid 
Decarboxylase (GAD65) employ’s in vitro transcription and translation systems 
(Promega Madison, WI).  
 
2.452. Preparation of 10 x Tris Buffer Saline Tween (TBST) Stock solution 
In 1 litre sterile Duran bottle add approximately 600ml of distilled deionised 
water and place on a magnetic stirrer. 
To this add 78.8 grams of Tris Hydrocloride (Sigma).  
Add 116.8 grams of Sodium Cloride (Analar grade) (BDH) 
Mix well on the stirrer to dissolve Tris Hydrocloride and Sodium Cloride check 
the PH and adjust to 7.2.  
Add 100ml of Tween 20 (Sigma) so that the final concentration of Tween equals 
1% after adjusting the volume of the stock solution to 1000ml with pure 
autoclaved water. The H2O is autoclaved at 120°C for 15 minutes in order as to 
extend the shelf life of the stock solution. 
The working solution 1x TBST was prepared by diluting 100ml of 10 x TBST 
with 900ml of pure water (Triple Red water purifier and autoclaved) and stored at 
4°C until required for the assay. 
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Serum  
From 
Prediabetic 
Twin 
Negative 
healthy 
control 
serum 
Dilution   WHO 
Units 
IU/ml 
200µl 0µl Neat 0 A 1209 
100µl of A 100µl 1:2 2 B 702 
100µl of B 100µl 1:4 4 C 417 
100µl of C 100µl 1:8 8 D 250 
100µl of D 100µl 1:16 16 E 126 
100µl of E 100µl 1:32 32 F 89 
100µl of F 100µl 1:64 64 G 51 
100µl of G 100µl 1:128 128 H 25 
100µl of H 100µl 1:256 256 I -19 
100µl of I 100µl 1:512 512 J -3 
100µl of J 100µl 1:1024 1024 K 0 
 
Table 2.5 Prepare a serial dilution of a positive control serum sample 
standardized to the WHO standard at 250IU/ml. 
Serial dilution of the standards was carried out as depicted in Table 2.5. 
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 1 2 3 4 5 6 
A SB 0 Dil SB 1:256 Dil Test 
4 
4 
B SB 1:2 Dil SB 1:512 Dil Test 5 5 
C SB 1:4 Dil SB 1:1024  Test 6 6 
D SB 1:8 Dil Negative Negative Test 7 7 
E SB 1:16 Dil Positive Positive Test 8 8 
F SB 1:32 Dil Test 1 1 Test 9 9 
G SB 1:64 Dil Test 2 2 Test 10 10 
H SB 1:128 Dil Test 3 3 Test 11 11 
 
Table 2.6 Assay Template for GADA & IA2A in a 96 well Millipore 
Filtration Plate (Test 1,2 etc= test samples tested in duplicate) 
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2.453. GAD65 and IA2ic Assay Protocol 
 
1 Pipette 2ul samples in duplicate as shown in the assay template Table 2.6 of the 
standard curve in a 96 well format plates from Millipore UK (Cat 
No:MAHVBN4550B). 
2 Pipette 2ul in duplicate of the positive control serum from a pre-diabetic twin and 
negative control serum sample in each well as shown in the template and 2ul in 
duplicate of the unknown samples. 
3 Add 50ul or the translated and diluted GAD65, IA2ic or ZnT8 antigen with 
approximately 20000 CPM per 50ul per well. Place on a shaker for 5 minutes and 
incubate overnight at 4°C. 
4 Dilute Protein A Sepharose (PAS) (Amersham Pharmacia) so that we have 
1mg/well. Dilute PAS 100mg in 25ml of TBST in a universal tube and allowed to 
swell, (1mg of PAS swells to 4ul of the packed resin volume).  
5 Add 50µl of PAS per each well and incubate on a shaker at 4°C for approximately 
1.5 hours to allow the immune complexes of Antigen/Antibody to bind to PAS. 
Protein A Sepharose CL-4B is Protein A covalently bound to Sepharose CL-4B 
using the CNBr method. 
6 Bound immune complexes were washed 12 times with Tris buffer saline and 
Tween on millipore plates (Catalogue No MHVBN4550B) using a Millipore plate 
washer system, were allowed to dry at room temperature before the addition of 
meltilex solid scintillant (Wallac, Turku ,Finland), and were counted on the 
Wallac 1260 Micro beta scintillation counter.  
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7 The current assay protocol for all the antigens utilises the Millipore plates 
MAHAN4B50 plates which eliminates the use of the solid scintillant and instead 
liquid scintillant Ultima Gold, 50µl per well for aqueous solutions was employed. 
This reduces the quenching effect on the CPM detected using the solid Meltilex 
scintillant system previously employed as well as improved the sensitivity of the 
assay procedure. 
 
 
2.454. Protein A Sepharose to bind serum immunoglobulins 
Note in serum the concentration of IgG is 12.5mg/ml, IgA 2.1mg/ml, IgM 
1.25mg/ml IgD 40µg/ml and IgE 0.04µg/ml respectively. This equates to 
16mg/ml of total immunoglobulin per ml of serum and 3mg of PAS binds 20mg 
of immunoglobulin and 1mg PAS will bind 6.66mg of immunoglobulin. PAS 
added to the assay per well (1mg/well) is added in excess as in 2ul of the serum 
per well, we have approximately 32µg of immunoglobulin. 
The pre-swollen PAS was washed twice in TBST buffer by adding 25ml of buffer 
mixing by inverting and centrifugation at 4°C for 4 minutes to pellet the PAS. 
Reconstitute the PAS such that where 100mg was employed for one plate the PAS 
was reconstituted in 5ml of TBST and for 2 plates 200mg was reconstituted in 
10ml of TBST. 
 
Protein A binds to the Fc region of immunoglobulins through interactions with the 
heavy chain. The binding of Protein A has been well documented for IgG from a 
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variety of mammalian species as well as for IgM and IgA. Protein A Sepharose 
CL-4B has been used as a powerful tool to isolate and purify classes, subclasses 
and fragments of immunoglobulins from biological fluids and from cell culture 
media. Since only the Fc region is involved in binding, the Fab region is available 
for binding antigen. Hence, Protein A Sepharose CL-4B is extremely useful for 
isolating immune complexes. 
 
2.455. Population study autoantibody sample analysis: All subjects were tested 
for ICA in a single laboratory (Ulm) by indirect immunofluorescence, with 
detection limit 5 JDF units, and >20 JDF units as
 
positive; assay
 
sensitivity and 
specificity was 100% in 13th Islet Cell Autoantibody Workshop
 
(1998) (Seissler 
et al.,1998).  
ICA positive subjects were tested for GADA and IA-2A, plus ZnT8A (tested in 
London, UK) using radio-immunoprecipitation as described in detail chapter 2 
and published previously (Hawa et al., 1997). The assay characteristics for Ulm 
for: GADA 86% sensitivity 95% specificity; IA-2A 73% sensitivity; 99% 
specificity. Characteristics of ZnT8A assay (London, UK) are described below 
under twin study.  
2.456. Twin study autoantibody sample analysis: All twins were tested for 
serum autoantibodies to GAD65 (GADA), IA-2 (IA-2A) and ZnT8 (ZnT8A) using 
established radio-immunoprecipitation assays as described above and previously 
published (Hawa et al., 1997). All twin samples were tested at a single laboratory 
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(London) in batched assays with values expressed as categorical 
(positive/negative) and continuous traits. Positive results were duplicated reducing 
false positives to <0.2%. In the latest Diabetes Antibody
 
Standardization Program 
(DASP 2008) London assay characteristics: GADA sensitivity 90%, specificity 
93%; IA-2A, sensitivity 68%, specificity 95%; and ZnT8A sensitivity 60%, 
specificity 88% (data unpublished).  
2.457. Diabetes Autoantibody Standardisation Programme (DASP) 
Over the last 8 years our laboratory has been participating in the diabetes antibody 
assay standardisation programme (DASP) which entails the analysis of coded 
samples from healthy volunteers as well as patients with diabetes for the presence 
of diabetes associated auto-antibodies including ICA, GAD65, IA2ic as well as the 
more recently described antigen ZnT8. The aims of the first proficiency 
evaluation of DASP were to assess general implementation of assay methods and 
to evaluate the new World Health Organization (WHO) reference reagent (250IU) 
for auto-antibodies to GAD65 and IA-2. The reference reagent was used to 
standardise the in-house assays for GAD65 and IA2ic. Forty-six laboratories in 13 
countries received coded sera in the first DASP programme from 50 patients with 
newly diagnosed T1D and 50 blood donor control subjects, together with the 
WHO reference reagent and diluent serum. 
Measurement of diabetes associated auto-antibodies to islet antigens has become 
invaluable in determining diabetes associated immunity. The measurement of 
diabetes auto-antibodies is now widespread and is used clinically to identify 
individuals at risk of developing T1D (Bingley et al.,2001), those requiring 
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immediate insulin treatment, as an aid to better characterise and classify diabetes, 
to study the natural history of diabetes and to measure the efficacy of intervention 
trials in assessing immunity to therapy (Expert Committee 1997),(Zeigler et al., 
1999) . In the DASP 2003 workshop our assay for GAD65 had a sensitivity of 
74% and specificity of 98% and for IA2ic a sensitivity of 62% and specificity of 
98% (Bingley & participating Laboratories 2003). In the DASP 2009 workshop 
our assay for GAD65 had a sensitivity of 76% and a specificity of 98%, for IA2ic a 
sensitivity of 54% and a specificity of 100% and for ZnT8 a sensitivity of 42% 
and a specificity of 99%. In the data for DASP 2003 workshop the samples were 
scored positive or negative based on the 99
th
 percentile of 100 healthy controls 
tested in house.  
 In the latest DASP 2009 workshop the samples were scored positive or negative 
based on the end point dilution of the standard curves utilised in the assays. The 
sensitivity for IA2 in general shows a decrease without a significant decrease in 
the specificity, this lower sensitivity corresponds with the higher ages of the 
patients as in general antibodies to IA2 are detected in the younger patients more 
frequently. The sensitivity is increased significantly by the measurement of 
combination of antibodies including GADA, IA2icA as well as ZnT8A all 
comprising the Islet Cell Antigens. 
 (Publications have resulted from the participation in the DASP (Bingley & 
participating Laboratories 2003), (Schlosser and participating Laboratories, 2011), 
(Lampasona V & Participating Laboratories, 2011)  
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2.5. Results: The results from this study with details of the characteristics of 
identical and non-identical twins discordant for T1D as well as the population 
based samples who were ICA positive for CML levels and autoantibody positivity 
are depicted in Table 2.7, Table 2.8 and Figure 2.2. CML levels were increased in 
population-based autoantibody positive and pre-diabetic subjects shown in the left 
panel in Figure 2.2 and the levels were significantly elevated in comparison to the 
population based healthy controls in both groups. Similarly in the twins, the CML 
levels were significantly higher in both the diabetic and non-diabetic twins when 
compared to the normal twins (all p<0.001).  
Furthermore the diabetic twins irrespective of their zygosity (MZ or DZ) tended 
to have antibodies more often than their non-diabetic co-twins. Of 64 twin pairs 
tested MZ and DZ, 37 diabetic twins had autoantibodies compared with 10 non-
diabetic twins (p<0.0001 with fishers exact chi square analysis) (Table 2.8).   
Elevated serum CML in ICA positive subjects in the population study was a 
persistent and additive predictive marker of progression to diabetes.  When 
analyzed as continuous traits, diabetic twins, compared to their non-diabetic co-
twins, had higher values for GADA (p=0.02) and IA-2A (p=0.001), but not 
ZnT8A. Neither age nor disease duration affected GADA levels, but older 
subjects had less presence of IA-2A (p<0.001) and ZnT8A (p=0.002). Twin 
correlations (r) were weak for the presence of autoantibodies in this cohort 
however I have presented data in this thesis of a positive strong correlation for 
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GADA and IA2A in twins who were concordant for T1D. 
Of 64 non-diabetic twins: 62 (96.9%) had a raised serum CML (>1097 ng/ml as 
99th centile of normal twin values) as did 57 (89.1%) of the diabetic twins (Figure 
2.2); 10 of 64 had diabetes-associated autoantibodies; 2 of these latter 10 
subsequently developed diabetes (Table 2.7). 
2.6. Predictive Values: 
To calculate positive and negative predictive values of a test for example presence 
of GADA in patients with and without diabetes, a number of parameters need to 
be recorded. 
Patients with diabetes and with GADA are termed True Positives (TP) 
Patients without diabetes and with GADA are termed False Positives (FP) 
Patients with diabetes and without GADA are termed False Negatives (FN) 
Patients without diabetes and without GADA are termed True Negatives (TN) 
For example, let us suppose we tested for GADA on the 1000 random people. 
Among these 100 patients had TID, 95 of them tested GADA positive, and 5 
tested GADA negative. Among the 900 people without Diabetes, 90 tested 
positive, and 810 tested negative. 
 In this case, TP=95, FN=5, FP=90, and TN=810. 
Sensitivity is calculated by dividing TP/(TP+FN) x 100%  
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95/(95+5) = 95% 
Specificity is calculated by dividing TN/(TN+FP) x 100%  
810/(810+90) = 90% 
Positive Predictive Value (PPV) is calculated by dividing TP/(TP+FP) x 100% 
95/(95+90) = 51.4% 
Negative Predictive Value (NPV) is calculated by dividing TN/(TN+FN) x 100% 
810/(810+5) =99.4% 
In the population samples positive and negative predictive values were: raised 
CML 46.5%, 83.1% (sensitivity 62.5%, specificity 71.9%); GADA 33.7%, 86.2% 
(sensitivity 87.8%, specificity 30.5%); IA2A 54.8%, 80.0% (sensitivity 50.0%, 
specificity 82.9%); and ZnT8A 60.0%, 85.0% (sensitivity 63.6%, specificity 
82.9%). 
In the MZ twin samples positive and negative predictive values were: raised CML 
47.9%, 22.2% (sensitivity 89.0%, specificity 3.1%); GADA 85.7%, 60.0% 
(sensitivity 37.5%, specificity 93.8%); IA2A 77.8%, 54.5% (sensitivity 21.9%, 
specificity 93.8%); and ZnT8A 50.0%, 50.0% (sensitivity 6.3%, specificity 
93.8%).  
In the combined MZ/DZ twin samples positive and negative predictive values 
were: raised CML 47.9%, 22.2% (sensitivity 89.0%, specificity 3.1%); GADA 
83.3%, 57,7% (sensitivity 31.3%, specificity 93.8%); IA2A 87.5%, 55.4% 
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(sensitivity 21.9%, specificity 96.9%); and ZnT8A 42.9%, 50.0% (sensitivity 
4.7%, specificity 93.8%).  
Twin Cohort (MZ=monozygotic 
DZ= dizygotic) 
Diabetic Twin Non Diabetic 
Twin 
MZ Number of Twins 32 32 
GADA 12 2 
IA2A 7 2 
ZnT8 2 2 
Serum CML ng/ml (range) 2638.5 [1911.5, 
3550.5] 
2248.5 [1708.5, 
2991.0] 
DZ Twins   
Number of Twins 32 32 
GADA 8 2 
IA2A 7 0 
ZnT8 1 2 
Serum CML ng/ml (range) 1776.5 [1185.5, 
2077.5] 
1616.5 [1252.0, 
1854.0] 
 
Table 2.7 Variables in MZ & DZ twins samples (n=64) Means (SD) are given 
unless indicated differently.   
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Variables T1D (n=33) noT1D 
(n=82) 
p-value 
 Mean (SD) Mean (SD)  
CMLinclusion 
visit,  
[interquartile 
range], in ng/ml  
669 [524, 761] 512 [424, 
619] 
<0.001 
CMLlast visit, 
[interquartile 
range], in ng/ml
 
 
773 [611, 831] 424 [381.5, 
452] 
<0.001 
    
Antibody 
positivity 
   
GADA, n (%) 29 (87.9%) 57 (69.5%) 0.04 
IA2, n (%) 17 (51.5%) 14 (17.1%) <0.001 
ZnT8, n (%)  21 (80.8%) 14 (28.6%) <0.001 
 
 
Table 2.8 Variables in the Population Study samples from 7,287 normal 
children of which, 115 were ICA positive Means (SD) are given unless 
indicated differently.   
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 FIGURE 2.2.  Mean (SD) baseline serum CML in population  (Left panel) and 
twin study (Right Panel). Control = normal children (n=2102); noT1D ICA+ = 
non-diabetic child ICA+ (n=82); T1D ICA+ = diabetic child with ICA+  (n=33); 
twin control = normal twins (n=168); noT1D twins = non diabetic co-twin of T1D 
twins (n=64); T1D twins = diabetic twin (n=64). There is a graded increase in serum 
CML from control subjects through to twins with T1D, related to age and diabetes 
duration. The differences in twins and the population study are potentially related to 
differential ages and temperature of sample storage. 
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2.7. Discussion: This study examined CML levels in a population based cohort 
and confirmed previous findings of elevated levels of AGEs in normal twins, that, 
the levels of CML are genetically determined, such that, both the diabetic as well 
as non-diabetic twin had raised but similar CML levels. Interestingly studying 
CML and auto-antibodies showed that twins tended to be discordant for the latter 
(which with twin modeling, but not described here showed are determined 
predominantly by non-shared environmental factors) but not for CML (which 
with twin modeling, not described here showed are determined predominantly by 
shared environmental factors) suggesting that non-genetic factors, most probably 
environmental factors, must contribute to these differences. 
If autoantibodies were genetically determined then both the diabetic as well as the 
non-diabetic twins would show concordance for them, however in this cohort of 
MZ and DZ twins discordant for diabetes such concordance was not the case. A 
twin study should ideally be performed prospectively in a population-based cohort 
from birth to determine the rate of induction of autoantibodies and diabetes, and 
as our twins were initially disease-discordant, so disease concordance rate is 
underestimated (Redondo et al., 2008) . 
The increased higher level of CML in twins in comparison to the population 
based children tested could be attributed to the activation of the peripheral 
immune cells due to chronic ongoing inflammation and oxidative stress however 
the raised levels were detected in twins discordant for diabetes as well as in the 
healthy twins, all of whom did not have diabetes associated antibodies. The raised 
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levels of CML in twins discordant for T1D therefore cannot be attributed to 
ongoing inflammation or oxidative stress. AGEs CML is known to assert its 
inflammatory effects via its binding to RAGE leading to the activation of a 
cascade of signaling molecules which together have an inflammatory response. 
The cause for the raised CML levels in twins irrespective of their zygosity as well 
as significantly higher levels in comparison to the ICA positive school children 
samples is unclear, however this could be attributed to dietary factors, intake of 
which could be the most likely source.  In particular thermally sensitive nutrients, 
including infant formula cow’s milk and heat-treated animal fat, are major sources 
of AGEs, including CML, which can reach adult serum levels by one year of age 
which, have been implicated in sustaining an altered inflammatory response  
(Mericq et al 2010). AGEs levels increase as a result of chronological ageing 
process most likely due to dietary intake. Increased levels of AGE CML in this 
study, provides a positive predictive value and furthermore raises the possibility 
of intervention early in life to modify the course of the disease process. These 
proposals are supported by the observation that RAGE genetic polymorphisms 
predicted increased risk of human T1D, and that declining circulating levels of 
soluble RAGE predict the disease (Forbes et al., 2011). In another autoimmune 
disease, multiple sclerosis, AGE Carboxy-Ethyllysine (CEL) is elevated and AGE 
inhibitors have been suggested to have beneficial neuro-protective effect  
(Sternberg et al., 2010). Moreover, studies in animal models of autoimmune 
diabetes have shown a reduction of AGE by diet or drug therapy which reduces 
not only AGE levels, but progression to diabetes (Peppa et al., 2003).  
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Chapter 3 
3.0. WHETHER AUTOANTIBODIES, INSULIN SECRETION AND INSULIN RESISTANCE 
ARE PREDICTIVE AND ARE GENETICALLY DETERMINED. 
3.1. The aim of the study was to investigate the appearance of autoantibodies 
in twins concordant and discordant for T1D. 
3.11. INTRODUCTION: 
Twin studies were first described by Sir Francis Galton on the role of genes and 
environment on human development and behaviour. Twin studies are a powerful 
tool in scientific research in assessing genetic as well as non-genetic factors in 
multifactorial diseases, as twins can be monozygotic (MZ) developing from a 
single fertilized egg and therefore share all of their alleles, or dizygotic (DZ) that 
is develop from two separate eggs and only share 50% of the polymorphic alleles, 
which is the same level of shared genetic similarity as found in non-twin siblings. 
Twin studies are therefore a powerful tool in assessing genetic as well as non-
genetic factors in multifactorial diseases. This important difference forms the 
basis of twin studies to investigate genetic and environmental features in disease 
and health.  
The classic twin study begins by assessing the variance of a behaviour (called a 
phenotype by geneticists) in a large group, and then attempts to estimate how 
much of this is due to genetic effects (heritability), and how much appears to be 
due to shared or unique environmental effects - events that affect each twin in a 
different way, or events that occur to one twin but not another. 
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Typically these three components are called A (additive genetics) C (common 
environment) and E (unique environment); the so-called ACE Model. Given the 
ACE model, we can determine what proportion of variance in a trait is heritable, 
versus the proportions which are due to shared environment or unshared 
environment.  Monozygotic (MZ) twins raised in a family share both 100% of 
their genes, and all of the shared environment. Any differences arising between 
them in these circumstances are random (unique events not shared). The 
correlation we observe between MZ twins provides an estimate of A + C . 
Dizygous (DZ) twins have a common shared environment, and share on average 
50% of their genes: so the correlation between DZ twins is a direct estimate of 
½A + C .  
Monozygotic twins are usually discordant for T1D i.e. only one twin is affected. 
Studies of twins have shown that the concordance rates for T1D is higher in 
monozygotic twins than dizygotic twins which is consistent with involvement of 
genetic factors in the aetiology of T1D (Kaprio et al., 1993). However despite this 
the concordance rates for immune mediated diseases fall well short of 100% and 
these rates have been reported to be lower in non-identical twins compared to 
identical twins. The majority of identical twins with autoimmune disease have an 
identical twin discordant for the disease as shown in (Table 3.01) (Salvetti et al., 
2000). Genetic and Environmental factors have been implicated in the 
pathogenesis of immune mediated disease, with the most powerful effect coming 
from the studies of identical twins. It is important to note that while some twins 
develop the disease soon after the index twin develops the disease, the majority of 
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twins however remain unaffected even after 40 years of follow up of the 
unaffected twin (Fava et al., 1998). At diagnosis of T1D, the islets are heavily 
infiltrated with T Lymphocytes and insulin secretion is markedly reduced or may 
even be absent (Foulis & Stewart 1984). The disease process is slow with a long 
prodrome period before diabetes ensues and immune changes (autoantibodies to 
islet antigens) can be detected many months or even years, before the clinical 
onset of TID.  
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Disease Identical Twin 
Pairs 
Non-Identical 
Twin Pairs 
Reference 
MS 26.7 3.5 Ebers & 
Sadovnick 1994 
RA 12.3 3.5 Jarvinen et al 1992 
IDDM 13 2.5 Kaprio et al 1993 
SLE 33 0  
Salvetti et al 2000 
 
Table 3.01 Disease concordance rates in identical and non-identical twin pairs in 
population-based studies of immune-mediated diseases. (Modified from M Salvetti 
et al 2000) 
Abbreviation: MS Multiple sclerosis, RA Rheumatoid Arthritis, IDDM insulin 
dependent diabetes, SLE Systemic Lupus Erethematosus 
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3.12. Methods: To test whether antibodies to Islet auto-antigens GADA and 
IA2ic are inherited and or can be detected in Twins Discordant and Concordant 
for Diabetes, available samples from the twin cohort’s stored at -20 ºC, were 
tested for autoantibodies to  key auto-antigens using radio-immuno-precipitation 
assays as previously described.  
3.13. Subjects: We tested a cohort of MZ and DZ twins discordant for diabetes 
and examined the appearance of autoantibodies to GADA, IA2A. Twins from 
United Kingdom (Caucasian) were ascertained as described earlier. Classification 
of T1D was based on 1) control of diabetes with insulin from time of diagnosis, 2) 
diabetic ketoacidosis or marked ketonuria at time of clinical onset. Twins were 
followed prospectively until they either developed diabetes or remained free of 
the disease. The twins who remained discordant for diabetes more than 5 years 
from the diagnosis of the index twin, are referred to as low risk twins with an 
estimated disease risk of less than 2%. 
From the Twin Study, consecutive samples were tested from 156 twin pairs; of 
these 67 subsequently developed T1D (termed Concordant Twin Pairs), and 89 
pairs who remained discordant. Stored serum samples were tested both before and 
at diagnosis of T1D. The mean period of follow-up in the twins who became 
concordant for T1D was 5.08 years (range 0.33–29.5 yrs), the mean age in 
concordant twins was 15.97 years (range 0.33–28.4 years), 35 females. From the 
DZ twins (n=81) sufficient sera was available from 32 pairs and were tested for 
diabetes associated autoantibodies (Table 3.02). 
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The mean period of follow-up in the twins who remained discordant for T1D 
(n=89) was 16.0  10 years (range 1.0–51.9 yrs), the mean age in the discordant 
twins was 15.97 years (range 1.07–51. years). 50 females. From these 188 twin 
pairs all available samples were tested for diabetes antibodies in particular GADA 
and IA2 and in selected cases ZnT8. 
3.14. Results: The results from this study are depicted in Table 1.8. Twins when 
initially referred to the study were discordant for diabetes. Twins  tested for 
autoantibodies were more often concordant for autoantibodies when both twins 
became  concordant for the disease, the concordance for the presence of 
autoantibodies between twins who became concordant was similar between these 
pairs (43.4% vs 46.4%) compared to those who were discordant for the disease 
46% vs 10% p < 0.0002 Chi Square analysis).  
There was a positive correlation for age between twin pairs who were concordant 
for diabetes, (Correlation coefficient (r) = 0.812835 (r² = 0.660701)) as shown in 
Figure 3.1 showing the correlation for age at diagnosis between the index twin 
and the co twin. The average follow up period between the twins was 5.3±5.9 
years and 28 pairs of the 67 pairs were diagnosed below 18 years of age.   
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 GADA/IA2 or 
ZnT8Index 
Twin 
GADA/IA2 
or ZnT8 
Co Twin 
Follow up(Yrs) 
Discordant 
Twins  
(n=89 pairs) 
41 (46%) 9 (10%) 16.0 (10.1) 
range 1.1-51.9 
Concordant 
Twins  
(n=67 pairs) 
33 (49.2%) 33 (49.3%) 5.1 (5.6) 
range 0.3-29.5 
DZ 
discordant 
Twins  
(n=81) 32 
pairs tested 
13 (41%) 2 (6%) 9.8 (6.3) 
Range 2.8-18.8 
 
Table 3.02 Autoantibodies in Concordant and Discordant Twin Pairs 
 
The risk was highest in twins who developed diabetes at a younger age and the 
mean age at diagnosis was 15.7±9.6 (range 1-47). Of those who became 
concordant for diabetes under 18 years of age, again there was a positive 
concordance with a Correlation coefficient (r) = 0.813354 (r² = 0.661545) (Figure 
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3.1) and the discordance between twins was less than five years (mean 1.72 ±1.99 
years). 
Of the twins who became concordant after 18 years of age (n=47) the mean period 
of discordance was 6.6 ± 5.7 years range  0 -21 years with a mean age at 
diagnosis of the index twin 31.8 ± 13.3 vs 38.5 ± 13.6 years in the co twin, with a 
discordance of 6.6 years (Table 3.03). Of the twins who became concordant under 
18 years of age the mean period of discordance was 1.7 ± 1.9 years, range 0-9 
years with a mean age at diagnosis of the index twin 7.1 ± 3.3 vs 8.8 ± 3.3 years 
in the co twin, with a discordance of 1.7 ± 1.9 years. 
A positive correlation was noted in both groups of twins irrespective of the age at 
diagnosis. In the twins diagnosed under the age of 18 years the correlation 
coefficient was (r=0.813354 r
2 
=0.6615) (figure 3.2) and similarly there was a 
positive correlation in those twins who became concordant for diabetes after 18 
years of age correlation coefficient (r=0.899178 r
2 
=0.808521) (figure 3.3). 
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Figure 3.1 Concordance for T1D between MZ twin pairs (n=67) cases plot of 
correlation using SPSS. 95% CI for population value of slope = 0.52381 to 
0.717356. Correlation coefficient (r) = 0.848202 (r² = 0.719447) 95% CI for r 
(Fisher's z transformed) = 0.762758 to 0.90454 t with 64 DF = 12.810961 Two 
sided P < 0.0001 Power (for 5% significance) > 99.99% 
134 
 
 
0 4 8 12 16
0
5
10
15
A
B
 
Figure 3.2 Concordance for T1D between MZ twin pairs diagnosed under 18 
years of age (r=0.813354 r
2 
=0.6615) plot of correlation using SPSS. 
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Figure 3.3 Concordance for T1D between MZ twin pairs diagnosed over 18 years 
of age correlation coefficient (r=0.899178 r
2 
=0.808521) plot of correlation using 
SPSS. 
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Age at 
diagnosis 
Index Twin 
Age at diagnosis 
co twin Discordance 
18.81918 22.47123 3.652055 
19.13699 20.47123 1.334247 
22.42192 23.08767 0.665753 
25.10685 32.86575 7.758904 
31.7726 37.90411 6.131507 
18.81644 18.90137 0.084932 
18.23562 47.7726 29.53699 
28.49589 40.33699 11.8411 
18.51781 23.52603 5.008219 
22.96164 26.96438 4.00274 
23.41644 44.26301 20.84658 
36.72877 42.64658 5.917808 
Mean age 
23.7±5.9 
Mean age 
31.8±10.4 
Mean discordance 
8.1±8.8 
   
 
Table 3.03 Concordant Twins diagnosed after 18 years of age on whom data 
was available for autoantibodies. Correlation coefficient (r) = 0.775205 (r² = 
0.600943)  
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3.15. Discussion: In a previous report (Fava et al., 1998 ) the age of onset in 116 
identical twin pairs concordant for T1D was strikingly correlated (correlation 
coefficient 0.94) and the correlation for age at diagnosis was higher in identical 
than non-identical twins. The data presented here shows a striking correlation 
irrespective of the age at diagnosis. A high correlation was noted in twins 
diagnosed under the age of 18 years age (r=0.813354 r
2 
=0.6615), as well as in the 
twins diagnosed over age of 18 years of age at diagnosis (r=0.899178 r
2 
=0.808521). 
Of the MZ/DZ Twins tested for autoantibodies, twins were more often concordant 
for autoantibodies when both twins were concordant for the disease, the 
concordance for the presence of autoantibodies between twins who became 
concordant was similar between these pairs (43.4% vs 46.4%) compared to those 
who were discordant for the disease 46% vs 10% p < 0.0002 Chi Square 
analysis), “No disease No autoimmune changes detected”. In the Dizygotic twins 
discordant for diabetes, diabetes associated autoantibodies were infrequently 
detected in the non-diabetic twin. 
There are a number of limitations of twin studies in assessing genetic impact on 
disease. First, identical twins may have a more similar environment both in utero 
and in childhood, leading to an over-estimate of heritability. Second, in contrast to 
nonidentical twins, identical twins are always the same sex and many autoimmune 
diseases are more common in females for example, RA, MS and SLE. Third, twin 
studies are hindered by potential biases in ascertainment. In the traditional ‘clinic-
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based’ approach, identical twin pairs concordant for a disease, or with severe 
disease, are more likely to be identified. In the ‘population-based’ approach, 
individuals are identified first as twins and are then assessed for illness. These 
population-based studies must ascertain large numbers of twin pairs to detect 
sufficient numbers of affected twins. Finally, most twin studies have been cross-
sectional, but, by following twins for a longer period, it might be possible to 
detect a higher concordance rate. 
Identical twins show a similar genetic regulation of the production of antibodies, 
even when they are reared apart (Kohler et al., 1985). A study of IgM and IgG 
rheumatoid factor isotypes in 70 identical and 84 nonidentical twins discordant 
for RA concluded that genetic factors were important in determining the levels 
and frequency of these isotypes; for example, IgM and IgG positivity was higher 
in healthy identical than healthy nonidentical twins ( Macgregor et al.,1995). In 
agreement with such a genetic effect, combinations of IDDM-associated 
autoantibodies were more often found in healthy identical than healthy 
nonidentical twins of IDDM patients (Hawa et al., 1997). Furthermore possession 
of the high risk Hph I insulin genotype in identical twins increases the risk for 
these twins to be concordant for T1D ( Metcalf K et al 2001) , as this gene was 
found significantly more often in concordant twins in comparison to the 
discordant twins 87.5% vs 59.5 (p=0.005). Another study suggested that sufficient 
long term follow up of identical twins discordant for diabetes followed for greater 
than 40 years eventually develop islet autoimmunity and T1D even if twins were 
initially discordant for T1D (Redondo et al., 2008). In that study all twins who 
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were discordant for TID were positive islet cell antigens and therefore were all 
pre-diabetic and would in theory go on to develop diabetes. In this present thesis 
data samples were tested from twins followed for more than 40 years who 
continue to remain free of diabetes associated autoantibodies as well diabetes, the 
former data remains to be confirmed. The threshold hypothesis indicates the 
requirement of a combination of both genetic as well as environmental factors 
reaching a threshold such that disease results, so it is possible in twins who 
remain discordant for TID, that such a threshold has not been achieved despite 
being genetically identical, implicating other additive factors are necessary in 
reaching the threshold. Metabolic changes can also be detected many months or 
even years before the onset of the disease, whether these changes are inherited can 
be tested in identical twins discordant for the disease. 
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CHAPTER 3.2 
3.2. IS INSULIN SECRETION AND INSULIN RESISTANCE PREDICTIVE 
AND GENETICALLY DETERMINED. 
3.21. INTRODUCTION: Type 1 diabetes is due to the destruction of the insulin 
secreting beta cells probably mediated by T lymphocytes recognizing critical beta 
cell antigens and it is probably caused by environmental factors in a genetically 
susceptible individual operating at critical time.  
There are views that these changes may be due to an early environmental insult or 
that the altered insulin secretion and sensitivity are genetically determined thereby 
predisposing an individual to the destructive process (Bennet et al., 1995), 
(Johnston et al., 1987). If the latter is the case then testing metabolic features 
could identify such changes in twins discordant for T1D. 
 
3.211. Insulin Sensitivity: Selected twins from the British diabetic twin’s cohort 
were tested to examine if there was any evidence for the alteration of the insulin 
secretion or sensitivity which predisposed them to TID. We studied prospectively 
27 identical twins of patients with TID who were initially non diabetic, as well as 
14 healthy control subjects over a period of 18 years. 15 twins remained non 
diabetic and were estimated as low disease risk twins and 12 developed TID (pre-
diabetic twins), Table 3.20 (Publication Diabetes Care Volume 28 June 2005 
pages 1415-1418). Subjects were tested on at least two separate occasions with an 
intravenous glucose tolerance test (IVGTT) at least six years apart from the initial 
test. 
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Insulin sensitivity: Was estimated as a ratio (HOMA-IR/first-phase insulin 
response [FPIR]), which is predictive of progression to T1D.   
 
 Control 
Twins 
Low Risk 
Twins 
Prediabetic 
Twins 
  
14 
 
15 
 
12 
 
Age at initial 
test 
 
21.1±7.5 
 
24.1±9.3 
 
17.4±5.8 
 
Gender (M) n 
 
9 
 
8 
 
5 
 
BMI (Kg/m2) 
 
20.7±2.5 
 
22.2±3.2 
 
20.1±2.5 
 
Table 3.20: The patient group tested for insulin sensitivity Data are represented 
as mean±SD 
 
3.212. First Phase Insulin Response (FPIR): We estimated FPIR following a 
glucose load (0.5 g/kg), measured as the area under the 0–10 min curve and above 
the fasting level. 
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3.213. Glucose clearance (Kg): calculated as the slope of the regression line of 
the natural logarithm of glucose between 10 and 30min after glucose infusion and 
expressed as percent per minute. 
 
3.214. Glucose Estimation: Glucose was determined by the glucose oxidase 
method on the Yellow Springs Analyser 23A, (Yellow Springs, Ohio, USA). 
Briefly blood samples are collected in fluoride oxalate tubes, 25ul sample was 
injected through a membrane into the chamber containing the enzyme glucose 
oxidase. The reaction between glucose and the enzyme glucose oxidase in the 
presence of oxygen yields gluconic acid and hydrogen peroxide. The latter is 
reduced to produce an electrical signal proportional to the amount of glucose in 
the blood sample. The latter signal records the amount of glucose present in the 
sample in mMol/L. 
 
3.215. Insulin  
Insulin is produced by the β-cells of the pancreatic islets, initially synthesized as a 
12 kDa pro-hormone (Pre-proinsulin), which undergoes intracellular processing to 
a 9kDA, 86 amino acid pro-hormone (pro-insulin) and subsequently packaged in 
storage granules. Within the granules, disulphide bonds are formed between the A 
and B chains of the insulin molecule and the C-peptide region is cleaved, resulting 
in the 51 amino acid, 6kDa mature insulin molecule. Upon stimulation, the islets 
release equimolar concentrations of insulin and C-peptide, and a small amount of 
143 
 
proinsulin and other intermediates of proinsulin (approximately <5% of the 
normal insulin secretion. 
Insulin is the most important hormone of the fed-state, and is the only physiologic 
hormone which significantly reduces the circulating blood glucose levels. In 
response to a number of substrates and stimuli, including glucose and amino 
acids, insulin is secreted into the hepatic portal circulation. More than fifty 
percent of the insulin secreted is removed on the first pass through the liver, the 
remainder, enters the general circulation and is carried to the target tissues to 
facilitate glucose utilisation. In contrast, C-peptide of insulin does not undergo 
significant liver or extra renal metabolism and therefore has a longer half-life in 
the circulation (approximately 30 minutes) and as such is employed to test the 
insulin secretory capacity of beta cells. 
Basal and glucose stimulated insulin concentrations are relatively stable during 
infancy and childhood, and increase during puberty due to decreased insulin 
sensitivity (Amiel et al., 1991). Insulin concentrations tend to be higher in obese 
individuals, particularly those with an increased proportional visceral abdominal 
fat (Bjorntorp 1991). 
The measurement of insulin concentrations can be useful in clinical diagnostics of 
several conditions. Raised serum insulin concentrations in the presence of low 
glucose concentrations may be indicative of pathologic hyperinsulinism e.g. 
nesidioblastosis and islet cell tumour (Haymond 1989). Elevated fasting insulin 
levels with normal or elevated glucose concentrations are characteristic of insulin 
resistant forms of glucose intolerance and diabetes mellitus. High circulating 
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insulin concentrations may be involved in the pathogenesis of hypertension and 
cardiovascular disease (Reaven 1991). Conversely, low insulin concentrations, in 
the presence of hyperglycaemia suggests insulin-deficiency, e.g. insulin 
dependent T1D. The measurement of the first phase insulin secretion after a 
glucose load is also predictive of T1D development (Robert et al., 1991).  
 
3.216. Insulin Radio-immuno Assay (RIA)  
Insulin autoantibodies can be observed in the pre-diabetic phase and can interfere 
with the insulin radioimmunoassay. Excess proinsulin as well as fragments of pro-
insulin can interfere with the estimation of insulin.  
In radioimmunoassay for immunoreactive insulin in serum, an unknown serum is 
compared to a standard curve prepared by the use of increasing amounts of an 
unlabelled insulin preparation that serves as a standard according to the methods 
of Morgan and Lazarow (Morgan & Lazarow 1963). The insulin standard is 
usually dissolved in a buffer solution containing bovine or human (Velasco 1974) 
serum albumin as the only protein. The absence of human serum from the 
standard is an uncontrolled variable and can affect the determination of the 
absolute concentration of insulin. 
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The reagents for the insulin assay buffer are shown in Table 3.30 
 
3.217. Insulin Assay Reagents: 
Table 3.21: Phosphate/albumin buffer pH 7.4 (PO4) (PBS)  
Disodium hydrogen orthophosphate 
NA2HPO4 (Mwt 141.96) 
4.54g 
Sodium dihydrogen orthophosphate 
NaH2P042H20 (Mwt 156.01)  
1.19g 
Sodium Chloride NaCl (Mwt 58.44) 9.0g 
Thiomersal 0.2g 
EthyleneDiaminetriacetic acid EDTA  3.72g 
Bovine Serum Albumin Fraction V (BDH) 
(Radio-immunoasssay grade)   
5.0g 
 
Make the contents of Table 3.21 to 1 Litre in distilled H2O. 
*Add the Bovine Serum Albumin (BSA) by gently sprinkling over the flask on a 
magnetic stirrer to allow the BSA to gently dissolve. 
Adjust the PH to 7.4 with 1 M NaOH and store at 4°C until required for the assay. 
 
3.218. Radiochemicals: 
Monoiodinated TyrosineA
14 
labelled 
125
I 0.5mg albumin/vial as stock (Amersham 
Pharmacia). The contents are dissolved in 1 ml of dH2O and 100ul aliquots stored 
at -20°C until required for use. Add 20 ml of phosphate buffer saline to one 100ul 
aliquot to give approximately 20000CPM/100ul for the assay. 
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3.219. 1
st
 Antibody Guinea Pig Anti Insulin antibody (Gift supplied by Nordisk 
Gentofte). In order to use the Guinea Pig Insulin antibody in the assay, dilution 
curves were initially prepared by serially diluting from the original 0.5ml stock of 
1:1000 dilution to give 1:10000,1:20000, 1:40000, 1:80000, 1:160000, 1:320000 
and 1:640000 dilutions respectively. 
An antibody dilution curve was set up in duplicate in polypropylene tubes (50 mm 
X 9.75 mm from Elkay Labs) as follows: 
Add 100ul cold unlabelled insulin 1 µIU/ml 
Add 100ul first antibody at the different dilutions (Nordisk Gentofte) 
Add 100ul Monoiodinated Tyrosine labelled 
25
I insulin  
Add 200ul Phosphate Saline buffer (PBS). 
Vortex the tubes and Incubate for 24 hours at 4°C. Add 500ul of the second 
antibody/PEG complex to the tubes while stirring the solution to allow the 
mixture to remain homogenous throughout. Incubate for a further 2 hours at 4°C 
and centrifuge the tubes for 30 minutes at 2500 Revolutions Per Minute (RPM) at 
4°C. Decant the supernatant into the designated radioactive waste sink and tap the 
tubes inverted onto tissues to remove excess liquid. Add 1.5ml of PBS to wash the 
unbound label by centrifuging for a further 30 minutes at 4°C. Decant the tubes as 
before and count the tubes on the Wallac Gamma counter for 60 seconds per tube. 
 From the antibody dilution curves with and without the addition of cold 
unlabelled insulin an antibody dilution curve was generated from which 50% of 
maximal binding was determined and used for the subsequent assays for Insulin. 
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3.220. Second Antibody to 1
st
 Antibody to insulin 
Dilute Rabbit antiguinea pig Precipitating serum A-PPT3 (5ml) (iDS Ltd UK): 
To 100ml of the phosphate buffer saline, add 0.4g Sodium Azide (preservative) 
and 15.8g Polyethelene glycol (PEG) (BDH) and mix thoroughly. 
To 40ml of the PBS add the contents of the second antibody A-PPT3 mix 
thoroughly on a magnetic stirrer and add 300ul of the Normal Guinea Pig Serum 
as a Carrier protein and allow it to mix thoroughly. Combine a & b and make the 
final volume to 200ml.  
 
3.221. Insulin Standard 
The insulin for immunoassay was purchased from the National Institute of 
Biological Standards Control. The insulin standard was purchased from the World 
Health Organisation, where one international unit is the activity contained in 
1.8233mg of the preparation and when dissolved in 1ml PBS and contained 3.0 
I.U (International Units). A 100ul aliquot of this dissolved in 3ml PBS (PH 7.4) to 
give a solution containing 0.1IU Insulin. This was further diluted taking 200ul 
into 100ml PBS to give 200 IU/ml and stored at -20°C. Serial dilution of the latter 
provides the standard curve with 100 IU, 50,25,12.5,6.25,3.125, and 1.56 IU 
respectively of insulin standard for the assay. 
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3.222. Preparation of hormone-depleted human serum 
 Pooled Human serum 100ml from healthy donors was treated with dextran-
coated charcoal (400ml). Treatment with Norit NK dextran-coated charcoal: (a) 
prepare a suspension of activated dextran-coated charcoal (Sigma); (b) centrifuge 
at 10,000 X g for 10 minutes at 4°C, (c) discard the supernatant; (d) resuspend the 
pellet in 100ml serum to be treated, leave at 4°C mixing overnight for the 
adsorption of the insulin as well as other hormones; and (e) centrifuge as before. 
On occasion, the last centrifugation may need to be repeated before the charcoal is 
completely removed. The hormone free plasma is stored in 2 ml aliquots at -20°C. 
 
3.223. Insulin Assay Protocol 
Day 1: Prepare tubes and standard as shown in Table 3.22. All standard samples 
were tested in triplicate and all test samples in duplicate including positive and a 
negative control sample.  
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Tube 
No 
Assay
Buffer 
Test 
Serum/ 
Hormon
e free 
serum 
Insulin 
Standard 
1
st
 
Antibody 
Standard 
concentration 
µIU/ml 
1-3 400ul    Non-specific 
binding tubes 
4-6 400ul   100ul 0 
7-9 200ul 100ul 100ul 100ul 1.56 
10-12 200ul 100ul 100ul 100ul 3.125 
13-15 200ul 100ul 100ul 100ul 6.25 
16-18 200ul 100ul 100ul 100ul 12.5 
19-21 200ul 100ul 100ul 100ul 25 
22-24 200ul 100ul 100ul 100ul 50 
25-27 200ul 100ul 100ul 100ul 100 
28-29 300ul 100ul  100ul Test Sample 
30-31 300ul 100ul  100ul Test Sample 
32-33 300ul 100ul  100ul Test Sample 
 
Table 3.22 insulin assay template 
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Day 2: Add 100ul of 
125
I insulin label (approximately 20000 cpm/tube) to all the 
tubes including three extra tubes for the Total Count. Vortex and incubate for 24 
hours at 4°C. 
Day 3: Add 500ul of the 2
nd
 antibody/PEG complex using the eppendorf repeater 
pipette to all the tubes ensuring that the complex is kept stirring constantly on ice 
whilst adding to the assay tubes. Vortex the tubes well and incubate for a 
minimum of 2 hours at 4°C. Centrifuge the tubes for 30 minutes, at 2500 RPM at 
4°C, decant the supernatant. Tap on a tissue to remove excess liquid. Add 1.5ml 
Phosphate buffered saline to the tubes and centrifuge again for 30 minutes at 2500 
RPM at 4°C. Decant as before and count the tubes on a Packard gamma counter 
for 60 seconds per tube (CPM). 
 
3.224. Results: The results obtained are shown in Table 3.23 at the initial and 
follow up test in 27 twin pairs discordant for diabetes of whom 12 went on to 
develop T1D and are termed as pre-diabetic twins of which all were autoantibody 
positive to GADA and or IA2A. The remaining non diabetic twins were all 
autoantibody negative and were termed as 15 low risk twins. A group of 14 age 
and gender matched healthy controls were also tested 6 years apart. Patients and 
controls were selected to be age as well as gender matched Table 3.20. Twins at 
low disease risk and healthy controls had similar fasting glucose levels as well as 
fasting insulin, glucose clearance and First Phase Insulin Response (FPIR) with 
no evidence of an impaired FPIR. In contrast the pre-diabetic twins had higher 
fasting insulin levels 10±6.0 compared to the controls 4.6±4.0, decreased glucose 
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clearance and FPIR as well as a decreased HOMA-IR to FPIR ratio which is 
predictive of the progression to T1D (p<0.01).  
 
 
 
 Control 
subjects 
initial test 
Control 
subjects 
Final test 
Low risk 
Non 
Diabetic 
Twins Initial 
test 
Low risk 
Non 
Diabetic 
Twins Final 
test 
Prediabetic 
Twins Initial 
test 
Pre-
diabetic 
Twins 
Final test 
N 14 14 15 15 12 12 
Fasting glucose 
(mmol/l) 
4.0 
±0.3 
4.4±0.4 4.1±0.2 4.2±0.3 4.0±1.3 4.9±1.
2 
Fasting 
insulin 
(mIU/ml) 
4.6±4.0 9.3±10.
1 
6.2±3.7 4.2±10.3 10.0±6.0 6.1±3.
5 
6.Glucose 
clearance 
(%/min) 
2.6±0.8 2.5±0.9 3.0±1.3 2.4±1.9 1.5±0.6 1.2±0.
7 
FPIR (mIU 
_ ml_1 _ 10 
min_1) 
796±62
2 
433±19
6 
465±367 499±293 245±129 138±1
12 
HOMA-IR–
to–FPIR 
ratio 
0.0011
8±0.00
09 
0.0036±
0.002 
0.0052±0
.0061 
0.0028±
0.0048 
0.0073±
0.0057 
0.002
46±0.
0338 
 
 
Table 3.23 Glucose and Insulin sensitivity: Data are means ± SD. The low-risk 
twins did not differ from the control subjects, in contrast to the pre-diabetic twins, 
who showed numerous differences from control subjects. *P _ 0.01 for all 
differences. 
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3.225. Discussion: It has previously been reported that monozygotic twins tend to 
develop T1D within 6 years of diagnosis of the index twin (Fava et al., 1998). 
Twins discordant for T1D, for more than 6 years have a decreased probability of 
developing diabetes, estimated at less than 2% and are likely to remain discordant 
(Tun et al., 1994), (Olmos et al.,1998).  
There was no evidence of an impaired beta cell function in the twins who were at 
low disease risk unlike pre-diabetic twins, in whom we found both reduced 
insulin secretion and reduced insulin sensitivity relative to levels of insulin 
secretion and went on to develop diabetes. Failure of the loss of the FPIR, are the 
hallmarks of loss of beta cell function and are earliest signs leading to 
hyperglycaemia and glucose intolerance in both T1D as well as type 2 diabetes. 
There was however, no evidence of any impaired beta cell function in the non-
diabetic twins consistent with a non-genetic event which affects the diabetic twin 
but not their genetically identical non diabetic twin. 
Metabolic, as well as immune, changes detected in the pre-diabetic twins 
however, were not detected in the non-diabetic twins, these features are therefore 
likely to be determined by non-genetic probably environmental or perhaps even 
epigenetic factors as a result of stochastic events. It is possible that with better 
techniques we may be able detect changes in the insulin secretory mechanism as 
well as immune changes which may pre-dispose the non-diabetic twins to the 
disease. This is however unlikely as most changes immune as well as metabolic, 
can be detected months even years prior to the diagnosis of T1D. It should also be 
noted that patients with metabolic changes can present with diabetes without 
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showing any immune changes such as the presence of autoantibodies to Islet auto-
antigen’s namely GADA, IA2, IAA or ZnT8.  
Furthermore presentation of impaired glucose tolerance and frank diabetes can 
occur in the absence of auto-antibodies. Patients can present with impaired 
glucose tolerance as well as presence of GADA but are non-insulin requiring at 
diagnosis with a high risk of progression to insulin therapy and are termed as 
LADA (Pozzilli  & DiMario., 2001). T1D can occur at any age and it is known 
that up to 10% of adults in the developed countries over the age of 30 years 
present with autoimmune diabetes of adults termed as LADA (Turner et al., 
1997). The presentation of T1D in adults appears distinct from diabetes presenting 
in children in terms of genetic, immune and metabolic as well as clinical features 
of the disease.  
Twin studies have shown that immune changes including presence of multiple 
autoantibodies to islet antigens as well as metabolic changes can be detected years 
before diagnosis of T1D. However follow-up date from the British Diabetic Twin 
study has shown that even genetically susceptible individuals such as identical 
twins can remain discordant for diabetes for greater that 50 years without showing 
any signs of immune or metabolic changes confirming that additional non-genetic 
factors are key in the initiation and induction of the disease which could be due to 
unique environmental or stochastic epigenetic events. 
These results suggest that the disease process is unlikely to be due to shared 
inherited defects in insulin secretion or sensitivity as they were not noted in the 
non-diabetic twins however it does not exclude other factors which could 
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accelerate the disease process or promote metabolic decompensation, such as 
increased linear growth and childhood obesity (Hypponen et al., 2000), 
(Bruining., 2000), (Kibirige et al., 2003). In line with this found a disruption in 
the insulin sensitivity to insulin secretion in autoantibody positive siblings who 
later developed diabetes (Fourlanos et al., 2004 ). Notably with the lack of 
identity of all the diabetes susceptibility genes, twin studies as long as they are not 
pre-diabetic are the most appropriate to test whether inherited metabolic changes 
predispose to T1D.   
In this dataset we were unable to support the hypothesis that inherited changes in 
insulin secretion or sensitivity could account for the genetic susceptibility to T1D. 
In contrast pre-diabetic autoantibody positive individuals can show a broad 
spectrum of clinical as well as metabolic phenotype, with normal, impaired or 
diabetic glucose tolerance or in adults as with one of our twin’s frank clinical non-
insulin requiring diabetes (LADA) with a high risk of progression to insulin 
requiring diabetes, (Turner et al., 1997) (Greenbaum et al., 2001).  
Immune as well as metabolic features are detected in TID as well as a proportion 
of cases presenting with diabetes later in life termed as LADA. Autoantibodies to 
Islet antigens have been described previously and are a useful tool in the 
prediction of TID (Bingley et al., 1994), however changes in antibody isotype 
pattern could provide a better understanding in the maturation of the antigen 
specific immune response leading to TID. In this thesis the antigen specific 
isotypes were predominantly of the IgG1 isotype pattern. 
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CHAPTER 3.3 
3.3. DETERMINE WHETHER THE ISOTYPE OF GADA AND IA-2A IN NON-INSULIN 
REQUIRING DIABETIC PATIENTS DIFFERED FROM THOSE FOUND IN TYPE 1 
DIABETIC PATIENTS. 
3.31. INTRODUCTION: The understanding of the pathogenesis of TID comes 
from random autopsy specimens of patients who died close to diagnosis of the 
disease. The degree of islet cell destruction varies from islets intact of beta cells to 
total beta cell destruction. At diagnosis up to 80% of sera from newly diagnosed 
patients can show reactivity to islet cell antigens (Kulmala et al., 2001), ( Hawa et 
al., 1997), (Leslie et al., 1999). The nature and intensity of the islet cell specific 
autoantibody responses to IAA, GADA and IA2A identifies individuals at risk of 
developing TID. Furthermore antigen specific isotype response as well as 
subclass distribution may reflect the maturation of the immune response in the 
progression to TID. The IgG subclass response produced by plasma cells can vary 
depending on the stimulus. The isotype switching is further dependent on the 
DNA rearrangement in the immunoglobulin gene which further relies on T-helper 
cells as well as cytokines.  
Both ICAs and GAD antibodies (GADA) can be detected in T1D patients before 
and after the onset of diabetes (Kulmala et al., 1998) in type 2 diabetic patients 
(Tuomi et al 1999), (Turner et al., 1997), and in patients with stiff - man 
syndrome (SMS), a rare neurological disorder (Solimena et al 1988). In T1D 
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patients, ICAs are polyclonal immunoglobulins (Millward et al., 1988), (Dozio et 
al., 1994).  
In general, ICA is restricted to immunoglobulin of the IgG1 isotype belonging to 
the IgG subclass (Millward et al., 1988), (Dozio et al., 1994). Interferon γ –
dependent antibody isotypes in mice are mainly IgG2a and IgG3 (probable human 
homologs, IgG1 and IgG3) which reflects a Th1 response (Abbas 1996), whereas 
a Th2 response is predominantly IgE or IgG1 (probable human homologs, IgG4 
and IgE) (Abbas 1996). Restriction of ICAs to IgG1 in T1D in humans may 
therefore represent a Th1 dominant immune response. Antigen-specific antibodies 
have been found in a fraction of patients who do not need insulin, although many 
progress to insulin dependency within a few years (Kulmala et al., 1998), (Tuomi 
et al., 1999). These non–insulin requiring diabetic patients with autoantibodies 
may actually suffer from a slowly progressive form of T1D or, LADA. Neither 
has the isotype profiles nor the clonality of antigen-specific antibodies in T1D and 
non-insulin requiring diabetes been characterized.  
3.32. RESEARCH DESIGN AND METHODS 
Patients of European origin with either T1D or non-insulin requiring diabetes 
were studied, and their type of diabetes was determined by standard guidelines 
(Expert Committee 1997); cases in which this definition was uncertain were 
excluded. Classification of T1D was based on 1) control of diabetes with insulin 
from time of diagnosis, 2) diabetic ketoacidosis or marked ketonuria at time of 
clinical onset, 3) lack of obesity, and 4) age at diagnosis (40 years). Classification 
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of type 2 diabetes was based on 1) adequate control of diabetes on diet alone or 
oral hypoglycemic agents at time of sampling, 2) no history of diabetic 
ketoacidosis or ketonuria, and 3) age at time of diagnosis (30 years).  
Non-diabetic twins were administered oral glucose tolerance tests in doses of 75 g 
or 1.75 g/kg, whichever dose was less, to confirm that they were neither initially 
diabetic nor diabetic at intervals there-after. A cross - sectional study of 
antibodies to GAD65 and IA-2 was performed in a consecutive series of selected 
patients who attended a diabetes center and in a prospective study of a cohort of 
non-diabetic identical twins of T1D patients.  
3.33. Subjects: The patients included 52 newly diagnosed T1D patients (mean 
age 20 years, range 5–36; 18 females) who were all tested within 1 month of 
diagnosis; 199 “type 2 diabetic” patients (mean age 57 years, range 30–75; 
disease duration 4 years, range 0–28; 101 female); and 200 normal healthy control 
subjects (mean age 29 years, range 14–71; 95 female) who were selected to have 
a similar distribution for age and sex to the combined groups of 251 diabetic 
patients. None of the control subjects had a family history of diabetes, were taking 
drugs, or had clinical signs of illness. The subjects gave informed consent, and the 
study was approved by the ethical committees at St. Bartholomew’s Hospital and 
the University of Rome, La Sapienza.  
Because isotype assays are expensive, the strategy was to test a sample of 
subjects, to identify, dominant isotypes and then to screen all type 1 and type 2 
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diabetic patients, for the dominant isotypes. Initially, antibody isotypes IgG1, 
IgG2, IgG3, IgG4, IgM, and IgE to both GAD and IA-2 were tested in: 
1) 10 type 2 diabetic patients (mean age 55 years, range 34–75; five female) 
who were all GADA positive, and 
2) A cohort of 34 non-diabetic identical twins of patients with T1D, 15 
subsequently developed T1D,  from the British Diabetic Twin study as described 
earlier and ascertained according to standard criteria, samples were tested both 
before and at diagnosis (NDDG 1979) (Expert Committee 2003). The mean 
period of follow-up was 47 months (range 4–156), the mean age at time of the 
first sample before diagnosis of T1D was 14 years (range 7–31), and the mean age 
at time of the second sample at diagnosis was 17 years (range 7–44; eight 
females). The 19 other twins remained nondiabetic (age at entry 17 years, range 
4–36; nine females) having been followed for a median of 107 months (range 55–
189); the earliest available samples on them were tested, and these twins had an 
estimated disease risk of 2% (1). 
3)  To establish a cutoff for positivity for this initial analysis, we also tested 
37 control subjects (mean age 26 years, range 9–47; 24 males). Subsequently, 
selected dominant isotypes were tested in 52 T1D patients and 199 type 2 diabetic 
patients, and established the cutoff for positivity for dominant isotypes in 200 
normal healthy control subjects.  
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3.34. Diabetes associated Autoantibody analysis: Autoantibodies to GADA and 
IA2A were measured as previously described in chapter 2. 
 
3.35. GADA & IA2A Antibody Isotype initial experiments.  
In vitro transcribed and translated GAD65 or IA-2 labeled with [3 5S]methionine 
were used as the antigens and were prepared as described earlier. A dose of the 
antigen GAD65 or IA2ic containing 50,000 counts/min (CPM)/ 50ul was 
incubated with 2 μl of test serum samples including a positive and a negative in 
house control sample, overnight, at 4°C in 96-well Millipore filtration plates 
(Millipore UK, (Catalogue No MHVBN4550B).  
Monoclonal biotinylated Mouse anti-human antibodies was then incubated with 
the antigen antibody complexes and the immune complexes were then separated 
by employing streptavidin agarose, which binds biotin. Monoclonal biotinylated 
Mouse anti-human antibodies were tested from different sources namely Europath 
Laboratories  as well as Southern Biotech (Clone IgG1 Cat No:9050-08, Clone 
IgG2 Cat No:9060-08, Clone IgG3 Cat No:9070-08, Clone IgG4 Cat No:9190-08, 
Clone IgG4 Cat No:9200-08 and Clone IgG3 Cat No:9210-08 at the 
manufacturer’s suggested dilution of 1:100 in Tris Buffer Saline Tween as well as 
Phosphate Buffer Saline Ph 7.4.  Positive as well as negative immune-reactivity 
was confirmed with the standard protein A sepharose protocol described in 
Chapter 2. 
The initial data from these experiments were not encouraging as the immune 
complexes did not bind sufficiently to the streptavidin agarose and furthermore 
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gave non-specific binding which may have been due to the source of the biotin 
anti human antibodies employed as well as the nature of the liquid phase assay 
performed. The biotinylated antibodies employed here had only been tested in 
Elisa and western blotting systems and not in a liquid phase radio-immunoassay. 
 
3.36. GADA and IA2ic Antibody isotypes assays 
In vitro transcribed and translated GAD65 or IA-2 labeled with [
3 5
S]methionine 
were used as the antigens and were prepared as described earlier in chapter 2. A 
dose of 50 μl of the antigen containing 50,000 counts/min (CPM) was incubated 
with 2 μl of test serum samples in duplicate overnight at 4°C in 96-well millipore 
filter plates thereby allowing an antigen antibody complex to be formed. The 
standard immunoprecipitation assays for GADA and IA2A employ Protein A 
Sepharose which does not bind all immunoblobulins as shown in Table 1.4, and 
cannot differentiate between the antibody isotypes. In order as to achieve 
specificity we employed biotin anti human isotype specific antibodies in 
conjunction with streptavidin agarose beads, the latter binds strongly to biotin, 
allowing separation of the antigen specific antibody isotypes in serum samples to 
overcome this issue. 
To the immune complex Monoclonal biotinylated anti-human antibodies (IgG1 
clone HP6069, IgG2 clone HP6002, IgG3 clone HP6047, IgG4 clone HP 6046, 
IgM clone HP6083 [Zymed, Camarillo, CA], and IgE clone G7-26 [Beckton 
Dickinson U.K., PharMingen, Oxford, U.K.]) at concentrations of 4, 4.8, 2.4, 1.6, 
2, and 5 μg, respectively, were added so as to achieve optimal binding to the 
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immune complexes and incubated at 4°C on a shaker for 1.5 h. Antigen-antibody 
complexes bound to biotinylated monoclonal anti-human antibodies were 
separated for 1.5 h at 4°C with 50 μl of immobilized streptavidin agarose 
immobilized beads (Pierce & Warriner, Chester, U.K.), which binds biotin on the 
antibody molecules. Bound immune complexes were washed 12 times with Tris 
buffer saline containing Tween on the Millipore plate washer, were allowed to dry 
at room temperature before the addition of Meltilex solid scintillant (Wallac, 
Turku , Finland), and were counted on the Wallac 1260 Micro beta scintillation 
counter.  
The current assay protocol for all the antigens utilises the Millipore plates 
MAHAN4B50 plates which eliminates the use of the solid scintillant and instead 
liquid scintillant Ultima Gold, 50µl per well for aqueous solutions was employed. 
This reduces the quenching effect on the CPM detected using the solid Meltilex 
scintillant system previously employed as well as improved the sensitivity of the 
assay procedure. 
 
Each assay for IA-2 and GAD65 isotypes included a serum sample from a patient 
with a rare nerve disease SPS characterized with spasticity of the axial muscles 
who showed reactivity to all the tested isotypes, a prediabetic individual (a twin 
who subsequently developed T1D but was not part of this study) who was 
positive for GAD and IA-2 antibodies, and an antibody negative normal control 
subject to confirm specificity and reactivity of the antibody isotypes. To establish 
a cutoff for positivity, the results were calculated in control subjects as the mean 
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CPM for each antibody isotype minus the blank CPM. Positive results in patients 
were defined as CPM 3 SD above control mean levels and all samples scoring 
positive were repeated to avoid false positive signals as well as where duplicate 
results showed a significant variation 
Each assay for IA-2 and GAD65 isotypes included a serum sample from a patient 
with a rare nerve disease SPS characterized with spasticity of the axial muscles 
who showed reactivity to all the tested isotypes, a prediabetic individual (a twin 
who subsequently developed T1D but was not part of this study) who was 
positive for GAD and IA-2 antibodies, and an antibody negative normal control 
subject to confirm specificity and reactivity of the antibody isotypes. To establish 
a cutoff for positivity, the results were calculated in control subjects as the mean 
CPM for each antibody isotype minus the blank CPM. Positive results in patients 
were defined as CPM + 3 SD above control mean levels and all samples scoring 
positive were repeated to avoid false positive signals as well as where duplicate 
results showed a significant variation. 
3.37. Clonality 
To determine clonality, T1D and non-requiring type 2 diabetes patients positive 
for the dominant GAD and IA-2 isotype as well as control subjects were tested. 
Sera were tested after immunoprecipitation as described above, except instead of 
using biotinylated monoclonal anti-human antibodies, we used biotin conjugated 
mouse anti-human  light chain (clone G20-193) and   light chain (clone JDC-
12) monoclonal antibodies at a concentration of 10 μg per well, the reactivity and 
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the specificity of these subclass specific monoclonal antibodies have previously 
been established in a large World Health Organization study (Jeffries et al., 1985). 
3.38. Results 
3.381. GADA & IA2 antigen specific antibody assays: GADA was detected in 
29/52 (56%)of the newly diagnosed TID patients, 10/199 (5%) type 2 diabetes 
and IA2 in 23/52 (44%) of the newly diagnosed TID and 5/199 (3%) of the type 2 
diabetes patients. GADA or IA2 were more frequently detected in the newly 
diagnosed 37 (71%) compared with only 10 (5%) in the type 2 diabetic patients (p 
<0.0001). 
3.382. Screening for dominant isotypes: Selected groups of patients who tested 
for positive GADA or IA2 were tested for isotypes IgG1, IgG2, IgG3, IgG4, IgM 
and IgE respectively as these assays were very costly. The groups included 34 
identical twins discordant for diabetes followed prospectively and 15 were tested 
both before and at diagnosis of diabetes, 19 non diabetic twins and 10 type 2 
diabetic patients (Table 3.30). The samples tested showed IgG1 dominance for 
both GAD & IA2 antigens both before occurring in 8 and 8 out of 15 and at 
diagnosis of diabetes in 7 and 10 out of 15 twins respectively. The isotype profile 
for isotypes other than IgG1 was noted for GADA  in the prediabetic samples for 
IgG3 (3 of 15), IgG4 (1 of 15) and IgM (1 of 15) and  for IA2 IgG2 (3 of 15). The 
isotype profile for isotypes other than IgG1 for GADA at diagnosis for IgG2 (3 of 
15) and for IA2 IgG2 (3 of 15) and IgE (2 of 15) respectively. In these samples 
both before and at diagnosis of diabetes there was no evidence of a significant 
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spreading or switching of the isotype response to either of the diabetes associated 
antigens tested (Table 3.30). Similarly there was no significant difference in the 
isotype antibody pattern with type 1 and type diabetes and in the latter GADA 
showed 5 out 10 with IgG1 isotype,  no other isotypes were noted for IA2 other 
than IA2 antibodies.  
Of the 19 non-diabetic twins tested GADA antibodies were detected in only 1 
patient who also had GADA IgG1 isotype but was negative for both IA2 antibody 
as well as isotypes and to date remain diabetes free. 
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Antibodies Non diabetic 
twin 
TID Twin pre-
diagnosis 
TID Twin 
At diagnosis 
‘Type 2 
diabetes ‘ 
Patients 
N 19 15 15 10 
GADA  1 12 10 10 
GADA IgG1 1 8 7 5 
GADA IgG2 0 0 3 0 
GADA IgG3 0 3 0 0 
GADA IgG4 0 1 0 0 
GADA IgE 0 0 0 0 
GADA IgM 0 1 0 0 
IA2A 0 13 12 4 
IA2A IgG1 0 8 10 0 
IA2A IgG2 0 3 3 0 
IA2A IgG3 0 0 0 0 
IA2A IgG4 0 0 0 0 
Table 3.30 Data shows numbers scoring greater than ±3SD of control (n-37) 
tested for each antibody GADA or IA2 and their antibody isotype. None of the 
control subjects were positive for any antibodies or antibody isotypes tested. 
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3.383. Screening for selected isotypes: The initial experiments had shown that 
the dominant isotypes for both GADA and IA2 was IgG1. A Th1 and Th2 
immune response in the mouse is associated with IgG2a and IgG1 antibodies, the 
human homologues are probably IgG1 and IgE which reflect the Th1 and Th2 
immune response. Evidence suggests that the Th2 immunity is associated with 
IgG4 and IgE responses, because both can be stimulated by the Th2 cytokine IL-4  
Lundgren et al., 1989), (King & Nutman 1993). Because IgG1 and IgE could 
reflect a Th1 and Th2 immune response we elected to screen all 251 patients (52 
newly diagnosed T1D and 199 “Type 2 diabetics”) for these two isotypes. 
Of the 52 T1D patients tested GADA IgG1 was detected in 15 patients (29%) and 
56% were GADA positive, IA2A IgG1 was detected in 22 patients (42%) and 
44% were positive for IA2A (Figure 1.4 & Figure 1.5) 
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Figure 3.4: IA2A antibodies and IA2 IgG1 and IgE isotypes in newly 
diagnosed TID (n=52). Intersecting regions indicate number of 
patients with combinations of antibodies and isotypes. 
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3.384. Discussion: The aim of the study was to determine whether the isotype and 
clonality to key antigens GADA and IA-2A in type 2 diabetic patients differed 
from those found in T1D patients and to test if there was any evidence of isotype 
switching before and at diagnosis. By employing biotinylated antihuman isotype 
specific antibodies in the context of a radiobinding assay we found that the 
majority of the response to these key antigens was restricted to IgG1 subclass in 
both T1D as well as ‘type 2 diabetes’. Furthermore in the twins there was no 
GADA 
GADA 
IgE 
GADA 
IgG1 
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 0 
 
0 
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4 
 
Figure 3.5, GADA antibodies and GADA IgG1 and  IgE isotypes in 
newly diagnosed T1D patients (n=199). (“Of Type 2 diabetics” none 
had GADA IgE). 
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evidence of isotype switch before or at diagnosis with IgG1 as the dominant 
isotype detected suggesting that a dominant Th1 type immune response may be 
present from initiation of the disease in these twins. 
These findings are consistent with the findings in the BABYDIAB study where 
diabetes onset and β cell destruction occurred during an early or subsequent IgG1 
dominant antibody response (Bonifacio et al., 1999). None of the other isotypes 
tested to either antigen GADA or IA2 were detected in more than a few of the 
patients tested. These findings are in agreement with other studies of ICA and 
GADA in newly diagnosed T1D patients and monoclonal GADA derived from 
T1D patients, all showing a predominant IgG1 isotype (Millward et al 1988), 
(Dozio et al., 1994), Madec et al., 1996), (Bonifacio et al., 1999). 
A broad isotype response to GADA was shown in our previous study in patients 
with a rare nerve disease SMS, but an IgG1 restriction in T1D and ‘type 2 
diabetes’ patients (Hawa et al., 1998). There was no shift in the Th1, Th2 
phenotype for the antibody isotype response to either GADA or IA2 in this study 
with IgG1 as the dominant isotype detected. There is evidence for an antibody 
response being characteristics of a Th immune response phenotype and in humans 
IgG1 is linked with a Th1 immune response while IgG4 is linked with Th2 
immunity. In the BABYDIAB study an IgG4 response was noted to insulin but it 
was not followed by an IgG4 response to GADA or IA2 indicating that IgG4 
response is not antigen specific Bonifacio et al., 1999). 
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Interestingly none of the healthy controls or T1D patients had GADA IgG1 in the 
absence of GADA antibodies. Previous reports have shown ‘type 2 diabetic’ 
patients who are ICA and or GADA positive tend to have similarities to the 
classical TID patients, including low or normal body weight, presence of HLA 
DR3 and DR4 and a tendency to go on to require insulin therapy (Tuomi et al., 
1999), (Leslie & Pozzilli 1994), Niskanen et al., 1995). In this present study the 
frequency of IA2 antibodies in patients with ‘type 2 diabetes’ was less common 
than GADA consistent with other reports (Seissler et al.,1998).                                                                      
These results support the hypothesis that patients with apparent type 2 diabetes 
because they are initially non-insulin requiring, but with autoimmune features, 
have similarities in the disease process to autoimmune T1D. If this is true than 
such cases would potentially be ideal for intervention studies to try and modulate 
the disease process, thereby avoiding the ethical concerns of intervention studies 
in antibody positive non diabetic healthy children. 
In conclusion these observations confirm that the nature of the antigen specific 
antibodies in both T1D and adult-onset non-insulin requiring diabetes 
masquerading as “type 2 diabetes”, are similar (with a dominant IgG1 isotype/ 
sub type)  and consistent with a Th1 type immune response. 
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CHAPTER 4 
4.0. WHETHER AUTOANTIBODIES IN ADULTS PRESENTING WITH APPARENT 
TYPE 2 DIABETES ARE PREVALENT AND SIMILAR TO T1D. 
4.01. Aims: 4.01) To characterize adult-onset autoimmune diabetes in European 
patients, presenting with type 2 diabetes. 4.02) Are autoantibodies prevalent in 
patients presenting with type 2 diabetes analysis of the Action Lada and 
Collaborative Atorvastatin Diabetes Study (CARDS) cohorts 4.03) Evidence of 
Bimodality using Quintile Quintle (QQ) Plot for GADA 4.04) Do autoantibodies 
differentiate LADA cases? 4.05) Is there evidence of non-diabetes associated 
autoimmunity in LADA patients. 
 
4.06. INTRODUCTION: Latent Autoimmune Diabetes of Adults onset (LADA) 
is defined by three criteria: 1) age of diagnosis >30 years 2) presence of diabetes-
associated antibodies and 3) insulin-independence for six months post-diagnosis 
(Rolandson 2010). The prevalence of LADA in adults presenting with non-insulin 
requiring diabetes is approximately 10% with 4-12% of Caucasian’s presenting 
with diabetes associated autoantibodies. LADA therefore may be more common 
or as common as T1D. However there remains extensive contention as to whether 
LADA can be classified as a separate disease to TID due to their adult age at 
onset, presence of autoimmunity, that they remain free from insulin therapy for at 
least 6 months after diagnosis and show less genetic load in comparison to the 
classic T1D (Desai 2008), (Gale 2005).  
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Action LADA is a European study which sought to address these questions by 
ascertaining adult-onset diabetic patients in nine European hospital-based clinics 
within a defined period and screening them for GADA. We hypothesized that 
autoimmune diabetes would be prevalent in Europe, that LADA would be more 
prevalent than T1D and would show phenotypic differences from it.   
4.07. Participating countries: Serum samples were obtained from 9 participating 
centres, Odense University Hospital (coded OUH), Denmark , Royal Victoria 
Hospital, Belfast UK (coded RGH), University of Rome "La Sapienza" Italy 
(coded IT, ITA,B,C,D,E,F,G &H), University of Düsseldorf, Germany(coded 
UKD & DDFI),  Rudolfstiftung Hospital, Austria(coded ISF),  National Public 
Health Inst, Finland (coded KTL A,B,C,D & E),  Hospital de Sabadell, Barcelona 
Spain (coded RIH),  Hospital Edouard Herriot, Lyon, France (coded UCB) and 
London (coded L). 
Participating centres collected samples from suitable patients fulfilling the 
inclusion criteria and shipped sample aliquots in duplicate on dry ice to London 
where they were stored at -20 C prior to analysis. Samples were tested in 
duplicate in batched assay’s to avoid assay variation.  
 
4.08. Research Design: The aim was to screen 10,000 newly-diagnosed non-
insulin requiring diabetes cases for GADA. To estimate the prevalence and 
epidemiology of LADA in Europe a sample size of around 1200 people per centre 
(nine centres involved in screening) will enable the prevalence to be estimated 
173 
 
with 95% certainty, as being between 8% and 12% (based on the UK study 
(Turner et al., 1997), by identifying 1,000 LADA cases (about 120 per center).  
In the present study a consecutive series of 6809 patients attending European 
clinics (age range 30-70 years) were examined cross-sectionally and centrally for 
autoantibodies to diabetes associated antibodies, glutamic acid decarboxylase 
(GADA), insulinoma-associated antigen-2 (IA-2A) and zinc-transporter8 
(ZnT8A). Autoantibody-positive patients were designated T1D (when insulin-
treated immediately at diagnosis), and latent autoimmune diabetes (LADA) (when 
they remained free of insulin treatment for 6 months).  
                                                                                                                                                                                                                                                                                                                                           
4.09. PATIENTS AND METHODS  
4.10. Action LADA Cohort: All patients came from 9 European hospital-based 
centers involved in the ACTION LADA Project, a European Union-funded multi-
centre European study with the aim
 
of identifying immune and clinical risk factors 
for adult-onset autoimmune diabetes (www.actionlada.org). Patients were 
designated with diabetes according to standard criteria and LADA was defined as 
patients aged 30- 70 years of age with autoantibodies to GAD65 and who did not 
require insulin treatment for at least 6 months post-diagnosis (Leslie et al., 2008) . 
 
4.11. Inclusion criteria:  Diagnosis of diabetes (with at least 2 fasting blood 
glucose measurements > 7 mmol/L); time from diagnosis < 5 years for all non-
insulin requiring diabetes patients; all patients were aged 30 – 70 years at 
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examination.  
4.12. Exclusion criteria: Incomplete data set,  pregnant at the time of sampling, 
renal disease with raised creatinine or proteinuria; acute illness at the time of 
testing; in addition, patients with non-insulin requiring diabetes > 5 years disease 
duration were excluded as well as subjects with a family history of autoimmune 
disease. Data on medication and risk factors were registered
 
by the attending 
physician based upon the medical
 
files. Serum and plasma samples were collected 
according to standard procedures and stored at –20°C in a freezer linked to the 
Tutela Alarm System. 
Each subject was tested locally for waist circumference, blood pressure as well as 
standard demographics where possible. Lipids, and lipoproteins (serum total HDL 
cholesterol
 
and triglycerides) were determined by standardized assays at each 
center. All patients were tested for GADA, IA2A and ZnT8 antibodies in the 
central laboratory (London).  
4.13. Collaborative Atorvastatin Diabetes Study Cohort (CARDS): The 
Collaborative Atorvastatin Diabetes Study (CARDS) was a double-blinded, 
randomized, placebo-controlled multicentre trial of atorvastatin for the primary 
prevention of cardiovascular disease in presumed type 2 diabetes patients (defined 
by WHO criteria, median age 62yrs and duration of diabetes 8yrs) who received 
atorvastatin or placebo and were evaluated for diabetes outcomes over a median 
follow up of 4yrs).  A total of 2838 patients were included in the study. 
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4.14. Antibody Measurement: The radio-immuno-precipitation assay for 
GADA, IA2A and ZnT8 were performed as described in chapter 2. All samples 
were tested centrally in London in duplicate including positive and negative 
control standard sera. In the DASP 2010 workshop our assay for GAD65 had a 
sensitivity of 76% and a specificity of 98%, for IA2ic a sensitivity of 54% and a 
specificity of 100% and for ZnT8 a sensitivity of 52% and a specificity of 98%. 
Positive samples were repeated to confirm GADA, IA2A and ZnT8 positivity and 
to reduce false positive rate.  
4.15. Thyroid peroxidase (TPOA) and parietal cell (PCA) 
TPOA and PCA autoantibodies were measured by ELISA in Germany by Dr 
Jochem Seissler on all diabetes-associated autoantibody positive patients (n=1130; 
mean age 52.3 ± 10.1years, range 30-69 years) and compared with a randomly 
selected cohort of diabetes-associated autoantibody negative patients (n=690; age 
54.5 ± 9.0 years,  30-70 years). All serum samples of patients positive for GADA, 
IA2 or ZNT8 were tested as well as GADA negative cases from five centres 
Germany, Austria, Belfast, Rome and London where sufficient sera was available 
were investigated in a blinded fashion for antibodies: thyroid peroxidase (TPO) 
and parietal gastric cells (PCA).  
4.16. Bimodal Distribution: A bimodal distribution in statistics is a continuous 
distribution of data with different modes and one example would be to look at the 
heights of men and women which when put together would have two different 
peaks with two different modes for each of the genders. In the NIRAD study, 
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(Buzzetti et al., 2007) the distribution of GADA titres showed an apparent bimodal 
distribution. In that study the patients (n=191 in total) were divided into two 
subgroups representing the two distributions namely low (<32U) and high (>32U) 
(Buzzetti et al., 2007) and the data was log transformed. This study based on the 
GADA titers identified two subgroups of patients with adult onset autoimmune 
diabetes having distinct clinical, autoimmune as well as genetic features. Patients 
with high GADA titers had features of insulin deficiency, extended autoimmunity 
as indicated by the presence of IA2 antibodies as well as TPO antibodies in the 
NIRAD study. In this present cohort the data set for GADA, IA2A and ZnT8A was 
similarly analyzed for evidence of bimodality.   
4.17. Statistical analyses 
 The differences between
 
groups were tested with X 
2
 test or Fisher’s exact test 
when appropriate. Quantitative variables were analyzed
 
with General Linear 
Model Univariate, a post-hoc analysis was performed with Bonferroni test and 
data presented as mean (SD). All analyses were performed using SPSS statistical 
software for Windows. A P value <0.05 was considered
 
statistically significant. 
Q-Q probability plots were used to analyze the distribution of GADA 
measurements for normality. Observed antibody values were plotted along the 
horizontal axis against expected normal values under normality on the vertical 
axis using Blom’s proportion estimation formula. The study protocol is in 
accordance
 
with the Declaration of Helsinki, and was approved by local ethics 
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committee in each study center. Informed written consent was obtained from all 
subjects before blood sampling. 
4.18. RESULTS 
4.19. QQ Plot Analysis: 
A Q-Q plot of GADA positive patients was performed to seek distinct 
populations, we identified an inflexion point corresponding to 70 and 200 WHO 
IU consisting with two modes. Further, a plot of log GADA titre according to 
patient frequency revealed a possible bimodality, and the lowest value between 
the two modes was at GADA titre 200 WHO IU. Therefore, we arbitrarily 
analyzed the data according to GADA positivity in those between 70 to 200 WHO 
units and those greater than 200 WHO units of GADA.  
The cut off for positivity was selected arbitrarily based on the end point of the 
standard curve and further confirmed with Quantile-Quantile (Q-Q) probability 
plots. QQ plots were used to analyses the distribution of measurements for 
normality and, for GADA, the vertical line at 70 WHO units indicated the 
laboratory cut off with values greater than 70 units scored positive Figure 4.1, 
For IA2A at 25 WHO units indicated the laboratory cut off Figure 4.2, Figure 
4.3 and for ZnT8A at 10 Laboratory units indicating the laboratory cut off for 
positivity Figure 4.4. and for the CARDS data set for GADA values greater than 
40 units scored positive 
178 
 
 
 
Figure 4.1: QQ plot of GADA positive cases. The red line indicates the cut off at 
70 units with a second inflection point at 200 units shown in purple with a further 
inflection at 400 units. 
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Figure 4.2: GADA QQ plot for all cases, the first vertical line indicates the 
Laboratory based cut off for positivity for GADA this was set at 70 units based on 
the end point dilution of the standard curve and as indicated by the vertical line in 
the QQ plot. The second vertical line indicates another inflection point equivalent 
to 200 units the limit for high titre GADA. A closer analysis of the dataset shows 
another inflection point at 400IU. 
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Figure 4.3 IA2A QQ plot for all cases, the vertical line indicates the Laboratory 
based cut off for positivity for IA2A this was set at 25 units based on the end 
point dilution of the standard curve and as indicated by the vertical line in the QQ 
plot. The red line indicates the calculated inflection point at 8 units. Changing to 
the lower cut off will improve the sensitivity of the assay but this could reduce the 
specificity of the assay. 
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Figure 4.4: ZnT8 QQ plot for all cases, the vertical line indicates the Laboratory 
based cut off for positivity for ZnT8A this was set at 10 units based on the end 
point dilution of the standard curve and as indicated by the vertical line in the QQ 
plot. 
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Figure 4.5: CARDS Study GADA QQ plot for all cases, the vertical line 
indicates the Laboratory based cut off for positivity for GADA this was set at 40 
units based on the end point dilution of the standard curve shown in black and as 
indicated by the vertical line in the QQ plot, the red line indicates the cut off at 70 
units. 
 
 
 
183 
 
4.20 Characteristics of adult-onset autoimmune diabetes in Europe in 
patients presenting with ‘type 2 diabetes’: A total of 6,809 patients were 
screened for diabetes-associated autoantibodies from the Action LADA cohort. 
Of these 654 subjects were misclassified, due to inappropriate age or disease 
duration, and were excluded. Of 6,155 subjects fulfilling the inclusion criteria: 
84.6% were Caucasian, 2.5% Asian, 1.2% African, 4.5% came from Middle East, 
and 7.2% were other. Their mean (SD) age was 54.4 (9.6) years, mean duration of 
diabetes was 2.2 (1.6) years and 58.5% were males.  
A) Of 6,156 patients aged 30-70 years presenting with diabetes, 598 (9.7%) were 
positive for at least one autoantibody, with mean age 49.6 (10.8) years, GADA 
alone was detected in 8.8%. The demographics of the GADA positive compared 
to GADA negative groups are shown in Table 4.1. The demographics of the any 
autoantibody positive compared to autoantibody negative groups are shown in 
Table 4.2.  Of autoantibody positive IA2A and ZnT8A(irrespective of  GADA) 
compared with autoantibody negative patients (i.e. patients with ‘type 2 
diabetes’), mean age and mean age of onset were significantly lower (p<0.0001) 
(Table 4.3).  
Analysis of BMI was corrected for age of onset, gender, duration of disease and 
other analyses were corrected for age of onset, gender, duration of disease, BMI. 
Of autoantibody positive compared with autoantibody negative patients after this 
correction: mean age, age of onset, BMI, waist hip ratio (WHR) and waist 
circumference were significantly lower (p<0.0001), while HDL cholesterol 
levels were higher (p <0.0001) (Table 4.2). Similarly and more important to note 
184 
 
patients with auto-antibodies that is having an antibody in the absence of GADA 
also tended to be younger, leaner and more often on insulin in comparison to the 
autoantibody negative cases (Table 3). 
B) Of 2838 CARDS patients, sufficient sera as well as clinical data was 
available for GADA screening in 2425 patients. (Ethical approval was acquired 
by the industrial partner Pfizer UK.) The demographics of the GADA positive 
compared to GADA negative groups are shown in Table 4.4. All CARDS study 
samples were tested in batched assays to avoid assay variability and all samples 
scored positive were repeated to avoid false positives. The cut off for positivity 
was based on the end point dilution of the standard curves in this batched assay 
was set at 40 WHO IU. The data obtained from the QQ plot analysis (Figure 4.5) 
again agreed with the cut off value set for positivity, though lower than in the 
Action LADA Cohort presented earlier where the cut off for positivity was 
established at 70WHO IU. This lower cut off set at 40 WHO IU however only 
added an additional 10 cases under the cut off of 70 WHO IU. Therefore caution 
must be heeded in analyzing such large sets of data and the utilization of tools 
such as the QQ plot should be considered. 
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 GADA Positive GADA Negative  
Cases 541 5615  
Females* 
Males 
n=279 (52.0%) 
n=258 (48%) 
n=2238 (40%) 
n=3335 (59.6%) 
P<0.0001 
Mean age (years)  49.5 (10.8) 55 (9.6)  P<0.0001 
Age of onset 
(years) 
47.4 (11.7) 53. 1 (18.6)  P<0.0001 
Duration Disease 
(years) 
2.2 (1.6) 2.2 (1.6) P=0.75  
BMI (kg/m
2
)
 
 27 (6.3) 30.9 (6.4) P<0.0001 
Subjects on 
insulin (%) 
259/509 (50.9%) 756/5109 (14.8%) P<0.0001 
Time to Insulin 
(years) 
0.61 (1.03) 0.87 (1.4) p<0.18 
Waist-Hip ratio 0.90 (0.1) 0.953 (0.09) P<0.0001 
Waist 
Circumference 
93.1 (16.1) 103.3 (14.4) P<0.0001 
HDL Cholesterol 
(mmol/L) 
1.47 (0.46) 1.27 (0. 47)  P<0.0001 
LDL Cholesterol 
(mmol/L) 
2.3 (1.01) 2.22 (1.01)  P=0.99  
 
Table 4.1. Features of Action LADA Cohort GADA positive versus GADA 
negative diabetes patients. Mean (SD). *missing information for gender (n=4). 
More autoantibody positive patients were receiving insulin (50.9% compared with 
14.8% autoantibody negative patients; p<0.0001). No differences were seen in 
LDL cholesterol values. 
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 Autoantibody   
Positive  
Autoantibody  
Negative  
P value 
Cases 598 5558  
Females* 
Males 
n=303 (50.7%) 
n=295 (49.3%) 
n=2260 (40.7%) 
n=3298 (59.3%) 
<0.001 
Mean age (years)  49.6 (10.7) 54.9 (9.4)  <0.001 
Age of onset 
(years) 
47.4 (11.7) 52.5 (10.6)  <0.001 
Duration Disease 
(years) 
2.2 (1.6) 2.3 (1.6) >0.50  
BMI (kg/m
2
)
 
 27.2 (6.2) 30.9 (6.5) <0.001 
Subjects on insulin 
(%) 
279/564(49.5%) 728/5508 (13.2%) <0.001 
Time to Insulin 
(years) 
0.61 (1.03) 0.87 (1.4)  0.180 
Waist-Hip ratio 0.90 (0.1) 0.95 (0.09) <0.001 
Waist 
Circumference(cm) 
93.7 (16.1) 
 
103.8 (14.6) <0.001 
HDL Cholesterol 
(mmol/L) 
1.44 (0.4) 1.29 (0. 39)  <0.001 
LDL Cholesterol 
(mmol/L) 
2.05 (0.95) 1.60 (0.82)  >0.50  
Systolic BP 
(mmHg) 
116.6 (29.1) 122 (31.0) <0.001 
TGL (mmol/L) 1.5 (1.4) 1.97 (1.5) <0.001 
 
Table 4.2: Features of any autoantibody positive versus autoantibody negative patients 
(Mean, SD) 
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 ZnT8 and/or IA-
2A  Positive 
(GADA negative) 
Autoantibody  
Negative  
P value 
Cases 57 5558  
Females* 
Males 
n=21 (36.8%) 
n=36 (63.2%) 
n=2260 (40.7%) 
n=3298 (59.3%) 
>0.5 
Mean age (years)  50.4 (10.3) 54.9 (9.4)  <0.001 
Age of onset (years) 47.5 (12.4) 52.5 (10.6)  0.005 
Duration Disease (years) 1.9 (1.7) 2.3 (1.6) 0.19 
BMI (kg/m
2
)
 
 28.5 (1.7) 30.9 (6.5) <0.001 
Subjects on insulin (%) 20/57 (35%) 728/5508 (13.2%) <0.001 
Time to Insulin (years) Insufficient data 0.87 (1.4) _______ 
Waist-Hip ratio 0.9 (0.1) 0.95 (0.09) 0.002 
Waist Circumference (cm) 96.1 (12.7) 103.8 (14.6) 0.003 
HDL Cholesterol (mmol/L) 1.42 (0.33) 1.29 (0. 39)  0.66 
LDL Cholesterol (mmol/L) 3.1 (0.6) 1.60 (0.82)  >0.5 
Systolic BP (mmHg) 121.9 (22.9) 122 (31.0) >0.5 
TGL (mmol/L) 1.6 (0.4) 1.97 (1.5) >0.5 
 
Table 4.3: Features of patients positive for autoantibodies other than GADA versus 
autoantibody negative patients. Mean (SD). 
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Baseline 
Characteristics 
GADA Positive 
(n = 173) 
GADA Negative 
(N = 2252) 
 
p-value 
Age at diagnosis 
(Years) 
51.51  9.28 54.98  9.43 < 0.0001 
Duration of 
diabetes (Years) 
10.16  7.04 7.63  6.24 < 0.0001 
BMI (kg/m
2
) 27.31  3.65 28.91  3.49 < 0.0001 
HbA1c (mmol / L) 8.459  1.509 7.778  1.380 < 0.0001 
LDL-C (mmol /L) 3.121  0.687 3.026  0.704 0.0876 
HDL-C (mmol /L) 1.559  0.392 1.389  0.319 < 0.0001 
TGL (mmol/L) 1.560  0.955 1.978  1.081  < 0.0001 
 
Table 4.4.  CARDS Cohort Characteristics GADA Positive versus GADA Negative 
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4.21. EVIDENCE OF BIMODALITY USING QUINTILE QUINTLE (QQ) PLOT FOR 
GADA 
To further differentiate autoantibody positivity, according to autoantibody titres 
on the whole cohort we used the QQ plot analysis. The QQ plot confirmed the 
selection of the laboratory based cutoff for positivity at 70 WHO IU based on the 
end point dilution of the standard curve employed independently, as well as 
identifying two distinct cohorts among GADA positive subjects, with an 
inflection at 70 and another at 200 WHO IU (GADA low) and another inflection 
at 200 WHO IU (GADA high) (Figures 4.1 & 4.2).  
In order to test for bimodality further, GADA titre data from the Action LADA 
cohort was log10-transformed and a histograms illustrating the distribution of 
GADA high and low log10-transformed titres were constructed using SPSS shown 
in Figure 4.6. Normality was analyzed in each of the distributions by the Shapiro-
Wilk statistic, which tests the null hypothesis that the sample in question 
conforms to a normal distribution. However from the statistical analysis using 
Shapiro-Wilk test for both low titre as well as high titre GADA it was apparent 
that the data was not normally distributed (p<0.05). A similar approach was 
utilized by Buzzetti et al 2007 to show a bimodal distribution for GADA titres 
((Buzzetti et al., 2007) where they log transformed the dataset. Of note log 
transformation changes the quality of the dataset and cannot be used to justify the 
presence of bimodality in the original data.  
It is important to note the number of subjects in each group, the Action LADA set 
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of n=701 (high titre (n=511) low titre (n=190)) was substantially larger in 
comparison to published NIRAD data (Buzetti et al 2007)  of which n= 191 (high 
titre (n=94) low titre (n=97).  
 
 
 
Figure 4.6  Action LADA dataset bimodality distribution analysis. A histogram of the log10 
transformed GADA titres for the Action LADA dataset revealed an apparent bimodal 
distribution. The distributions showed two modes however each mode was not normally 
distributed. 
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Figure 4.7:  Action LADA & CARDS combined dataset bimodality distribution analysis A 
histogram of the log10 transformed GADA titres for the combined data for Action LADA and 
CARDS dataset revealed an apparent bimodal distribution. The distributions showed two 
modes 70-200 and another >200 in a total of 701 cases. 
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Autoimmune diabetes patients with high titre GADA (n=403), in contrast to low 
titre GADA (n=138), were more likely to be female, younger, with lower BMI 
(p<0.01 for all comparisons) and lower triglycerides (p=0.01) and systolic blood 
pressure (p=0.04) (data not shown) with more on insulin treatment (54.6% versus 
39.7%; p=0.0045) (Table 4.5). When compared with GADA negative patients, 
high GADA titre patients had lower waist circumference, WHR as well as higher 
HDL cholesterol, and more patients were insulin treated (p<0.0001 for all 
comparisons) (Table 4.5). Compared to GADA negative patients, the low GADA 
titre group also had lower waist circumference, WHR and BMI (p<0.01 for all 
comparisons), as well as higher HDL cholesterol levels (p=0.02) and more 
patients were insulin treated (p<0.0001) (Table 4.6). Among all GADA positive 
patients there was an inverse correlation between GADA titre and BMI (r= -
0.054, p=0.243), WHR (r=-0.103, p=0.047) and time to insulin therapy (r=-0.156, 
p=0.032), but not age at diagnosis (r=0.129, p=0.010). Time to insulin was 
positively correlated with age at diagnosis (r=0.214, p=0.007); the younger the 
age at diagnosis, the earlier insulin was likely to be introduced. 
 
 
 
 
193 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.5 . Features of GADA High versus GADA Low titre patients. (Mean, SD) 
 
 
 GADA High GADA Low P value 
Cases 403 138  
Females 
Males 
220 (54.4%) 
180 (44.6%) 
59 (42.8%) 
78 (56.5%) 
0.02 
 
Mean age (years)  49.3 (10.7) 50.2 (10.9) 0.09  
Age of onset (years) 47.0 (14.0) 47.6 (10.8) 0.08 
Duration Disease 
(years) 
2.14 (1.6) 2.46 (1.7) 0.07 
BMI (kg/m
2
)
 
 26.7 (6.1) 28.5 (6.6) 0.008 
Subjects on insulin 
(%) 
207/379 (54.6%) 52/131 (39.7%) 0.005 
Time to insulin (y) 0.67 (1.0) 0.86 (1.4) 0.81 
Waist-Hip ratio 0.90 (0.1) 0.89 (0.1) 0.10  
Waist 
Circumference 
92.0 (15.7) 96.7 (16.6) 0.013 
HDL Cholesterol 
(mmol/L) 
1.49 (0.5) 1.44 (0.5) 0.6 
LDL Cholesterol 
(mmol/L) 
2.36 (0.98) 2.16 (1.08) 0.33 
Systolic BP (mmHg) 116.3 (28.8) 116.0 (31.1) 0.96 
TGL (mmol/L) 1.23 (0.9) 1.81 (1.7) 0.002 
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Table 4.6:  Features of GADA low versus antibody negative patients. Mean (SD).  
 GADA Low Autoantibody  
Negative  
P value 
Cases 138 5558  
Females* 
Males 
59 (42.8%) 
78 (56.5%) 
n=2260 (40.7%) 
n=3298 (59.3%) 
>0.5 
Mean age (years)  50.2 (10.9) 54.9 (9.4)  <0.001 
Age of onset (years) 47.6 (10.8) 52.5 (10.6)  <0.001 
Duration Disease 
(years) 
2.46 (1.7) 2.3 (1.6)  0.076 
BMI (kg/m
2
)
 
 28.5 (6.6) 30.9 (6.5) < 0.001 
Subjects on insulin 
(%) 
52/131(39.7%) 728/5508 (13.2%) < 0.001 
Time to Insulin 
(years) 
0.86 (1.4) 0.87 (1.4)  >0.5 
Waist-Hip ratio 0.89 (0.1) 0.95 (0.09) <0.001 
Waist 
Circumference 
(cm) 
96.7 (16.6) 103.8 (14.6) < 0.001 
HDL Cholesterol 
(mmol/L) 
1.44 (0.5) 1.29 (0. 39)   >0.5 
LDL Cholesterol 
(mmol/L) 
2.16 (1.08) 1.60 (0.82)  < 0.001 
Systolic BP 
(mmHg) 
116.0 (31.1) 122 (31.0) < 0.001 
TGL (mmol/L) 1.81 (1.7) 1.97 (1.5) < 0.001 
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4.22. DO AUTOANTIBODIES DIFFERENTIATE LADA CASES FROM TYPE 2 
DIABETES AND TID? 
Of the 6156 patient tested 598 were positive for at least one autoantibody GADA 
IA2A or ZnT8A and 1035 subjects were on insulin therapy. Autoantibodies 
distinguished LADA from type 2 diabetes cases the former tending to be younger 
as well as leaner at diagnosis unlike autoantibody negative type 2 diabetes 
patients (Table 4.2). 
Of 598 patients positive for at least one autoantibody (GADA, IA-2A or ZNT8A) 
275 (46%) were on insulin. Of 275 insulin-treated patients, information on precise 
time to insulin therapy was available on 203 cases of whom 114 were designated 
as T1D, 65 classified as LADA (free of insulin for more than 6 months from 
diagnosis) and 24 intermediate cases (4%). Of all patients positive for at least one 
autoantibody, 114 started insulin at diagnosis (19%) (i.e. designated classic T1D) 
with mean age 44.1 ± 9.9 years and 51.8 % were males. While 323 were on other 
therapy (oral anti-glycaemic agents or diet) and by inference 388 (65.0.%) did not 
start on insulin therapy for at least six months from diagnosis (i.e. designated 
LADA) mean age 51.9 ± 10.5 years and 50.2% were males Table 4.7. 
 It follows that LADA was more prevalent than classic T1D (Odds Ratio = 3.4).A 
third group of 24 (4.0%) autoantibody positive patients started on insulin after 
diagnosis and within 6 months (i.e. designated neither T1D nor LADA); mean age 
46.5 (10.2), 45.8% male.  
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Of autoantibody positive patients, those classified as T1D compared with LADA 
had a lower age, age of onset, BMI, waist circumference and WHR (p<0.0001 for 
all comparisons), higher LDL cholesterol levels (p<0.01) and a higher, but not 
significant, number with high GADA titre (81% vs 71%) (Table 3.8). It follows 
that there were limited quantitative, and no categorical, phenotypic differences, 
between T1D and LADA, the former being younger, leaner, with higher GADA 
titre and higher LDL cholesterol.  
GADA (n=541) autoantibodies identified the majority of cases with 
autoantibodies (90%), with IA2 (7.2%) and ZnT8 (2.3%) accounting for the 
remaining 10% of diabetes autoantibodies (Venn diagram Figure 4.8). 
Measurement of combination of autoantibodies to IA2A, ZnT8A in addition to 
GADA improved the predictive value of autoantibodies by adding an additional 
10%. 
Among the autoantibody positive subjects positive for GADA, IA2A or ZnT8A 
data when separated according to the age groups, 30-40 years, 40-50 years, 50-60 
years, for of age at diagnosis similar to the UKPDS analysis, autoantibody 
positive cases in each age group were significantly leaner with a lower BMI in 
comparison to autoantibody negative ‘type 2 diabetes’ cases except. In those in 
the age group 60-70 years of age at diagnosis no difference was noted between the 
autoantibody positive and negative group (Table 4.6). It is possible that there is a 
gradation of the auto-antibody positivity with age as in the patients aged 60-70 
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years of age at diagnosis there was a similar BMI between antibody positive and 
negative cases. 
 
 
 
 T1D LADA  
Cases 114 388  
Females* 
Males 
55 (48.2%) 
59 (51.8%) 
 188(49.8%) 
 189(50.2%) 
NS 
Mean age (years)  44.1 (9.9) 51.9 (10.5) p<0.001  
Age of onset (years) 41.8 (15.2) 49.7 (12.3) p<0.001 
BMI (kg/m
2
)
 
 25.6 (5.0) 28.6 (6.6) p<0.001 
Waist-Hip ratio 0.87 (0.08) 0.90 (0.1) p<0.001 
Waist Circumference 88.3 (12.7) 96.8 (16.6) p<0.001 
LDL Cholesterol (mmol/L) 2.8 (1.0) 2.2 (1.0) P=0.013  
 
Table 4.7. Features of T1D versus LADA patients. Mean (SD) 
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Age of onset 30-40 years 40-50 years 50-60 years 60-70 years 
LADA Cases  
(with information 
for age at onset) 
549 250 366 192 
Autoantibody 
Positive 
BMI 
130 (23.7 %) 
 
26.4 (6.1) 
32 (12.8 %) 
 
27.2 (4.6 %) 
31 (8.5 %) 
 
28.1 (4.8 %) 
12 (6.3 %) 
 
29.2 (4.9 %) 
Autoantibody 
Negative 
BMI 
419 (76.3 %) 
 
31.9 (8.1) 
218 (87.2 
%) 
 
31.0 (6.7) 
335 (91.5 
%) 
 
30.9 (5.8) 
180 (93.7 %) 
 
30.5 (6) 
P (for BMI) <0.0001 = 0.0003 = 0.012 = 0.33 
 
Table 4.8. Presence of Auto-antibodies and BMI at different age of diagnosis 
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Figure 4.8. Venn Diagram depicts Action Lada patients with GADA/IA-2A or ZnT8A, 
n=598 of 6156 (9.8%). Of the autoantibody positive samples GADA identified 90% of the 
samples when an autoantibody was detected, IA-2A and ZnT8A accounting for the 
remaining 10% of the autoantibodies detected. GADA n=541 (8.8%), IA-2A n=144 
(2.3%), ZnT8A n=110 (1.8%) 
 
 
 
 
GADA 
ZnT8A IA-2A 
410 
30 
14 
53 
48 
13 
30 
200 
 
4.23. EVIDENCE OF NON-DIABETES ASSOCIATED AUTOIMMUNITY IN LADA 
PATIENTS. 
 
In a subgroup of samples where sufficient sera was available we tested  for organ-
specific autoantibodies TPO and PCA  in 1130 patients (mean age 52.3 ± 
10.1years, 30-69 years) of the 6156 sample cohort. In diabetes-associated 
autoantibody positive and GADA positive patients we found: 28.9% and 29.7% 
TPO positive respectively (p<0.0001 for both) and 15.9% and 16.8% positive 
PCA. positive respectively (p=0.069 and 0.0136 respectively) (Table 4.90 and 
4.91). 
 Importantly, while high titre GADA positive subjects had more TPO 
autoantibodies than GADA low titre subjects (32.4% versus 21.6% (p=0.035), the 
latter group were more often TPO autoantibody positive than GADA negative 
patients (9.9%, p=0.01) (Table 4.92).  Measurement of GADA identified 94% of 
patients positive for T1D associated autoantibodies in this subgroup. The 
prevalence of organ-specific autoantibodies was increased in patients with GADA 
compared to patients negative for GADA. 
 
 Any Ab Positive Any Ab Negative P value 
PCA 83/521 (15.9%) 
(28M/55F) 
73/609 (11.9%) 
(37M/36F)  
0.069 
 
TPO 151/521 (28.9%) 
(59M/92F) 
55/609 (9%) 
(22M/33F) 
<0.0001 
 
 
Table 4.9 Non Diabetes associated antibodies PCA & TPO in antibody positive 
versus antibody negative patients 
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 GADA Positive GADA Negative P value 
PCA 80/474 (16.8%) 
(26M/54F) 
76/657 (11.6%) 
(39M/37F) 
0.0136 
TPO 141/474 (29.7%) 
(54M/87F) 
65/657 (9.9%) 
(27M/38F) 
<0.0001 
 
Table 4.91 Non Diabetes associated antibodies PCA & TPO in GADA positive 
versus GADA negative patients 
 
 GADA High >200 
units 
GADA Low >70 & 
<200 units 
P value 
PCA 66/358 (18.4%) 
(22M/44F) 
14/116 (12.1%) 
(4M/10F) 
0.148 
TPO 116/358 (32.4%) 
(41M/75F) 
25/116 (21.6%) 
(13M/12F) 
0.035 
 
 
Table 4.92 Non Diabetes associated antibodies PCA & TPO in GADA High Titre 
versus GADA Low Titre patients 
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4.24. Discussion: This dataset of patients collected from a large cohort of adult-
onset diabetes patients attending primary and secondary care European centres 
shows that autoimmune diabetes of slow onset presenting with diabetes associated 
autoantibodies is prevalent and found in 9.7% of phenotypically type 2 diabetes 
patients. The prevalence of LADA has been reported in adults presenting with 
non-insulin requiring diabetes at approximately 10% with 4-12% of Caucasian’s 
presenting with diabetes associated autoantibodies (Tuomi et al., 1999), (Zinman 
et al., 2004), (Leslie 2006), (Turner et al., 1997), (Leslie et al., 2008), (Buzzetti et 
al., 2007), (Hosszufalusi et al., 2003), (Rosario et al., 2005). The majority of 
patients presenting with diabetes in adulthood, (approximately 90%) tend to have 
type 2 diabetes, presenting with abnormal insulin secretion and peripheral insulin 
resistance (muscle, liver and adipose tissue), the remaining present with 
autoimmune features.  
Of these latter presenting with autoimmune features, at diagnosis, but with similar 
features as type 2 diabetes, we found that they tend to be younger and leaner. In 
contrast to type 2 diabetes, T1D usually presents in childhood, with rapid loss of 
islet cell mass, loss of insulin secretory capacity, aggressive infiltration of the 
islets with T lymphocytes, detection of multiple islet cell antibodies with a major 
genetic component. In vitro competitive inhibition studies have shown that GAD 
and IA2 can block ICA staining in up to 60% of sera from T1D subjects but only 
37.5% in sera from LADA cases suggesting that autoantibodies to other antigens 
other than GAD and IA2 are prevalent in LADA (Seissler et al., 1998), (Falorni et 
al., 2000), (Hampe et al., 2002). These studies reported GADA from LADA 
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patients have different recognition patterns as well as conformational epitopes 
compared with T1D patients using 35S-GAD65/67 fusion proteins with sera of 
65% LADA patients binding to the COOH–terminal portion of GAD65 in 
comparison to 90% of T1D patients. Furthermore 20% of LADA patients 
recognized the NH2-terminal of GAD65 in comparison to 5% of T1D patients.  
T cell responses to multiple islet proteins have been reported in LADA patients 
with and without autoantibodies (Mayer et al.,2007)(Zaval et al., 1992) in type 
diabetes patients (Brooks-Worrel et al., 1996) and in subjects at risk of developing 
T1D before the development of clinical diabetes (Brooks-Worrel et al., 2001).  
Whether LADA cases should be collectively classed as a separate group to T1D 
due to; adult age at onset, presence of autoimmunity, the ability to remain free 
from insulin therapy for at least 6 months after diagnosis, and, the fact that they 
show a less genetic load in comparison to the classic T1D, remains to be 
universally agreed. Nevertheless GADA autoantibodies have been reported in 
around 10% (range 5-15%) in these non-insulin requiring cases (Hosszufalusi et 
al., 2003), (Rosario et al., 2005). Our study found GADA autoantibodies in 9.7% 
of phenotypically type 2 diabetes patients, other similar studies have been much 
smaller with selection bias selecting patients only with ‘type 2 diabetes’. In this 
present study all patients attending the clinic were included and benefits from 
being the largest such study, screening for three diabetes associated 
autoantibodies. Furthermore unlike other studies we increased the specificity for 
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all autoantibodies tested by repeating all samples that were scored positive 
thereby reducing false positive results.  
A recent study in subjects aged 0-40 years reported that ZnT8A complements 
GADA, IA2 and IA2β and may replace IAA in particular in those over the age of 
10. This finding is valuable in the use of ZnT8A as an additional marker as 
reproducibility and standardization of the IAA assays has remained an issue in 
comparison to the liquid phase radio-binding assays (Ilse et al., 2011). In our 
study testing for GADA autoantibodies identified the majority of cases with 
autoantibodies (90%), with autoantibodies to IA2A and ZnT8A accounting for 
(7.2%) and (2.3%) auto-antibodies respectively. Of 541 GADA positive patients 
131 (24%) had IA2icA or ZnT8A, and these latter were younger, leaner as well as 
a lower waist to hip ratio, however there was no statistical difference in insulin 
requirement between those who had single (GADA alone) or multiple 
autoantibodies. Autoantibodies in the absence of GADA were detected to IA2A 
and ZnT8A in 57 (10.5%) cases. A small Japanese study in 47 GADA positive 
cases reported that the determination of other antigens namely IAA, IA2icA and 
ZnT8A improves the prediction of future insulin insufficiency in adult onset 
autoimmune diabetes as superior to GADA titre (Kawasaki et al., 2010). 
However, our large study did not show a difference in insulin requirement 
between those who were GADA alone positive and those with antibodies in 
addition to GADA. However, the numbers on insulin therapy were higher in those 
with IA2A or ZnT8A compared to those without autoantibodies.  
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When analyzing antibodies, it is important to identify thresholds for positivity in 
antibody measurements which can distinguish the presence or absence of 
antibody. Most Laboratories participating in the Diabetes Autoantibody 
Standardization Program (DASP), tend to use the 99
th
 centile of a group of control 
samples tested historically for the specific auto-antibody tested. Unfortunately this 
methodology has a flaw in that it does not account the day to day variation in the 
translated protein employed and variation in the assay. These factors can affect 
the background noise and as a result the cut off for positivity in particular when 
historical data is employed to determine the cut off levels. Notably other 
laboratories have successfully employed the use of the 99
th
 centile in the assays. 
In our laboratory the use of the end point dilution of the standard curve for the 
Action LADA Cohort was confirmed by the use of the QQ plot which identifies 
the change in the shape of the frequency distribution of the whole cohort tested 
(Figures 4.1 and 4.2).  
The use of the normal QQ plot aided the identification of the point at which this 
change was noted. Similarly in the CARDS cohort we were able to utilize QQ 
plots to determine the change in the shape of the frequency distribution which for 
this cohort was less than the Action LADA cohort and again confirmed the cut-off 
point set from the standard curves employed (Figure 4.5). In this thesis it is 
evident that where large dataset’s not normally distributed are analyzed, then the 
point of inflection identified from the QQ plots identifies the point where the 
distribution altered. Interestingly for each of the autoantibody tested this point 
was consistent with that determined by the methodology of employing the 
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standard curve for determining the end point. More significantly the QQ plot also 
identified that the end point for ZnT8A (Figure 5.4) could possibly be reduced 
further to 8.0 units, however this may affect the specificity of the assay. Therefore 
in conclusion when analyzing large datasets the use of QQ plots would be a 
valuable tool to confirm the point above which the data is different from that 
below the point where the data set follows a normal distribution. This approach 
further confirms previous report in the BABYDIAB study and adds support to the 
use of QQ plots in large population studies to define cut-off points (Ziegler et al., 
1999). 
We identified at least two modes within the GADA positive patients from the QQ 
plot analysis, with a cut-off of 70 WHO IU (low GADA titre) and another at 200 
WHO IU (high GADA titre), remarkably this similar cut off for positivity was 
found also in the CARDS study cohort. In the latter a lower cut off for positivity 
was established at 40 WHO IU, but, this point only identified an extra 10 cases, 
with the majority identified above 70 WHO IU as confirmed by the QQ plots. 
Those patients with high titre GADA compared with low titre GADA were more 
likely to be female, younger at onset, leaner, with lower HDL cholesterol, systolic 
blood pressure and higher triglycerides and risk of insulin treatment. Moreover, 
patients with low GADA titre, compared to those who were GADA negative, 
were also younger at diagnosis, leaner with higher HDL cholesterol and 
proportion treated with insulin. Other studies have shown that high titre GADA 
positive patients had a tendency to greater HLA genetic disease risk compared to 
low GADA titre patients (Buzzetti et al., 2007).  
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A potential bias in this study was the use of hospital-based clinics since patients 
with autoimmune diabetes are more likely to be ascertained in such clinics given 
their greater risk of insulin treatment. Such a bias would increase the relative 
proportion of cases with autoantibodies, and specifically the proportion with T1D 
compared with LADA, but not the characteristics of autoantibody positive versus 
negative patients, a bias exacerbated by a tendency to start insulin treatment early 
if local assays were available to document patients as GADA positive (Sinead et 
al., 2008),(Davies et al., 2008),. In addition there was an excess of patients 
presenting with autoimmune diabetes in comparison to T1D (Table 4.1), implying 
that most cases at presentation of autoimmune diabetes in adults are presented as 
non-insulin requiring diabetes cases and not as LADA, or T1D. 
In a separate study we found that individual components of Metabolic Syndrome 
were similar in both T1D and LADA, but in each, much less frequent than in type 
2 diabetes (Hawa et al., 2009). Our data also shows that metabolic differences 
between low titre GADA and GADA negative patients extends to another 
autoimmune biomarker, namely TPOA which was detected more often in GADA 
positive than GADA negative subjects. 
For decades autoimmune diabetes has been considered as a childhood onset or 
juvenile onset disease however the overwhelming data has shown that the disease 
affects all ages and in particular those over 30 years of age affecting up-to 9.7% 
of phenotypically type 2 diabetes patients. There is therefore evidence of a 
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gradation of autoimmune and metabolic features from childhood onset to adult 
onset autoimmune diabetes and as a result T1D and LADA need to be viewed as a 
broad spectrum of the same autoimmune disease.  
The most prevalent form of diabetes is adult-onset type 2 diabetes which affects 
about 4-7% of the adult European population.  Childhood-onset T1D, on the other 
hand, affects only some 0.25% of European children and adolescents, though a 
life-time disease-risk analysis suggested that up to 1% develop classic T1D, with 
a proportion doing so after age 30 years (Lorenzen et al., 1994). We now show 
that nearly 10% of adult-onset diabetes patients have autoimmune diabetes, it 
follows that adult-onset autoimmune diabetes is probably more prevalent than 
childhood onset T1D. In summary, these results show that the majority of adult-
onset autoimmune diabetes patients are non-insulin requiring at diagnosis. In the 
tendency to be adult-onset, with variable destruction of the target organ, leading 
to a broad clinical spectrum, autoimmune diabetes can now be seen to resemble 
other autoimmune diseases. 
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CHAPTER 5 
5.0. WHETHER AUTOANTIBODIES TO CD38 ARE OF ANY VALUE IN T1D AND TYPE 
2 DIABETES. 
5.01. Aim: To test if antibodies to CD38 were a feature of T1D and Type 2 
diabetes patients.  
5.02. INTRODUCTION: CD38 is a type II transmembrane glycoprotein, the 
extracellular domain acting as an ectoenzyme, catalyzing the conversion of 
nicotinamide adenine dinucleotide (NAD
+
) into nicotinamide, adenosine 
diphosphate–ribose (ADPR), and cyclic ADPR. CD38 is expressed on many types 
of cells, (white blood cells), including CD4+, CD8+, B and natural killer cells. 
CD38 mRNA and/or protein have been detected in the mammalian, brain, spleen, 
heart, liver, kidney, intestine and pancreas (Cinzia et al., 1999),
 
(Ikehata et al., 
1998). Human CD38 is a single chain glycoprotein that is commonly used as a 
marker of differentiation and activation in haematopoietic cells. It is a bi-
functional ectoenzyme that catalyzes the conversion of NAD+ to cyclic ADP-
ribose (cADPR) and the hydrolysis of cADPR back to ADPR. It is also involved 
in the glucose induced insulin release from pancreatic islets. CyclicADP-ripose 
(cADPR) has been shown to be a mediator for intracellular calcium mobilization 
for insulin secretion by glucose in pancreatic β cells (Cinzia et al., 1999). 
CD38 also functions in cell adhesion, signal transduction and calcium signaling. 
CD38 is a leukocyte differentiation antigen that has been thought to be a 
phenotypic marker of different subpopulations of T- and B-lymphocytes. The 
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earliest report of involvement of the cADPR in insulin metabolism came from 
experiments using a cell-free system of islet microsomes (Takasawa et al., 1993). 
CD38 was first cloned from rat pancreatic islets and was shown to be homologous 
to the human CD38 exhibiting 58% overall identity and 76% similarity and is 
expressed at comparable levels in Wistar rats and GK rats (a genetic model of 
NIDDM). The presence of CD38 in pancreatic islets suggested that it is involved 
in insulin secretion via the cADPR pathway (Li et al., 1994). Mice overexpressing 
CD38 exhibit enhanced glucose-induced insulin release, while CD38 KO mice 
display severe impairment of β cell function.  
A previous report on human diabetes revealed that 13.8% of Japanese type 2 
diabetes patients have autoantibodies against CD38 (Ikehata et al., 1998). Their 
experiments showed that anti-CD38 antibodies inhibited the glucose induced 
insulin release and recombinant CD38 abolished this effect, suggesting that anti-
CD38 autoantibodies may be one of the major causes of impairment of glucose 
induced insulin release (Ikehata et al., 1998). CD38 is involved in the glucose 
induced insulin secretion and has been proposed as a candidate auto-antigen in 
type 2 diabetes patients. Conflicting results to Okamoto’s group (Ikehata et al., 
1998) have been shown by another study where anti-CD38 antibodies potentiated 
the release of insulin from isolated human pancreatic islets (Cinzia et al., 1999). 
Both insulin resistance as well as insulin deficiency are involved in the 
pathogenesis of type 2 diabetes and autoantibodies to islet antigens ICA, GADA 
and a protein tyrosine phosphatase like molecule IA2 have been shown in a 
proportion of these patients. The presence of these antibodies in particular high 
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titre GADA, have been associated with early insulin requirement (Buzzetti et al., 
2007). The presence of autoantibodies to CD38 has previously been evaluated 
using Western blot analysis in 236 patients with type 2 diabetes and 160 T1D 
patients with positivity in 9.7% and 13.1% respectively (Cinzia et al., 1999). 
Okamoto et al showed that of 377 Japanese type 2 diabetes patients tested  13.8% 
patients had autoantibodies against CD38 (Ikehata et al., 1998),  These data 
suggested that anti CD38 antibodies in ‘type 2 diabetes’ patients might be a major 
cause of impaired glucose induced insulin secretion.  
These observations as well as the availability of molecular and immunological 
techniques already employed for other diabetes associated antigens prompted me 
to employ these analytical procedures using CD38 cDNA, to insert it into a vector 
allowing in-vitro transcription and translation of CD38 protein, for the subsequent 
use in a liquid phase immune-precipitation assay to detect autoantibodies in 
patients with T1D as well as ‘type 2 diabetes’. 
5.03. Methods: The human CD38 cDNA encoded as the human lymphocyte 
differentiation antigen CD38 (Jackson & Bell 1990). The gene encoding the 
human CD38 antigen has been previously cloned from T cells and normal 
lymphocytes, located on chromosome 4 (Jackson & Bell 1990). The CD38 cDNA 
a gift from Professor Malavassi at the University of Torino, Italy, was supplied as 
an agar stab inoculated with E-Coli strain MC1061/PB containing the plasmid 
pCDM8-HCD38 an expression vector, containing the human CD38 cDNA cloned 
into the Hind 111 – Not 1 sites with an insert size of 1.4kb. The transfected COS 
cells, expressed a surface protein of Mr46000 similar to the native CD38 
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molecule on B cell line recognized by the CD38 specific monoclonal antibody. To 
isolate and grow the plasmid a stab of CD38cDNA was taken from the glycerol 
stock and grown in Luria Broth Medium (LB) containing 12.5µg/ml Ampicillin 
and 7.5µg/ml Tetracyclin.  
5.04. Reagents: The reagents required for the procedure included: Ampicillin 
(Sigma), Luria Broth (Sigma), Tetracyclin (Sigma), CD38 cDNA, Sterile culture 
plate (Sterilin). 
5.05. Preparation of Ampicillin Stock: Dissolve 100mg Ampicillin (Sigma 
Aldrich UK) in 1ml of sterile H2O and store 100µl aliquots at -20°C and use 
62.5µl/500ml LB medium (12.5µg/ml final concentration). 
5.06. Preparation of Tetracyclin Stock: Dissolve 100mg Tetracycline in 1ml of 
sterile H2O and store 100µl aliquots at -20°C and use 37.5µl/500ml LB medium 
(7.5µg/ml final concentration).  
5.07. Prepare Luria Broth Medium (LB) 
Components of Luria Broth Millers Modification Sigma Cat No:L3397 
 Kit Component: Tryptone (pancreatic digest casein) 10g/L 
 Yeast Extract 5g/L 
 NaCl 0.5g/L 
Dissolve 15.5grams of LB medium (Sigma) in 1 litre of Ultra Pure water, 
autoclave for 15 minutes at 121°C to dissolve LB media and sterilize. 
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When the LB medium solution is hand cool to touch add antibiotics as follows: 
12.5µg/ml Ampicillin 
7.5µg/ml Tetracycline  
5.08. Ladder Molecular Weight Marker:  
Source Gibco BRL 
Cat No:10416-014  (50 base pair DNA Ladder marker) 
Low melting point Agarose Gel: 1.0% (1.0g/100ml H20) 
5.09. Prepare 50 x Stock Tris Acetate Buffer (TAE) 
242 grams Tris Base 
57.1ml Glacial Acetic Acid 
100ml of 0.5M Ethylene Di-amine Tetra Acidic acid (EDTA)  
Once dissolved adjust the pH to 8.0 and store at 4ºC. From this stock solution 
prepare a 1 x solution for running the gels to give a final concentration of 0.04M 
Tris Acetate containing 0.001M EDTA.  
5.10. Preparation of CD38 Plasmid: 
A. A stab from the original CD38 glycerol stock containing the E Coli strain MC 
1061/PB containing the CD38 expression plasmid PCDM8 – HCD38 (Figure 1) 
was placed in 10ml of LB medium in a 50ml Falcon tube containing Ampicillin 
and Tetracyclin. The cells were incubated overnight at 37°C in a grants incubator 
with vigorous shaking at approximately 150 revolutions per minute.  
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B. After the overnight incubation cells were centrifuged, the cell pellet was 
reconstituted in 1ml of LB/Ampicillin/Tetracyclin media and the contents added 
to 500ml of LB/Ampicillin/Tetracycline media in a flat bottom conical flask to 
further expand the colony as in (A) above at 37°C overnight. 
C. Following overnight incubation the cells were placed into 100ml centrifuge 
flasks and centrifuged in a Sorvall RC5B centrifuge at 5000 x g for 10 minutes at 
22°C. Discard the supernatant and reconstitute the pellet in cell re-suspension 
solution for the extraction of DNA using the Promega Maxi Prep DNA extraction 
kit as described previously in chapter 2. 
The pCDM8 4.4kb comprises the CD38 cDNA insert as shown in  Figure 5.0, 
which consists of the T7 promoter site making the vector suitable for in-vitro 
transcription and translation of the CD38 protein by utilizing the Promega TNT
TM
 
transcription and translation kit as described previously in chapter 2. 
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Figure 5.0 Map of pCDM8, the original mammalian CD38 expression vector 
with T7 promoter site as shown. 
 
 
 
5’  CD38 cDNA   3’ 
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5.11. Initial Results: The extracted CD38 DNA from section C above was 
purified using the Promega Maxi Prep kit according to the manufacturer’s 
instructions. The extracted DNA concentration was measured by measuring the 
optical density (OD) at 260nm using the Beckmann spectrophotometer and 
visualised by low melting point agarose gel electrophoresis in Tris Acetate Buffer 
as shown in Figure 5.1 
OD of extracted DNA = 0.0406 
OD of 1.0 = 50ug/ml 
Concentration of CD38 Sample = 50 x 0.0406 =2.03ug/ml 
5ul = 1ug of DNA 
 
 
            Lanes                           1               2              3 
Figure 5.1.: Purified CD38 DNA was separated by electrophoresis on a 1% 
Agarose gel. Lane 1 = CD38 DNA 1 ul , Lane 2 = Ladder molecular weight 
marker, Lane 3 = 5ul DNA 
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5.12. CD38 In-vitro Translation: Using the CD38 cDNA prepared as above the 
protein was subsequently translated using the Promega TNT
TM
 translation kit as 
previously described in chapter 2 and the translate was electrophoresed on a 10% 
SDS page gel Figure 5.2. 
 
 
Figure 5.2.  Shows autoradiograph of proteins separated on a 10% SDS Page gel 
Lane 1  = Molecular weight marker (range 200k, 69k, 46k, 30k and 21k 
respectively), Lane 3 = GAD65, Lane 4 = IA2ic, Lane 6 & 8 = CD38 translated 
proteins which appear to resolve at the dye front. 
 
Following electrophoresis and autoradiography the proteins noted were unrelated 
to CD38 Figure 6.3, the only bands visible were that of GAD65 and IA2 which 
were included as control proteins previously translated separately. No band was 
noted for the CD38 antigen in the 46 kilodalton region, a band was seen in lanes 6 
Lanes      1           3     4               6             8            
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and 8 below the expected region of 46kd and was attributed to non-specific  
translation.  
 
The question arose whether the PCDM8 CD38 cDNA containing the T7 
polymerase promoter enzyme was translating CD38 protein. 
 
5.13. Immunoprecipitation of CD38: To test and confirm if CD38 antigen was 
present, translated proteins were immuno-precipitated with monoclonal antiCD38 
antibody CD38 AT1 Cat No Sc-7325 (Santa Cruz Biotechnology). The mouse 
CD38 AT1 antibody corresponds to CD38 of human origin reacting with Human 
CD38 in western blotting, immunohistochemistry and FACS and is not cross 
reactive with other cell surface markers. The stock solution of CD38 AT1 
monoclonal antibody was stored at 4°C.   
 
The immuno-precipitation was performed using the following combinations: 
1. In a micro-centrifuge tube add 10µl of the stock CD38 AT1 Monoclonal 
antibody as a positive control, (Stock solution 200µg/ml equal at 2µg) to 10µl of 
the CD38 translate. The combination was repeated with 1µg of Monoclonal CD38 
AT1 antibody 
2.  In a micro-centrifuge tube add 10µl of the stock CD38 translate. To this 
add 2µl of  serum sample from a pre-diabetic individual (coded SB) a sample 
known to be positive for CD38 in another laboratory using western blot 
technique.  
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3. In a micro-centrifuge tube add 10µl of the stock CD38 translate. To this 
add 2µl of serum sample from a healthy individual (coded GM) with no family 
history of diabetes or any other autoimmune disease. 
4. In a micro-centrifuge tube add 10µl of the stock IA2ic translate. To this 
add 2µl of serum sample from a pre-diabetic individual (coded SB) throughout 
the text.  
5. In a micro-centrifuge tube add 10µl of the stock IA2ic translate. To this 
add 2µl of serum sample from a healthy individual (coded GM) with no family 
history of diabetes or any other autoimmune disease. 
 
The above tubes were vortexed and incubated overnight at 4°C. To immuno-
precipitate immune complexes Protein A Sepharose was employed. The latter was 
used at a concentration of 3mg per tube with a binding capacity of 20mg of 
human IgG per ml. Therefore 1.5mg will bind 20mg of Human IgG and 1mg will 
bind 6.66mg IgG. 
 
In blood the expected concentration of IgG is 12.5mg/ml, IgA 2.1mg/ml, IgM 
1.25mg/ml, IgD 40µg and IgE 0.04µg respectively, equivalent to approximately 
16mg/ml of total immunoglobulin per ml of serum.  
= at 16mg immunoglobulin per 1000µl of serum. 
= at 1.6mg immunoglobulin per 100µl of serum. 
= at 0.16mg immunoglobulin per 10µl of serum. 
= at 0.016mg immunoglobulin per 1µl of serum or 16µg per ul of serum 
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5.14. CD38 Monoclonal antibody: CD38 ATI Cat No #SC-3725  
Supplier: Santa Cruz Biotechnology Incorporations 
Autogen Bioclear, Holly Ditch Farm, Mile Elm, Colne, Wiltshire SN11OPY 
Source: CD38 (ATI) is a mouse monoclonal IgG1 antibody, corresponding to the 
CD38 of human origin. 
Product: 200µg IgG1 per ml in PBS containing 0,1% Sodium Azide and 0.2% 
gelatine. 
Specificity: CD38 (ATI) reacts with CD38 of human origin by western blotting, 
immunochemistry as well as FACS analysis, it is not cross reactive with other cell 
surface markers. Storage: 4 º C. 
 
For the above the incubation was performed with 1mg of Protein A Sepharose per 
tube. Now 100mg of Protein A Sepharose swells to 400µl of packed resin volume, 
therefore the diluted PAS per tube or well swells to 4µl sufficient to bind 6.6mg 
of IgG. For the immunoprecipitation 2ul of serum was used containing 
approximately 32µg of IgG to which 1mg of PAS was added which is in excess to 
attain optimal binding of the antigen antibody complexes. 
 
5.15. . Results:  
1. Positive control monoclonal anti-CD38 antibody failed to immuno-precipitate 
CD38 protein, no band was noted. 
2. CD38 was not immuno-precipitated using the control sera SB. 
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3. As expected negative control sera GM did not immuno-precipitate CD38 
molecule. 
4. IA2 antigen was immuno-precipitated with the positive control sera SB as 
expected with IA2 as the antigen source (data not shown) 
5.16.  Interpretation: 
The transformed colony from the original glycerol stock was successfully grown 
on ampicillin/tetracycline resistant agar plates. The protein translated however 
failed to immuno-precipitate CD38, the control antigen immuno-precipitated as 
expected the antigen IA2. These initial experiments raised the question as to 
whether any CD38 protein was being translated or perhaps the incorporation of 
methionine into the CD38 was insufficient, such that insufficient protein was 
translated. 
Taking the latter into account the primary sequence of CD38, its nucleotide 
sequence as well as the predicted amino acid sequence was examined, which 
indicated that the number of methionine residues (n=5) in comparison to leucine 
(n=31) was substantially lower (Jackson & Bell., 1990). This could be a reason 
for the insufficient incorporation of methionine in the translation of CD38 protein. 
As a result of these initial experiments radioactive Leucine (Amersham Code No: 
SJ126) instead of Methionine in the translation cocktail was employed. However 
this also failed to show any significant improvement in the amount of CD38 
protein translated. 
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This raised another question as to whether any transcription from the synthesized 
CD38 cDNA was occurring. As a result experiments were carried out to test 
mRNA synthesis. 
 
5.17. CD38 mRNA synthesis: 
To test whether transcription using the CD38 cDNA was active we carried out in-
vitro transcription assays to generate RNA according to the according to 
manufacturer’s protocol, Promega UK. 
 
1. 5 x Transcription Buffer  4µl 
2. 100mM dithiothrietol (DTT) 2 µl 
3. Rnasin Inhibitor   1 µl 
4. ATP    1 µl 
5. GTP    1 µl 
6. UTP    1 µl 
7. CTP    1 µl 
8. Dnase Free H2O   5 µl 
9. CD38 DNA   2 µl 
10. T7 Polymerase   2 µl 
    Total volume  20 µl 
 
Vortex gently and incubate the mixture at 37C for 1 hour, the synthesized RNA 
was electrophoresed on 1% Agarose gel.  
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The result from this experiment failed to show any RNA band using the original 
CD38 cDNA. 
 The vector pCDM8 was an expression vector and it was decided to utilise 
selected enzymes to excise the CD38 insert of 1.4 Kb from the 4.4Kb pCDM8 
vector and re-insert into a suitable translation vector pGEM-11Z to enable 
translation of the protein of interest namely CD38. 
 
5.18.  Protocol to cut the 1.4 Kb CD38 Insert from pCDM8 Plasmid: 
The CD38 insert was digested enzymatically using selected restriction enzymes  
Hind III and Not I to cut out the CD38 insert from the pCDM8 Plasmid. These 
restriction enzyme sites are shown on the original pCDM8 plasmid as depicted in 
figure 6.1, each restriction enzyme with specific requirements of buffer, 
incubation time and concentrations for optimal enzymatic activity. 
 
5.19. Restriction Enzyme Reagents 
Hind III Reagents: 
1. Hind III (Cat No R604A Product ID:9170302; Promega, UK) 5000U 
(10U/µl). 
2. Multicore ™ 10 x buffer Cat No R999A Product ID:9240804; Promega, 
UK) (250ul). 
3. Buffer E 10 x Cat No R005A Product ID:7544308; Promega, UK (1ml). 
4. Bovine Serum Albumin Acetylated Cat No R396E Product ID:8560821; 
Promega, UK (100 x stock used in dilution) 
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Not 1 Reagents: 
1. Not 1 CQ Cat No R643A Product ID:8827008; Promega, UK (10u/µl) 
2. Buffer D Cat No R004A Product ID:7090225; Promega, UK (10 x 
Concentrate) 
3. Multicore Buffer Tm Cat No R999A Product ID:9240804; Promega, UK 
(10 x Concentrate 0.25ml)  
To linearize and digest the 4.4Kb pCDM8/CD38 vector using restriction enzymes 
HIND 111 and Not 1, the following protocol was employed.  
 
5.20. Protocol to digest CD38 insert from pCDM8/CD38 expression vector 
using HIND 111: 
1. Sterile H2O       32.6µl 
2. Restriction Enzyme (x10) Buffer E               4.0 µl 
3. Acetylated BSA      0.4 µl 
4. PCDM CD38 DNA 1 µg/ µl                 2.0 µl   
           (Mix by pipetting then add) 
5. Restriction Enzyme HIND 111    1.0 µl 
Total volume                    40 µl 
The reaction mixture was incubated at 37C for 4 hours for optimal activity 
according to the manufacturers protocol for the procedure 
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5.21.  A) Purification of the HIND111 Linearized PCDM CD38 
Plasmid 
The plasmid from A) above was purified using Promega’s Mini Prep DNA 
purification reagents.  
1. Add 1ml of Promega’s Wizard miniprep DNA purification resin, mix gently by 
inversion several times  
2. Pass resin bound DNA through the purification column provided with the 
miniprep kit 
3. Wash the column with column wash solution 
4. Elute DNA with 1ml TE buffer/ or Dnase free H2O. 
 
B) After purification the linearized PCDM CD38 DNA template was further 
digested with the restriction enzyme Not 1, to release the 1.4KB CD38 insert. 
 
5.22. Protocol to digest CD38 insert from pCDM8/CD38 and release insert: 
1. From step B above utilise linear CD38 DNA   34.6 µl 
2. Add Buffer D       4.0 µl 
3. Acetylated BSA       0.4 µl 
4. Mix gently by pipetting then add Not1 Restriction Enzyme 1.0 µl 
Mix gently, spin in a microcentrifuge for 5 seconds and incubate at 37ºC for 4 
hours. 
Purify the DNA insert as above using the Promega wizard mini prep DNA 
purification. 
227 
 
 Following the digestion with Hind111 and Not1 enzymes the digestion products 
were separated on low melting point agarose gel (0.8%).  
 
5.23. Results: 
From these experiments we expected a 1.4 kb insert of CD38 and this was 
visualised after electrophoresis. Figure 5.3 
 
 
        Lane             1       2      3     4       5  
 
Figure 5.3:  The pCDM8 vector after digestion with the Hind 111 and Notch 1 
enzymes electrophoresed on a 0.8% agarose gel, released a 1.4kb insert indicated 
by the arrow, from left to right Lane 1 = Uncut pcCDM8 CD38, Lane 2 = Not 1 
cut pcCDM8 CD38, Lane 3 =Ladder molecular weight marker, Lanes 4 & 5 Not1 
& Hind111 digestion (4µl, 1µl respectively) 
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5.231. Elution of the 1.4 kb insert 
The insert of 1.4kb from above was cut out of the 0.8% agarose gel placed in a 
sterile eppendorf centrifuge tube, heated to 65º C to elute the DNA fragment. To 
this add 1ml Wizard DNA binding Gel (Promega UK). This bind’s the DNA 
ready for elution using the DNA wizard miniprep system as described earlier and 
eluted with 30µl of ultra-pure water heated to 70 º C. The product from this was 
used for the ligation into PGEM11Z vector. 
 
5.232. Ligation Protocol for PGEM11Z and CD38 insertion: 
The insert digested from pcCDM8 CD38 vector using Hind111 and Not1 
enzymes was ligated according to the manufacturer’s recommended protocol 
(Promega UK) using T4 DNA ligase which catalyzes the joining of two strands of 
DNA between the 5’ phosphate and the 3’ hydroxyl groups of the adjacent 
nucleotides. 
Promega recommend using a ratio of 1:1, 1:2 or 1:3 molar ratio of vector to DNA 
to be inserted when cloning a fragment into a plasmid vector (Table 5.0).  
 
5.233. Ligation of CD38 insert into PGEM 11Z  
For the ligation we used the following ratios of vector and insert Table 6.0: 
 NB: DNA Ligase = 3Units/µl Therefore 1.5U/0.5ul After gently mixing Incubate 
the tubes containing the ligation cocktail at 4 º C overnight. The ligation products 
are now ready for the Transformation of competent E Coli cells 
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Table 5.0 Ligation of CD38 insert into PGEM 11Z 
 
 Ligation ratio 1:1 Ligation ratio 
2:1 
Ligation ratio 3:1 
Vector DNA 2.0µl 2.0µl 3.0µl 
Insert CD38 2.0µl 1.0µl 1.0µl 
DNA Ligase buffer 
(x10 conc) 
1.0µl 1.0µl 1.0µl 
T4 DNA Ligase 0.5µl 0.5µl 0.5µl 
Nuclease free H2O 4.5µl 5.5µl 4.5µl 
Total incubation 
volume 
10. 0µl 10. 0µl 10. 0µl 
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5.234. Transformation protocol of cloned CD38 into competent EColi  
Competent Cells Source: Promega Catalogue No: L2001  
Product: JM109  Competent cells in FSB (100mM KCL,45mM, MnCl2, 10mM 
CaCl2, 3mM HACoCl3, 19mMKAcetate, 5% sucrose & 10% glycerol) JM109 
cells were made competent by the method of Hanahan) 
For the transformation use the Ligation products from the ligation experiment 
above A,B & C at ratios 1:1, 2:1 and 3:1 and D control DNA. 
1. Use 100µl of competent cells add 10µl of the ligation mixture in an 
Eppendorf tube, mix gently and leave on ice for 10 minutes. 
2. Heat shock the contents by placing the tubes in a water bath  at 42ºC for 
approximately 45-50 seconds. 
3. Return to ice for a further 2 minutes 
4. Add 900µl of ice cold LB Ampicillin medium and incubate at 37ºC for 1 
hour in a shaking water bath. 
 
5.235. Preparation of Luria Broth Agar containing IPTG and xGAL: 
Prepare fresh Luria Broth Agar (LBA)  
Use 30.5g/litre autoclave in order as to dissolve the agar. When hand cool add 
50µg/ml Ampicillin (Sigma Aldrich) Stock solution 1000mg/ml used 
500µl/1000ml to give a final concentration of 50µg/ml Ampicillin.  
Prepare IPTG (Isopropyl β-D-1-thio-galacto-pyranoside) (Molecular Weight 
238.31) Stock solution 1 gram dissolve in 50ml distilled H2O = 0.08Molar 
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solution. Sterile filter and store at 4º C. Use 6ml/ litre of LBA . xGAL Stock 
50mg/ml use 800µl/L of LBA (Final concentration 40µg/ml). 
 Pour LBA containing Ampicillin, IPTG and xGAL into sterile petri dishes in a 
hood and allow agar to set. Seal the petri dishes with Para film and store upside 
down at 4 º C, until ready to use. 
 
5.236. Growth of Transformed cells 
The transformed plasmid remains gal
-
 and cannot metabolize Xgal to a blue 
pigment. Resulting insert bearing colonies, grown on LB ampicillin plate 
supplemented with IPTG and xGAL will remain white. In contrast, a non-insert 
bearing plasmid complementing the E coli host, become gal
+
 and form blue 
colonies on LB/Ampicillin plates with IPTG and Xgal.  
Following ligation and transformation single white colonies were picked from the 
LBAgar/IPTG/Xgal/Amp plates and grown overnight in an incubator at 37ºC 
containing the insert in the LacZ position after inoculating a 50ml Falcon Tube in 
10ml luria broth ampicillin medium (Note each transformation reaction was 
prepared neat (undiluted), diluted 1:10 and 1:100). The colonies with the insert 
grow white and those without the insert are gal+ and can therefore metabolise 
Xgal and produce blue colonies however no Blue colonies were noted. 
After overnight growth of the transformed E Coli cells on 
LBAgar/IPTG/Xgal/Amp plates, five colonies were picked labeled A, B, C, D, E 
& F respectively and grown in LBA media. DNA was extracted using Promega’s 
SV miniprep DNA extraction kit as previously described. 
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5.237.  Results & Interpretation 
Following digestion of the original PCDM CD38 Plasmid with the restriction 
enzymes and ligation into PGEM11Z vector the DNA was again linearized with 
Hind 111 restriction enzyme and the DNA was electrophoresed on agarose gel 
both before and after digestion with the restriction enzyme. Figure 5.4 shows the 
bands for the products of PGEM11Z vector digested as well as undigested. 
 
 
                                  8   
Figure 5.4: Linearized Vector PGEM11Z with CD38 insert. PGEM11Z uncut in 
the left panel A-F uncut, right panel A-F digested with Hind111 enzyme. A: refers 
to the transformation of ligation products (1:1) colony with JM109 competent 
cells undiluted and CD38 DNA, A, B, C & D: refers to the transformation of 
ligation products (2:1) colony with JM109 competent cells diluted 1:10 and CD38 
DNA. Molecular weight markers are in the first and last lanes. Lane 8 equates to 
the linearized pGEM11Z vector (labeled 8) 
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The PGEM 11Z vector employed was 3223bp and the insert of CD38 1.4kb so we 
would expect a 4623bp linearized product after digestion with restriction enzymes 
Hind111. However the bands noted in figure 6.5, were running a little higher than 
2652bp region (bands A & D). The bands for B, C, E and F were noted to be 
running at the same level as the vector indicating no insert was present in the 
construct from which DNA was extracted. In order as to test these products, DNA 
from A, D and E as a control was tested by translating the proteins of interest 
using Promega’s TNT translation system as previously described with both T7 
and SP6 promoter enzymes in chapter 2. The translate proteins were then purified 
on a NAP5 column as previously described and  translated proteins  then 
separated by electrophoresis on 10% SDS page gel as depicted in figure 5.5 
following autoradiography. 
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                1                            8                             15  16     18 
Figure 5.5: The figure shows translated proteins following SDS page gel 
electrophoresis, autoradiography and purification on a NAP 5 column. The only 
proteins detected were as indicated in lanes 1 and 8 which separated at the same 
point as GAD65 in lane 15, Lane 16= IA2ic is indicated, Lane 18 Molecular 
weight Marker. No CD38 translate was detected. 
The translated proteins upon electrophoresis and autoradiography for 24 hours 
showed bands similar to GAD65 which was used as a control together with IA2ic 
intra-cytoplasmic domain (amino acids 605-979). In western blot analysis serum 
sample from an individual with SPS (CB) reacted with the GAD65 and CD38 
construct but not IA2ic (data not shown). This further raised a question regarding 
the identity of the CD38 construct, despite bands detected around the 40kd region 
as shown in lanes 1 and 8 Interestingly the translations that were note was only 
with the T7 polymerase enzyme which notably is also present in the GAD65 
cDNA.  
IA2ic 
GAD65 
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5.238. To test for reactivity of translated protein in a Liquid Phase Immuno-
precipitation Assay  
A liquid phase immune-precipitation assay was performed using the CD38 protein 
translated from the CD38 construct prepared earlier, to confirm previous findings 
on coded samples tested in another laboratory for CD38 using western blot 
analysis (Eli Ferrannini group) and antibody and for GADA in our laboratory 
Table 5.1).  
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Ferrannini 
Code 
Ferranni 
Blot 
result 
GADA 
assay 
result in 
house 
IA2ic 
assay 
result 
in-house 
CD38 
translate in 
house 
263 Negative Negative Negative Negative 
145 Negative Negative Negative Negative 
241 Negative Positive Negative Positive 
214 Negative Negative Negative Negative 
281 Negative Negative Negative Negative 
177 Positive Negative Negative Negative 
48 Positive Negative Negative Negative 
194 Positive Negative Negative Negative 
227 Positive Positive Negative Negative 
S013 Positive Negative Negative Negative 
Negative GM Negative Negative Negative Negative 
Control SB Negative Positive Positive Positive 
Control CB  Negative Positive Negative Positive 
Table 5.1: Comparison of data tested by western blot and immuno-precipitation (Control 
Sample CB = SMS patient sera, SB = Pre-diabetic sera, GM = Negative control sera 
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5.239. Interpretation: These results show a discrepancy between the data for 
CD38 using Western blotting shown in Table 6.1 (Ele Ferrannini group) and the 
liquid phase radio-immuno-precipitation assay, as the recognition of the antigen 
in the two formats was inconsistent. In the former western blot assay linear 
epitopes are recognized whereas the latter recognizes conformational epitopes. 
Furthermore immuno-precipitation data gave a similar result with a lack of 
reactivity of the sera as might have been expected based on the data by Ferrannini 
et al, with the CD38 antigen. However the reactivity detected following immune-
precipitation indicated that the bands following immuno-precipitation, 
electrophoresis and autoradiography were in the region of 64Kd similar to GAD65 
Figure 6.7.  
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Figure 5.6: Shows an Autoradiograph following Immuno-precipitation experiment to 
detect CD38 reactivity with serum samples. Lane 1 Molecular weight marker (range 
200kd – 14kd)rainbow marker labeled with 14C, Lane 2 Sample 151, Lane 3 Sample 227, 
Lane 4 Sample 48, Lane 5 Sample 120, Lane 6 Sample 6, Lane 7 Sample 20, Lane 8 
Sample 241, Lane 9 CB Positive for GADA, Lane 10 SB Positive for GADA(Table 5.2 
Details) 
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Ferrannini  or Lab Code Ferrannini Blot 
result 
Previous GADA data 
151 Positive Positive 
227 Positive Positive 
48 Positive Negative 
120 Positive Negative 
6 Negative Positive 
20 Negative Negative 
241 Negative Positive 
CB Negative Positive 
SB Negative Positive 
 
Table 5.2 shows findings in routine GADA assay in comparison to western blot 
data of samples previously tested for Ferrannini in London Laboratory (Tested by 
M Hawa). 
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 These results indicated that the cDNA prepared could not have been the expected 
CD38, rather and the data obtained indicated that, it was more closely associated 
with GAD65. 
5.240. Sequencing Data: The CD38 cDNA from above was subsequently 
sequenced to confirm its precise identity. Sequencing was performed in the 
Laboratory of Professor Adrian Clarke by Dr Lou Mattheral. Sequencing data 
produced gave a significant alignments with the enzyme and known auto-antigen 
Glutamic Acid Decarboxylase (GAD65) and confirmed that the cDNA was GAD65 
not CD38 Figure 5.7.  
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Figure 5.7: Sequencing of the isolated DNA matched with the sequence of   
GAD65. 
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5.241. Conclusion: A key message from these experiments is that even with 
extreme care contamination can occur, in particular when working in a laboratory 
where work with other plasmids is routinely carried out. The data presented in 
Table 6.2 from the immune-precipitation experiments was further confirmed by 
the sequencing data to be GAD65 cDNA and not CD38 cDNA. 
 
As a result of these experiments a new batch of PCDM8 CD38 cDNA stock was 
obtained from the original source (Malavasi et al), to digest out the 1.4kb CD38 
insert.  
5.25. Digestion of new batch of PCDM8/CD38 Plasmid with restriction 
Enzymes  
Stock PCDM8/CD38 DNA = 150µg was diluted in 150µl to give a concentration 
of 1µg/µl, 25µl of this was employed in the digestion (25µg). This CD38 DNA 
was cut with the restriction enzyme Xba1 thereby releasing the 1.4kb insert of 
CD38.(Xba1 Catalogue No:R6181; lot number:106306; concentration 10u/µl). 
The enzyme activity is defined as the amount of enzyme required to digest 1µg of 
DNA in 1 hour at 37ºC in a reaction mixture of 50µl. 
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5.26. Protocol to digest PCDMCD38 and PGEM11Zf with Xba1 restriction 
enzyme: The following reaction mixture was set up by pipetting into a sterile 
Eppendorf tube: as depicted in Table 5.3. 
 
 Tube A Tube B Tube C 
H2O 5.6µl 5.6µl 13.8µl 
Restriction 
Enzyme Buffer D 
4.0µl 4.0µl 2.0µl 
Acetyl BSA 0.4µl 0.4µl 0.2µl 
DNA 25µl CD38 25µl CD38 3.0µl 
PGEM11Zf 
Restriction 
Enzyme Xba1 
5.0µl 5.0µl 1.0µl 
Total 40µl 40µl 20µl 
 
Table 5.3: Digestion of PCDMCD38 and PGEM11Zf with Xba1 restriction 
enzyme 
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The contents were vortexed and spun in a microcentrifuge for 10 seconds to allow 
the reaction mixture to be homogenous at the bottom of the tube and incubated at 
37ºC for 5 hours. 
 
5.27. Visualization of products following digestion with Xba1 enzyme: 
Following digestion with Xba1 restriction enzyme of the PCDM-CD38 DNA and 
PGEM11Zf, products were visualized on a low melting point 0.8% agarose gel 
resulting in the production of a 1.4kb band for CD38 and a linearized band for 
PGEM11Zf at 3.223kb Figure 5.8.  
 
Figure 5.8: Linearized PGEM11Zf vector and CD38 insert following digestion 
with restriction enzyme Xba1 to release 1.4kb CD38 insert. 
 
5.28. Purification of CD38 insert and linearized PGEM11Zf vector 
The 1.4kb CD38 insert was cut out of the low melting point agarose gel and 
eluted using PCR prep purification system (Promega UK) as described earlier, 
1.4 kb CD38 insert 
3.223 kb  PGEM11Zf 
2652 
800 
350
 2652 
 
50
 2652 
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and subsequently used for the ligation into linearized PGEM11Zf vector. Starting 
concentration per tube for CD38 = 25µg and in our sample we recovered 
approximately 100ng per 1µl. Starting concentration for PGEM11Zf = 3µg and in 
our sample we recovered approximately 60ng per 1µl. 
5.29. CD38 Ligation and Transformation of Competent Cells: Following 
recovery of the CD38 insert and the linearized PGEM11Zf vector the products 
were ligated as described earlier and in the details are shown in table 5.4, the 
ligation products were then used to transform competent cells JM109 (Promega 
Catalogue No L2001) as described earlier. 
 A B C D E F 
Vector DNA 
PGEM11Z 
2µL 3µL 2µL 2µL 2µL 2µL 
Insert CD38 0µL 1µL 6µL 4µL 2µL 2µL 
control 
DNA 
Buffer x 10 1µL 1µL 1µL 1µL 1µL 1µL 
T4 DNA 
ligase 
0.5µL 0.5µL 0.5µL 0.5µL 0.5µL 0.5µL 
H2O 6.5µL 4.5µL 0.5µL 2.5µL 4.5µL 4.5µL 
 
Table 5.4 Ligation of CD38 into PGEM11Zf (A) 
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Vortex and spin down the reaction mixture and incubate the ligation mixture 
overnight at 4ºC. Following ligation competent cells (JM109) were transformed as 
discussed earlier under transformation protocol section 2.42. The presence of the 
CD38 insert in the transformed cells was again confirmed after digestion of the 
PGEM11Z plasmid with restriction enzyme XBaI as discussed earlier..  
5.30. Sequencing Data to confirm CD38 identity Following agarose gel 
electrophoresis the insert was cut out, eluted as described earlier and the identity 
of the insert confirmed by sequencing (performed by Dr Lou Matterhall, Bart’s 
and The London Hospital) (Figure 5.9), giving sequence alignment with CD38 
DNA. 
 
Figure 5.9: DNA sequencing of the insert matched the sequence of CD38 DNA. 
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5.31. In-vitro transcription and translations using PGEM11Z CD38 DNA: 
Translation of CD38 a 42kd protein was carried out using in vitro transcription 
and translation system (Promega) as previously described. The concentrations of 
reagents were also optimized to improve the translation of the CD38 protein using 
both the SP6 as well as T7 polymerase enzymes. To this end optimal 
concentrations of Mg Acetate (5mM) and KCL (0.5mM) were also employed. 
Two colonies were tested for the translations respectively using T7 and SP6 
polymerase enzymes (Table 5.5) and the translated proteins separated on a 10% 
SDS page gel. 
 Colony 1 Colony 2 
Rabbit Reticulocyte 25µl 25µl 
Amino acid mix less methionine 1µl 1µl 
Buffer 2µl 2µl 
Polymerase T7 & or SP6 2µl 2µl 
Rnasin Inhibitor 1µl 1µl 
CD38 DNA template 2µl 2µl 
KCl 90.5mM0 2µl 2µl 
Mg Acetate (5mM) 2µl 2µl 
35S Methionine 4µl 4µl 
H2O Dnase free 10µl 10µl 
Total 50µl 50µl 
 
Table 5.5.   In Vitro Transcription & Translation protocol for CD38 synthesis.  
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5.32. Interpretation: The Translates from both clones gave protein band in the 
region of 30kd and 38-40 kd region, with no bands in the region of 42kd (data not 
shown). Furthermore when tested in a liquid phase immuno-precipitation assay as 
described earlier in chapter 2, CD38 Monoclonal antibody MCA109, T1D sera as 
well as type 2 diabetic sera previously shown to be positive in western blot 
analysis in Ferrannini et al laboratory, failed to react or show differences with the 
translated CD38 protein.  
5.33. Detection of CD38 protein by western blotting 
The presence of autoantibodies to CD38 has previously been evaluated using 
western blot analysis in 236 patients with type 2 diabetes and 160 T1Dpatients 
with positivity in 9.7% and 13.1% respectively (Cinzia et al., 1999). Another 
report using western blot technique reported that of 377 NIDDM Japanese 
patients, 13.8% had autoantibodies against CD38. (Ikehata et al.,1998).  
CD38 protein was therefore tested in a western blotting system to try and confirm 
reactivity of the protein with the assumption that, reactivity may be to linear 
epitopes of the CD38 protein not recognized in the liquid phase immuno-
precipitation assay. 
5.34. Western Blot Procedure for CD38 antigen: To test the translated CD38 
protein 40µl translate from clones 1 and 4 using  SP6 and T7 polymerase enzymes 
respectively were added to 40µl of SDS sample buffer, boiled in a dry block 
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heater set at 100ºC for 3 minutes and electrophoresed on 10% SDS page gel at 
50mVolts for 1 hour. 
Following electrophoresis the gel was placed in transfer buffer and the negatively 
charged proteins transferred onto Nitro-cellulose membrane Hybond NC 
(Amersham) after preparing a sandwich of Filter paper/ Gel/ Nitro-cellulose/ 
Filter Paper and transferred at 190 volts for 1 hour in Transfer buffer.  
1. The proteins transferred onto nitro cellulose paper, was blocked overnight 
with Blocking solution containing 0.05% tween 20 in a petri dish. 
2. The nitro cellulose membranes were then exposed to the primary antibody 
anti-CD38 monoclonal antibody (Serotech MCA 109 clone ATB/S) (Primary 
antibody Mouse Anti-Human CD38 antibody) at 1:1000 dilution on a gentle shaker 
for 4 hours at room temperature (10µl/10ml solution). 
3. The nitro-cellulose membrane was then washed with 10ml wash solution 
0.2% Tween Tris Buffer Saline followed by the addition of Anti-mouse Alkaline 
Phosphatase conjugate (AKP conjugate) at 1:10000 dilution. 
4. The membrane was washed with 10ml wash solution 0.2% Tween Tris 
Buffer Saline followed by the addition of NBT solution which develops the colour 
to visualize the bands.  
5.35. Western Blot Results: The results are shown in figures 6.1 & 6.2 showing a 
band in the region of 30kd with a weak band at approximately 40kd from both 
clones 1 and 4 irrespective of the polymerase (T7 or SP6) enzymes employed. 
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Figure 5.91:  Immunoblot showing a band in the region of 30kd and a weak band 
about 40kd with CD38 protein translated with SP6 polymerase enzyme. 
 
Figure 5.92:  Immunoblot showing a band in the region of 30kd and a weak band 
about 40kd with CD38 protein translated with T7 polymerase enzyme. 
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5.36. Test serum samples for reactivity in Western Blot:  CD38 protein 
transferred as above in another experiment was tested with serum samples 
previously tested in the western blot system in Ferrannini laboratory (negative and 
positive samples) (Tables 5.91 and 5.92) as well as monoclonal anti-CD38 
antibody as shown in Figure 5.93. 
 
 
 
Figure 5.93: Lane 1&2 –Ferrannini sample 151 (positive for CD38), Lane 3 GM 
(Negative control), Lane 4 Ferrannini 6 (negative for CD38), Lane 5 Rainbow 
molecular weight marker, Lane 6 Mouse anti Human CD38 (Santa Cruz) antibody 
1:1000 dilution, Lanes 7 & 8 Mouse anti Human CD38 (Serotech) antibody 
1:1000 dilution. 
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5.37. Interpretation: Following western blot and probing for immune reactivity 
using both monoclonal anti-CD38 antibodies from Serotech and Santa Cruz as 
well as positive and negative serum samples to CD38, bands at approximately 
30kd and 40kd were noted. These bands were considered to be irrelevant as when 
luciferase control DNA (supplied as part of the translation kit) was employed to 
translate luciferase as a control protein (unrelated to CD38) as well as rabbit 
reticulocyte lysate alone (with no added DNA), were tested in the immune-blot 
analysis, both gave similar band of approximately 30kd and 40kd (data not 
shown). Reticulocytes are juvenile red cells and contain remnants of ribosomes 
and nucleic acids which are present in larger amounts in the cytoplasm of the 
nucleated precursors from which they are derived.  Luciferase DNA  synthesizes a 
protein of 61kd and with reticulocytes no specific protein should have been 
translated.  
5.37. Conclusion: Our results failed to identify any distinct bands for CD38, that 
is we were unable to detect CD38A, in patients with type 1 diabetes or type 2 
diabetes. Bands were noted in the 30kd and 40kd region, using immuno-
precipitation experiments as well as following  immune-blot analysis as shown in 
Figure 5.93 implying proteins were present, as immunoglobulins in patients sera, 
showed reactivity, however reactivity to these proteins was non-specific, as they 
were also noted with luciferase and reticulocyte lysate both unrelated to CD38. 
By implication we found no evidence for the existence of CD38A in diabetes, 
irrespective of its type.  
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Glucose induced insulin release has been reported to be attenuated in mice that 
over express CD38 in the islets (Kato et al., 1995), and attenuated in CD38 
knockouts (Kato et al., 1999). In a Japanese study (Fumiko et al 1999) sera 
containing auto-antibodies to CD38 inhibited insulin secretion from pancreatic 
islets. While another study (Cinzia et al., 1999) reported that CD38 antibodies 
potentiate insulin secretion in isolated pancreatic islets and this latter study 
proposed CD38 as a candidate auto-antigen in type 2 diabetes patients. 
The apparent involvement of CD38 in insulin secretion also led to the finding of a 
mutation of the CD38 gene (Arg 
140
Trp) in 13% of Japanese type 2 diabetic 
patients with a family history of the disease (Yagui et al., 1998). Functional and 
gene studies of CD38 have also been previously reported (Malavassi et al., 2008). 
The original identification of CD38 autoantibody in diabetes patients (Cinzia et 
al., 1999) employed, a solid phase immunoblot system. However it was unclear 
whether conformation of the CD38 molecule was a prerequisite for reactivity to 
the CD38 protein, as in these experiments only the solid phase assay system was 
employed to test for reactivity to the CD38 protein. The liquid phase assay 
systems, unlike the solid phase assay systems, have been shown to be more 
sensitive as well as specific (Wilkin et al., 1989). This feature has been reported 
in previous DASP work shop data using different autoantigens (Bingley et al., 
2003) and the evidence is that solid-phase systems are less sensitive and less 
specific than liquid-phase assays, the former recognizing linear epitopes of the 
antigen as opposed to the liquid phase assays which recognize conformational 
epitopes The difference between solid or liquid phase assay systems could also 
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reflect differences in the detection of different subpopulations of antibodies to 
different auto-antigens. For example with insulin, small amounts of high affinity 
antibody have been reported to be readily detected in radioactively-labelled 
binding assays, while large amounts of low affinity antibodies are more readily 
detected by solid phase ELISA assays (Wilkin et al., 1989).  
The low reactivity of the CD38 antigen was a major drawback in this project, this 
could have been due to the low incorporation of 
35
S methionine into the CD38 
protein (low incorporation even when Leucine was used in place of methionine as 
discussed earlier). We failed to show clear reactivity to CD38, similar low 
reactivity and a failure to detect relevant binding of antibodies to recombinant 
CD38 has also been reported previously using a similar liquid phase assay system 
(Sordi et al 2005). The data presented confirms previous reports of low reactivity 
to the CD38 antigen and question its relevance as a marker in differentiating T1D  
from type 2 diabetes.   
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6.0. CHAPTER 6 
GENERAL DISCUSSION  
Diabetes affects about 6% of the population of the United States about half of 
whom are undiagnosed, with ‘type 2 diabetes’, accounting for 90% of the cases and 
in the United Kingdom approximately 2.8 million people suffer from the disease. A 
large global variation in the incidence of T1D has been reported and the north south 
gradient was not confirmed (Karvonen et al., 2000). Autoimmune T1D has been 
described classically as being predominantly of childhood-onset, insulin-requiring 
and presenting with ketoacidosis and weight-loss. Over the last decade there has 
been an explosion of cases of diabetes reported in children and young adults 
presenting as overweight or even obese leading to an excessive stress on the beta 
cell function and accelerated islet cell destruction. Increasing obesity, including 
childhood obesity, favouring insulin resistance, autoimmunity and double diabetes, 
has become a major concern in the youth accounting for the Islet cell immunity 
through different mechanisms (Naik & Palmer 2009). This increase cannot be 
explained by an increase in the genetic load in the short space of time but rather 
points towards a changing environmental impact as well as lifestyle in the youth. 
The threshold hypothesis describes the putative interaction of the genetic as well as 
environmental loads and the impact of these in TID (Wasserfall C et al., 2011). The 
thresholds for developing TID have also changed with increased migration, 
decreased genetic load and the wide impact of environmental factors on susceptible 
individuals (Bodansky et al 1992). 
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WHETHER AUTOANTIBODIES AND CARBOXY METHYL LYSINE (CML) ARE 
GENETICALLY PREDICTIVE OF T1D.  
Advanced Glycation End Products are formed both enzymatically as well as non-
enzymatically and the products of AGES activation can have profound effects 
physiologically, with the production of reactive oxygen species as well as a 
plethora of reactivation cycles of AGES. Following a prolonged hyperglycaemic 
state reactive oxygen species, chemokines, as well as gene expression result, 
leading to the formation of AGES which bind to receptors on endothelial cells, 
smooth muscle cells as well as immune cells (monocytes, macrophages and 
dendritic cells), activating formation of reactive oxygen species, as well as further 
activating the immune system. This activation in turn induces intracellular 
signaling leading to increased oxidative stress to the cells and tissues, with further 
production of reactive oxygen species and pro-inflammatory cytokines, that can 
lead to microvascular as well as macrovascular damage. 
The data presented here show ICA positive children at risk of TID had 
significantly elevated levels of CML both before and at diagnosis of TID in 
comparison to their controls. Serum CML levels tended to increase in those 
progressing to T1D. Similarly elevated CML levels were noted in twins 
discordant for T1D, irrespective of whether they had T1D or not, consistent with a 
non-genetic environmental effect. CML levels in twins were also higher than in 
children with TID and their controls. This difference can be accounted as an age 
effect as the twins were older such that they would be exposed to a significantly 
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longer period of AGES in comparison to the children but also potentially to 
storage differences as samples in Germany were stored at -80C and in -20C in the 
UK. However such differences would not explain the results as control samples 
were under similar storage conditions in each population.  
Raised CML levels in the twins and the school children may be the result of 
dietary factors, given that they are likely due to shared environmental factors and 
CML is known to increase due to ingestion of heat-treated food. Raised CML 
levels could have a harmful effect in the long term, through promoting a pro-
inflammatory response, but our data cannot determine this categorically, however 
raised serum CML is predictive of the disease. Moreover, serum CML was 
predictive additively with serum autoantibodies: raised CML and presence of 
autoantibodies gave a PPV in population and twins 46.5% and 47.9%, and 33.7% 
and 85.7% respectively. 
On the other hand autoantibodies were discordant in the twin pairs, in that the 
non-diabetic twins tended not to have autoantibodies and the diabetic twin did, 
consistent with a non-genetic determinant event for presence of auto-antibodies 
unlike CML levels which were elevated in both the index twin and the co-twin. 
So raised CML in twins discordant for diabetes cannot simply be attributed to an 
increased auto-inflammation as it was detected in both index as well as their non-
diabetic twins, of whom none of the latter had auto-antibodies to GADA, IA2 or 
ZnT8. But the predictive values imply that these two processes, one 
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proinflammatory and the other adaptive immunity (as reflected by CML and 
autoantibodies) act additively to predispose to T1D. 
WHETHER AUTOANTIBODIES, INSULIN SECRETION AND INSULIN RESISTANCE ARE 
PREDICTIVE AND ARE GENETICALLY DETERMINED?  
Twin studies have provided a powerful tool to investigate genetic and 
environmental factors by comparing identical and non-identical twins. It is clear 
that both immune as well as metabolic changes can be detected many months or 
even years before diagnosis of T1D, changes that are distinct between twins who 
develop diabetes and those who do not.  These immune as well as metabolic 
changes can predict the onset of development of T1D.  
Autoimmune diseases affect up to 5% of the population and are a major cause of 
morbidity and mortality. Autoantibodies to key islet cell antigens can be detected 
in 80% of newly diagnosed T1D patients and are a hallmark for it. Twin studies 
have provided evidence that both genetic as well as environmental factors are 
involved in the pathogenesis of autoimmune diseases as the concordance rate for 
TID ranges from 40-60%, well short of 100%, indicating that other non-genetic 
environmental factors are involved in the triggering of the disease. The study of 
twins discordant for TID in the United States of America suggested that with 
sufficient follow up of twins the concordance rate would be much higher 
(Redondo M et al., 2008). Studies have shown that the majority of twins with an 
autoimmune disease have a co-twin who is unaffected and continues to be 
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unaffected, confirming our data of discordance for T1D even after >40 years of 
follow-up from the diagnosis of the index twin.  
Loss of the FPIR, is a hallmark of beta cell failure and is amongst the earliest 
signs together with autoimmune changes leading to hyperglycaemia, glucose 
intolerance and frank diabetes. There was however, no evidence in the data 
presented of any impaired beta cell function in the non-diabetic twins who remain 
discordant for diabetes, results which are consistent, with a non-genetic event 
which affects one twin but not their genetically identical co-twin. In the pre-
diabetic twins higher fasting insulin levels as well as lower FPIR and glucose 
clearance were noted and these twins went on to develop diabetes. The hypothesis 
that altered islet beta cell function might be genetically determined and predispose 
to T1D, was rejected. Pre-diabetic twins furthermore showed evidence of 
autoimmune features with the presence of diabetes associated auto-antibodies to 
GADA, IA2ic and ZnT8. Auto-antibodies to islet antigens GADA, IA2A and 
ZnT8 has provided a valuable tool in the prediction of T1D in at risk patients as 
well as in the general population.  
DETERMINE WHETHER THE ISOTYPE OF GADA AND IA-2A IN TYPE 2 DIABETIC 
PATIENTS DIFFERED FROM THOSE FOUND IN TYPE 1 DIABETIC PATIENTS. 
The historical methods employed for the detection of antibodies to islet antigens 
employed immunoflourescence of human group O cryofixed pancreatic sections. 
This assay is prone to variability due to: 1) nonspecific binding to islet cell 
components, 2) variation of the amount of antigen containing tissue, 3) variation 
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of the results due to operator interpretation which is highly subjective and 4) 
inability to confirm the identity of the islet antigens involved. In general, ICA is 
restricted to immunoglobulin of the IgG1 isotype belonging to the IgG subclass 
(Millward et al., 1988), (Dozio et al., 1994). In the ICA technique it is however 
impossible to determine the exact nature of the lslet antigen without performing 
pre-absorption assays using purified antigens, this in itself is an added step with 
no guarantee of the heterogeneity of the islet cell antigens present in the section 
employed. Enzyme Linked Immunosorbent Assays have been described using 
glutamic acid decarboxylase from brain extracts which is rich in the two isoforms 
GAD65 and GAD67 for the detection of autoantibodies, however these assays 
lacked specificity and sensitivity.  
In this study the earliest available samples from pre-diabetic Twins, non-diabetic 
twins and noninsulin requiring diabetes but antibody positive cases were screened 
for antigen specific isotypes. Antigen specific isotype profile to GAD65 and IA2ic 
did not show any evidence of maturation in the immune response, with IgG1 the 
dominant isotype detected in the samples before as well as at diagnosis of T1D. 
Similarly in the noninsulin requiring diabetes GADA positive patients again there 
was no evidence of antibody isotype’s other than IgG1. However SPS patients, 
tended to have isotypes other than IgG1, in particular, IgG4 as well as subtypes 
IgE isotype, which T1D patients lacked (Lohman et al 2000). Our findings were 
consistent with the findings in the BABYDIAB study where diabetes onset and β 
cell destruction occurred during an early or subsequent IgG1 dominant antibody 
response (Bonifacio et al 1999). 
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In conclusion, isotype response to both GAD as well as IA2 were both restricted 
to the IgG1 isotype in both T1D as well as type 2 diabetes patients confirming 
that the nature of the antigen specific antibodies in type and type 2 diabetes are 
similar and consistent with a Th1 type immune response. 
WHETHER AUTOANTIBODIES IN ADULTS PRESENTING WITH TYPE 2 DIABETES 
ARE PREVALENT AND SIMILAR TO T1D. 
The American Diabetes Association Expert Committee proposed an etiologic 
classification of diabetes with type 1A diabetes representing immune-mediated 
diabetes and type 1B a non-autoimmune idiopathic form of type 1 diabetes 
(Expert Committee 1997). In this classification autoimmunity was defined as the 
presence of one or more islet cell autoantibodies to insulin, GADA, IA2A and 
ICA in 80-90% of the patients being present when hyper-glycaemia is detected. 
The definition of LADA set by the Immunology of Diabetes Society and Action 
Lada (www.actionlada.org), age 30-70 at diagnosis, free of insulin for at least 6 
months and presence of autoantibodies.  
Auto-antibodies to islet cell antigens ICA, Insulin (IAA), GAD65, IA2ic, and 
ZnT8 are a feature of T1D particularly in children and can also be detected in a 
small proportion of adults presenting with non-insulin requiring diabetes, termed 
as LADA (Leslie RD et al 2006). The prevalence of LADA in Caucasian adults 
presenting with non-insulin requiring diabetes has been reported to be between 4-
12%, but usually based on measurement of GADA alone (Leslie RD et al., 2006). 
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Such LADA patients exist, however, are they distinct from T1D and ‘type 2 
diabetes’ patients. Studies by (Falorni et al., 2000), (Hampe et al., 2002) using 
fusion proteins indicated that there was a distinct reactivity in GADA positive type 
2 diabetes patients termed LADA. However one caveat of employing recombinant 
fusion proteins, not discussed is that fusion proteins do not maintain the secondary 
structure of the synthesized proteins. Fusion protein folding as well as epitope 
recognition by antibodies can be affected when fusion proteins are employed as has 
been confirmed in studies with fusion proteins using circular dichroism 
spectroscopy (Wang et al., 2011). Such protein modifications could affect protein 
conformation which could explain previously reported differences in T1D and 
LADA, (Falorni et al., 2000), (Hampe et al., 2002).    
The majority of typical T1D patients, on the other hand, have auto-antibodies in 
the serum and these auto-antibodies are predictive of the disease. It has further 
been reported that a proportion of auto-antibody negative ‘type 2 diabetes’ 
patients can also have T cell reactivity to islet extracts transferred onto 
nitrocellulose membrane, if this is confirmed in larger studies the reported 
prevalence of autoimmune diabetes in adults would be higher than currently 
proposed (Brooks-Worrell et al., 2011). However, whilst T-cells appear to have a 
central role in the pathogenesis of autoimmune diabetes, the study of T-cells is 
technically laborious and requires extensive expertise in performing T cell 
activation/proliferation assays. Furthermore the reported studies employed islet 
extracts from nitrocellulose exposing linear epitopes which can modify both T-
cells as well as B-cell reactivity.  
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The focus of diabetes-prediction studies, have been predominantly to test auto-
antibodies as markers of autoimmunity in the course of the disease. In this report 
of 6156 clinic based patients tested for several diabetes-associated antibodies, the 
prevalence of autoimmunity was noted to be 9.7%. Other similar studies have 
been much smaller with a marked selection bias, based on selecting only cases 
with apparent ‘type 2 diabetes’ or cases likely to have LADA. In this present 
study cohort all cases presenting with diabetes and within the selection criteria 
were included. At diagnosis in the Action LADA study, antibody positive patients 
were leaner and younger and more often put on insulin therapy in comparison to 
the antibody negative patients classified as ‘type 2 diabetes’ patients. GADA 
antibodies alone were identified in 8.8% accounting for 90% of all cases 
presenting with diabetes associated antibodies. Retesting of samples that were 
scored positive for any antibody reduced the false positive errors to <2%. 
Furthermore in the analysis of the dataset, in house controls were employed 
including a positive control sample tested by titrating to end point to determine 
the cut off for positivity. This methodology was further confirmed by employing 
QQ plot analysis which further confirmed the selected cut off for positivity for 
each antigen as well as the strategy followed in the BabyDIAB study (Zeigler et 
al., 1999). The interpretation of the data from this thesis recommends the use of 
QQ plot where large data sets are analyzed, instead of using percentiles of healthy 
controls alone. The data also adds to the validity of the use of end point titration 
curves employed here to evaluate the cut off levels for auto-antibody assays.  
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Importantly, the consistently high prevalence of patients with adult-onset diabetes 
who can be ascribed to have autoimmune diabetes i.e. about 10% (5-15%) implies 
a high prevalence of autoimmune diabetes in general (Akinson & McLaren 1994), 
(Redondo et al., 2008), (Peppa et al., 2003), Rosario et al., 2005). Indeed, these 
observations suggest that the most prevalent form of autoimmune diabetes is in 
adulthood and not in childhood as previously thought.  This present study is the 
largest to date, and benefits from an analysis of all cases attending these clinics, 
irrespective of clinical features, and screening with three major diabetes-
associated auto-antibodies. A small fraction of the patients had diabetes-
associated auto-antibodies other than GADA, so the projected shortfall of 
ascertainment using GADA alone would be small. Interestingly these patients 
with auto antibodies other than GADA had similar characteristics to the GADA 
positive cases in that they were leaner as well as younger. Within the GADA 
positive cases at least two modes were identified using the QQ plot analysis, with 
a cut-off of 70 WHO IU (low GADA titre) and another inflection at 200 WHO IU 
(high GADA titre). However there was no clear evidence of a bimodal 
distribution of the dataset in this analysis unlike the log transformed data 
presented by the NIRAD study (Buzzetti et al 2007). A bimodal distribution 
would have to show two normal distributions one for the low GADA titre and 
another one for the high GADA titre.  The NIRAD study was substantially 
smaller in comparison to the dataset presented here (n=191 versus 701). In this 
present study, we did not confirm that a bimodal distribution was evident, though 
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the log transformed data did show two apparent modes, however each mode was 
not normally distributed.  
In this cohort of 6156 clinic based patients presenting with diabetes, 
autoantibodies to GADA, IA2A and ZnT8 identified 90% of adults with 
autoimmune features. The information presented here makes the term LADA an 
increasingly inappropriate term to describe adults presenting with a spectrum of 
autoimmune features which are similar to T1D and distinct from ‘type 2 diabetes’ 
patients.  
ARE AUTOANTIBODIES TO THE ADP RIBOSYL CYCLASE/CYCLIC ADP-RIBOSE 
HYDROLASE (CD38)  ASSOCIATED WITH AUTOIMMUNITY IN TYPE 1 AND TYPE 2 
DIABETES. 
Autoantibodies to CD38 have been reported previously in 13.8% of Japanese 
Type 2 diabetes patients (Cinzia et al., 1999). Anti CD38 antibodies, both 
inhibitory as well as stimulatory to the release of insulin have been previously 
reported (Ikehata et al., 1998), (Cinzia et al., 1999), suggesting that anti CD38 
auto antibodies, may be an additional cause of impaired glucose induced insulin 
release. They, as well as others, employed western blotting, assay procedures, 
which recognize linear rather than conformational epitopes of the CD38 molecule 
with a lower specificity and sensitivity. 
The aim in this project was to insert the CD38 cDNA into a suitable vector to 
allow transcription and translation of the CD38 protein, for subsequent use, in a 
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liquid phase immuno-precipitation assay. As auto-antibodies have been noted to 
be predictive for the development of TID and ICA comprises auto antibodies to 
several antigens including GADA, IA2A, ZnT8A as well as other antigens yet to 
be identified, it was conceivable that the antigen CD38 (antibodies to which were 
reported in type 2 diabetes patients), could be an additional marker in TID 
prediction. Since genetic susceptibility through HLA is part of normal genetic 
variation and since monocyte changes, found by us in T1D and by others in ‘type 
2 diabetes’, are also associated with T1D, it is possible that the spectrum of 
changes leading to T1D extends across the whole spectrum of diabetes, so that 
selected auto antibodies could occur in all forms of diabetes.    
A number of hurdles were encountered in the process of preparing the CD38 
insert into the PGEMIIZ vector which in itself is an important point to make in 
particular when working in a laboratory where other vectors are routinely 
employed. It was noted that the initial CD38 insert into the vector PGEM11Z and 
growth of subsequent colony on agar plates had actually resulted in the insertion 
of the GAD65 cDNA instead of CD38 cDNA.  
Despite adherence to good laboratory practice this problem only became evident   
after performing extensive purification as well as immune-precipitation 
experiments, confirming an experimental issue with the CD38 cDNA prepared. 
This was later confirmed to be GAD65 following sequencing data analysis of the 
presumed CD38 cDNA. So an important message from these observations was 
that experiments must be performed under the strictest care. Furthermore before 
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embarking on detailed experiments it is vital to confirm the identity of the cDNA 
being prepared. 
In subsequent experiments anti CD38 antibodies using CD38 translated protein 
did not differentiate between healthy control subjects, TID or cases with type 2 
diabetes. This finding has also been confirmed by another researcher (Sordi V et 
al 2005) and in that study they too failed to show any reactivity to the CD38 
antigen in the liquid phase assay system consistent with the data presented here. 
Auto-antibodies to islet antigens IAA, ICA, GADA, IA2A and ZnT8 identify the 
majority of autoimmune diabetes patients. The appearance of auto-antibodies does 
not follow any specific pattern and can vary substantially. However, the presence 
of multiple auto-antibodies provides the highest positive predictive value for T1D.  
T-cells are the earliest hallmark of beta cell infiltration of the islet cells in the 
pancreas. A recent report by (Brooks-Worrell et al., 2010) identified a group of 
phenol-typically type 2 diabetic patients, all of whom were autoantibody negative 
but showed T cell reactivity using islet cell extracts transferred to nitrocellulose, 
such patients could not have been detected by testing for auto-antibodies alone. 
However given the lack of a reliable, reproducible and easy to perform T-cell test, 
measurement of auto-antibodies to GADA, IA2A, ZnT8, IAA and ICA will 
continue to be the best line of identifying at risk individuals with active 
autoimmune features leading to T1D. 
A number of environmental factors have been implicated in genetically 
susceptible individuals including, chemicals, early infant diet, virus infection 
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(Mumps, rubella, cytomegalovirus, entero-viruses such as coxsackie) and 
exposure to cold environmental conditions have been implicated. The gut 
microbiome may also play a part in the cause of T1D following infection 
affecting the gut permeability leading to the activation of the immune system. 
Exposure to cow’s milk early in life has been implicated in both the BB rat model 
as well as humans. A number of population based studies have been initiated and 
these include the DIPP, DAISY, BabyDiab, TRIGR and PANDA studies, results 
from these studies will provide more information on the factors involved in the 
cause of T1D. 
6.1. FUTURE WORK 
The concordance rates, for T1D ranges from 10-60%, depending on the 
ascertainment of the cohorts studied indicating a dominant environmental effect. 
A preliminary paper by us identified DNA methylation variable positions in 
monocytes (CD14+) associated with T1D, implying one possible cause of this 
missing non-genetic effect could be epigenetic. These changes in monocytes 
could also be found in children at risk of the disease (Vardhman et al., 2011). The 
large EU programme BLUEPRINT has funded us to examine these questions in 
more detail. With respect to environmental agents we also intend to study the gut 
microbiome in twins concordant and discordant for T1D, to determine the impact 
of the gut microbiota on the disease. Other environmental factors include the food 
we ingest and we are interested in the character of AGE which might offer a clue 
relating to the reason high levels of CML in the serum are predictive of T1D.  
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